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Abstract
Aims: The primary aim was to assess the role of specialisation, particularly that of specialist surgery, in
the management of epithelial ovarian cancer and in particular the extent to which differences in the surgery 
performed are related to survival. Secondary aims evolved from initial observations. The survival difference 
between gynaecologists and general surgeons was explored and further evidence for the role of the 
multidisciplinary clinic [MDC] was examined. The role of specialisation in the management of patients with 
endometrial cancer was explored to allow parallel observations to be drawn for this neglected cancer that 
is treated by the same gynaecologists treating ovarian cancer.
Methods: Three studies were undertaken: (i) A retrospective case note review of patients
registered with ovarian cancer between 1995 & 1997 in Scotland was undertaken. Pre-defined and piloted 
datasets were abstracted from patient medical case records. These were linked to survival data. This study 
was used to explore the relationship between the operating surgeon’s approach to surgery, surgery 
performed, success of surgery and survival. Information on the MDC and chemotherapy was also 
collected. This data was compared with previously reported data from 1992-1994 to examine changes in 
treatment over time and to relate these to survival. Statistical analysis with Cox proportional hazards model 
was used to correct for important prognostic factors, (ii) A prospective observational study of 1077 patients 
recruited into an international phase-lll prospective randomised clinical trial in ovarian cancer [SCOTROC] 
was undertaken. Detailed surgical data was collected in addition to other treatment and patient data. This 
study was used as a vehicle for exploring international variations in surgery and their relationship to 
survival, (iii) A retrospective case note review of all patients registered with endometrial cancer between 
1996 & 1997 in Scotland was undertaken. Pre-defined and piloted datasets were abstracted from patient 
medical records. This was used to explore the relationship of staging quality and specialisation and the 
relationship between staging and the use of adjuvant treatment and survival.
Results: (i) Data on 83% of registered patients could be abstracted for patients with ovarian cancer 
diagnosed between 1995 & 1997. The Scottish ovarian cancer study showed that although there were 
differences in the approach to surgery, the actual success in terms of the probability of optimal debulking 
was no different between ‘specialist’ and ‘non-specialist’ gynaecologists. This was reflected in no observed 
survival difference. A difference in survival between gynaecologists and general surgeons was shown. 
This could be explained by statistical correction for bowel obstruction found at laparotomy. Comparison of 
the Scottish 1995-97 cohort with similarly collected data from 1992-94 showed no improvement in the 
extent of surgery. There was a modest improvement in survival between the cohorts that was maximal at 
18 months. In multivariate analysis this could be accounted for by increased attendence at the MDC. (ii) 
SCOTROC demonstrated that patients recruited from the United Kingdom underwent less extensive 
surgery and these patients had a lower probability of being optimally debulked. These patients’ operations 
took less time to perform. Only early survival data is available. However at present no statistical 
differences in survival are seen, although there is evidence that survival curves are beginning to diverge. 
Full survival data are awaited, (iii) Data on 94% of patients diagnosed with endometrial cancer in 1996/7 
was abstracted. Multivariate survival analysis of the Scottish endometrial cancer study shows that patients 
who were more adequately staged were more likely to receive appropriate adjuvant radiotherapy and, in 
those patients with advanced disease, survived longer.
Discussion: The benefits of specialist surgery in ovarian cancer in Scotland are less certain than
previous studies have suggested. The survival difference between general surgeons and gynaecologists 
may be a result of lead-time bias. A difficulty is that the exact role of surgery in advanced ovarian cancer is 
still uncertain. SCOTROC provides a unique opportunity to use international variations in surgery to 
assess the benefits of more extensive surgery. Final conclusions from SCOTROC should be guarded until 
full survival data are available. It may be that survival in advanced ovarian cancer cannot be improved by 
improvements in surgery alone. The importance of the MDC as a favourable prognostic factor is confirmed 
and strengthened by the study results. The importance of staging as a process is demonstrated as an 
important prognostic factor in patients with endometrial cancer and the role of the MDC as a decision­
making forum is discussed. Although specialist gynaecologists in Scotland perform more appropriate 
staging the study was not powered to demonstrate a survival advantage by this group of clinicians and 
none could be demonstrated.
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CHAPTER 1
Introduction & Literature Review
l
1.1 An overview
International comparison of 5-year survival outcomes for common cancers, including 
ovarian cancer, show that Scotland has demonstrated consistently poor results compared 
with other countries (Berrino et al. 1995), (Selby, Gillis, & Haward 1996). Evidence 
from observational studies from Scotland has shown that survival from ovarian cancer 
improves when patients are first seen by a gynaecologist, operated on by a 
gynaecologist, receive multidisciplinary therapy and when the operation performed 
results in remaining tumour deposits being less than 2cm in diameter (Junor, Hole, & 
Gillis 1994), (Junor et al. 1999a). These findings have since been confirmed (Kehoe et 
al. 1994), (Woodman et al. 1997). This work provided the basis of a treatment guideline 
published by the Clinical Audit and Resource Group [CRAG] (CRAG 1995). Recent 
work has suggested that ‘specialist’ gynaecologists operating on patients with ovarian 
cancer improved survival (Junor, Hole, McNulty, Mason, & Youngl999a). Most 
patients with ovarian cancer present with advanced disease (FIGO stage III/IV)1 and are 
operated upon by general gynaecologists, thus any improvement in outcome in stage III 
disease will have a significant impact on overall survival. These findings were based on 
1866 patients diagnosed during 1987, 1992, 1993 and 1994. The survival benefit 
observed in this study was observed in patients with FIGO (International Federation of 
Obstertics & Gynaecology) stage III disease. It was most pronounced between 1 and 2 
years of follow up, with a 12 per cent survival benefit at 18 months. The data were 
adjusted for confounding variables; age, stage, socio-economic status, tumour grade and 
ascites.
1 See appendix
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These studies did not identify the key components of treatment responsible for the 
benefit conferred by ‘specialist’ gynaecology, however the surgery performed appears 
to be an important factor. Thus the question to be addressed in this thesis is what 
specific aspects of specialist surgical treatment confer this survival benefit?
An aim is to evaluate to what extent there are differences in the surgical management 
between ‘specialist’ gynaecological surgeons and ‘non-specialists’ that might explain 
differences in survival outcome of patients. Additionally this thesis will try to explain 
the role of surgical management on the survival outcome of patients with ovarian cancer 
both within Scotland and between the United Kingdom and other countries.
These questions are important and relevant as they allow the potential for improving the 
outcomes of patients with ovarian cancer. This is particularly relevant at a time when 
there is doubt about the effectiveness of health care in the United Kingdom (Anon 
2001).
A number of approaches were used to answer this question. The surgical management 
of all cases of ovarian cancer diagnosed between 1995 and 1997 in Scotland were 
examined, to identify evidence for differences in the current approach to surgical 
treatment and to relate these to survival.
Another approach has been to determine whether the dissemination of a national 
guideline, on the management of ovarian cancer, has altered the management of the 
disease and whether there have been any related improvements in survival.
Thirdly a large international prospective phase-3 drug trial in ovarian cancer, where 
chemotherapy was closely controlled, was prospectively used to collect surgical data.
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This provided the opportunity to describe the range of surgical procedures being 
performed internationally and to relate these to survival outcome.
This thesis is primarily concerned with the role of surgical specialisation in relation to 
ovarian cancer. However a similarly conducted study examining the relationship of 
treatment variables with outcome in endometrial cancer will be presented. Although 
there are fundemental differences between ovarian and endometrial cancer, there are 
sufficient similarities to justify drawing insights from this. In particular the fact that 
over the same time period, the same gynaecological surgeons as those treating ovarian 
cancer treated patients with endometrial cancer in Scotland makes this comparison 
relevant.
Methodology of Literature Review
A systematic review of the literature was undertaken by the author using a search 
strategy utilising both keywords and MESH headings. The Medline database was 
examined from 1966 to 2001. The search was not restricted to any particular type of 
study. After this had been performed individual author searches were performed for 
authors identified as being significant contributers to the literature. The main search was 
supplemented by the identification of several additional publications cited in the 
previously obtained literature. Additionally the reference lists of several important 
national and international documents were examined and leads followed up. Further 
literature was identified through personal communication with colleagues 
acknowledged previously. As a final check an additional search was performed by the 
North Glasgow University Hospitals librarians using Embase, CancerLit, Cochrane and 
pre-Medline databases.
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1.2 International variation in the survival of patients with 
ovarian cancer
Introduction
There are three types of study available to assess how effectively cancer is treated: 
randomised controlled trials, hospital based clinical series and population based studies.
Population based data vs randomised trials
National population-based analysis of cancer survival allows the assessment of how 
effectively cancer is treated within a population (Coleman et al. 1999a). Whilst 
randomised trials allow the identification of what is possible under optimal conditions, 
they rarely include all patients in a population, often excluding old and ill patients 
(Vasey 1998). Population studies are observational studies of survival in a defined 
geographical population and allow the measurement of what is actually achieved for all 
patients as a group. Whilst analysis of survival from these studies might lack the 
precision of a randomised trial they allow an assessment of the effect of the 
multifactorial elements, to the extent that these are known, that influence cancer 
survival in a population. Thus elements of individual clinical management, processes of 
care and the organisational structure in which care is delivered are represented by 
population based survival data. Thus population-based survival data are a composite 
figure that needs to be unravelled in order to understand the basis for differences in 
survival outcome for different groups of patients. This is important as it provides the 
basis for improving outcomes for groups of patients through the identification of factors 
that are modifiable.
Hospital based clinical series
Hospital based clinical series can be misleading, and it is not usually possible to make 
direct comparison between them. They contain many sources of potential bias
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(Coleman, Babb, Damiecki, Grosclaude, Honjo, Jones, Knerer, Pitard, Quinn, Sloggett, 
& De Stavolal999a). They are generally published by ‘specialists’ and as such, survival 
is likely to be unrepresentative of the patient population in general. Bias can be 
introduced from differences in, and definitions of, case-mix (Fanning, Gangestad, & 
Andrews 2000), as well as incomplete inclusion of all cases. Publication bias makes it 
less likely that a series whose results are poor would be published and this will tend to 
overestimate patient survival. Clinical series are less likely to be published in a directly 
comparable form; being less likely to be standardised for age and for the relative 
mortality rate in the population (Berrino, Esteve, & Coleman 1995). Nevertheless such 
studies are often the only form of data from which to generate hypotheses. This point is 
highlighted in the appraisal of the evidence for surgery in ovarian cancer.
Comparison o f national population-based data
There are a number of international population studies. Some of these are part of 
ongoing national surveillance processes (ISD-Scotland 2000b) whilst others are ad hoc 
studies. A problem is that the data from some countries is based upon all patients in the 
population, such as in the UK (ISD-Scotland2000b), (Coleman, Babb, Damiecki, 
Grosclaude, Honjo, Jones, Knerer, Pitard, Quinn, Sloggett, & De Stavolal999a), 
whereas for other countries the data relates only to a small sample such as the USA 
where only 10% of the population is covered (Ries et al. 2001b). When only a 
proportion of the population is represented bias can be introduced. In the USA, the 
Surveillance, Epidemiology and End results [SEER] programme tends to overrepresent 
more highly educated, affluent patients from urban areas. Another problem is that data 
are standardised to account for the national age distribution. Age standardisation 
minimises the effect of differences in age distribution when camparing survival rates. 
Not all published data are uniformly standardised (Coleman, Babb, Damiecki,
6
Grosclaude, Honjo, Jones, Knerer, Pitard, Quinn, Sloggett, & De Stavolal999a). 
Another difficulty is that people with cancer can die directly of their cancer or from 
other causes. Although published survival data (relative survival) is often adjusted for 
this, the methods and definitions used can vary. Thus it is difficult to assess the extent to 
which routinely published survival data can be used for direct comparison. However 
these data allow the accurate assessment of trends over time.
Figure 1.2-1 shows the variation in age-standardised relative 5-year survival of patients 
with ovarian and endometrial cancer from a number of published studies.
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This table shows routinely published data from a number of sources. It 
shows that the published 5-year survival varies between countries. 
However it is difficult to compare data because of differences in 
standardisation as well as differences in the definition of the 
population studied. The effect of age standardisation on the relative 
survival can be seen from the Scottish data. Such standardisation can 
change the 5-year survival by up to 5%. The effect of age 
standardisation is variable across tumour types; in ovarian cancer, 
lung cancer and pancreatic cancer age standardisation tends to inflate 
the 5-year survival whilst for endometrial cancer and cervical cancer 
amongst others it tends to deflate 5-year survival (ISD 2000b). The data 
from FIGO is based upon cases from FIGO affiliated centres. It is not 
obvious from the FIGO report what criteria are used to select or 
exclude cases. There is no evidence of standardisation. It is unlikely 
that these data can be simply directly compared.
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Figure 1.2-1: comparison of routinely published 5-year survival data for patients 
with ovarian and endometrial carcinoma.
Source Country Time
Period
Ovarian
cancer
Endometrial
cancer
Reference
EUROCARE-II2 Europe 1985-89 33(32-34)s 73 (72-74) (Gatta, Lasota, &
Verdecchia
1998b)
ISD-Scotland4 Scotland 1986-90 33.7 70.9 (ISD-
1991-95 35.9 73.9 Scotland2000b)
ISD-Scotland5 Scotland 1986-90 28.0 74.6 (ISD-
1991-95 28.9 76.0 Scotland2000b)
ONS-England6 England 1986-90 28 (28-29) 70 (69-70) (Coleman, Babb, 
Damiecki, 
Grosclaude, 
Honjo, Jones, 
Knerer, Pitard, 
Quinn, Sloggett, 
& De
Stavolal999a)
SEER -white7 USA 1986-88 42.1 82.7 (Ries, Kosary,
1989-95 50.0 83.5 Hankey, Miller, 
Clegg, & 
Edwards2001b)
Einhoven population Netherlands 1975-80 28 - (Balvert-Locht et
study 1981-85 42 al. 1991)
FIGO-annual report8 International 1987-89 - 72.7 (FIGO 2001)
centres 1993-95 48.4 76.5
2 age standardised relative survival
3 (95% confidence intervals)
4 age standardised relative survival
5 relative survival without age standardisation
6 age standardised relative survival
7 not complete population coverage, SEER represents c.9.5% of USA population
8 not population based and ad hoc
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Eurocare
Direct comparison of international cancer survival was first attempted by the 
EUROCARE study. This examined and compared international differences in cancer 
survival within Europe (Berrino, Sant, Verdecchia, Capocaccia, Hakulinen, & 
Estevel995). In this study survival rates in the United Kingdom for 18 out of 25 cancer 
types were poorer than the European average.
The EUROCARE [European Cancer Registry based study on survival and care of 
cancer patients] study was conceived in the 1970’s. It has been an ongoing programme, 
with the aim of allowing a valid comparison of cancer survival between countries in 
Western Europe (Berrino, Sant, Verdecchia, Capocaccia, Hakulinen, & Estevel995). 
Until this time valid international comparisons were limited to comparisons of cancer 
incidence only (Doll 1966). The demonstration and analysis of variation in survival 
outcome were seen as a prerequisite to the identifying the reasons for it.
Before EUROCARE, problems of standardisation and classification made survival 
comparisons difficult. EUROCARE drew attention to these difficulties and sought to 
reduce them (Berrino, Esteve, & Colemanl995). Thus EUROCARE was an attempt by 
European cancer registries to estimate and directly compare survival between European 
populations.
The first EUROCARE study (Berrino, Sant, Verdecchia, Capocaccia, Hakulinen, & 
Esteve1995) compared data from cancer registries covering the total population in 12 
countries during the period 1978 to 1985. Despite the acknowledgement of 
methodological difficulties, the authors demonstrated wide variation in survival for 
many cancer sites and whose magnitude made it unlikely to have occurred by chance 
(Berrino, Esteve, & Coleman1995). These survival differences included the
10
gynaecological cancers. These variations were especially marked in the elderly 
population. There was a general relationship between better overall survival and 
countries with a higher wealth and investment in healthcare. Survival variations were 
greater for tumours that were more amenable to surgery (Coebergh et al. 1998).
The second phase of the EUROCARE project was EUROCARE-II (Berrino et al. 
1998), (IARC 1999). The aim of this was to allow interpretation of the differences 
observed between populations, and by time. This reported on the survival of patients 
diagnosed in 1985 to 1989. Forty-five cancer registries from 17 European countries 
participated and all cancer sites were covered. The differences initially seen in the 1978 
to 1985 cohort were confirmed and trends seen allowed the generation of hypotheses. 
On a population basis, large differences in age-standardised survival were apparent 
during the 1980s and it was believed that this was due in part, or in combination, to 
differences in the stage distribution at diagnosis and also to differences in the access to 
quality specialist medical care (Coebergh, Sant, Berrino, & Verdecchial998).
The EUROCARE methodology is described elsewhere (Berrino, Gatta, Chessa, 
Valente, & Capocaccial998), however great attempts have been made to maximise the 
validity and accuracy of the data to allow comparisons to be made.
EUROCARE has been influential. Despite questions relating to the quality and validity 
of the initial survival comparisons EUROCARE has emphasised the need for better data 
quality and stimulated debate on the determinants of quality healthcare (de Takats 1999; 
Irwig & Armstrong 2000; Kunkler 1999; Rodger & Taylor 1999; Summerton 1999), 
(Coebergh, Sant, Berrino, & Verdecchial998). Within the United Kingdom, 
EUROCARE has resulted in an acknowledgement that the outcomes of patients with 
cancer may not be as good as the best in Europe. Specifically this has been accepted by
11
government and has driven strategy. Firstly in the appointment of a national cancer 
director and the publication of the National Cancer Plan in England & Wales 
(department of health 2000).
A limitation of the initial EUROCARE studies was that the data from the participating 
cancer registries did not include stage at diagnosis (Sant, Berrino, & Coebergh 1999). 
The third phase of the EUROCARE project has been a series of so-called ‘high- 
resolution’ epidemiological studies (Forman 2001). The purpose of the high-resolution 
studies has been to correct the overall survival for stage at diagnosis as well as for some 
basic treatment data. Such studies have been performed for breast, colorectal, stomach 
and testicular cancer. The first of these has recently been published for colorectal cancer 
(Gatta et al. 2000). This shows that much of the variation is accounted for by 
differences in survival in the first few months after diagnosis, suggesting that in 
colorectal cancer at least, the stage of disease at diagnosis may account for a large part 
of the variation seen. This suggests that there are differences in the distribution of 
cancer stage at the point of diagnosis between countries. However even after correcting 
for stage at diagnosis international variation exists. Although these ‘high-resolution’ 
studies are a worthwhile attempt to identify the factors that are associated with the 
observed variation they are not population based and are based on relatively small 
numbers of patients. The high-resolution studies validate the previously observed 
variations in survival between countries participating in EUROCARE.
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Evidence that there are international survival differences
Variation in the survival o f  patients with ovarian and endometrial cancer 
EUROCARE-II demonstrated variations of survival amongst patients with ovarian and
endometrial cancer (Gatta, Lasota, & Verdecchial998b). These are shown
diagrammatically in the figures 1.2-2 and 1.2-3, which show the 5-year age-standardised
relative survival rates with estimated 95% confidence intervals by country. For both
tumour sites, survival in the United Kingdom, including Scotland, is poor and in the
lowest quartile of countries represented.
Possible bias
Although EUROCARE is a population study there are possible biases that might affect 
the reliability of any analysis. Population based survival analysis requires the 
standardisation of a number of parameters. These include the inclusion of all patients, 
whose cancer has been accurately defined, from the complete national population. Also 
there needs to be consistency with the definition of the date of diagnosis (Berrino, 
Gatta, Chessa, Valente, & Capocaccial998), (Berrino, Esteve, & Colemanl995), 
(Coleman, Babb, Damiecki, Grosclaude, Honjo, Jones, Knerer, Pitard, Quinn, Sloggett, 
& De Stavolal999a), (Katz 1999a). The key factors that can introduce bias into 
population studies are summarised in Figure 1.2-4. The EUROCARE methodology has 
attempted to address these issues though it should be appreciated that only six of the 17 
countries participating had complete population coverage, and eight countries covered 
less than 20% of the population.
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Figure 1.2-2; This barchart shows the relative survival of patients 
diagnosed with ovarian cancer between countries participating in 
EUROCARE II. 95% confidence intervals are shown. This shows that 
the relative survival of patients in England and Scotland is poor 
compared to comparable countries in Europe.
Figure 1.2-3; This barchart shows the relative survival of patients 
diagnosed with endometrial cancer between countries participating in 
EUROCARE II. 95% confidence intervals are shown. This shows that 
the relative survival of patients in England and Scotland is poor 
compared to comparable countries in Europe. The relative position of 
United Kingdom is similar for both ovarian and endometrial cancer.
14
Figure 1.2-2: survival of patients with ovarian cancer; EUROCARE-II [1985-1989].
Figure 1.2-3: survival of patients with endometrial cancer; EUROCARE-II
Data from (Gatta, Lasota, & Verdecchia1998b)
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Figure 1.2-4: desirable factors that can influence data quality in population based 
studies.
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Despite attempting to optimise the methodology adopted by EUROCARE, there have 
been some concerns regarding the validity of the 5-year survival data for ovarian cancer 
from EUROCARE. For example, Sweden is represented by registries covering less than 
20% of the national population. Their data suggests that 100% of cases have been 
microscopically verified. This seems unlikely for a cancer that requires a laparotomy to 
reliably obtain tissues for histology. Although tissue obtained by needle biopsy can 
differentiate between benign and malignant pathology, there is often uncertainty of the 
exact primary site in these situations (Pombo et al. 1997). Other concerns relate to the 
validity of using 5 year survival as a useful measure for a cancer that generally presents 
with advanced stage disease and whose 5 year survival for advanced stage disease is 
often much less than 5 years, even in the best centres and series (FIGO2001), (Ries et 
al. 2001a), (Gatta, Lasota, & Verdecchia1998b). Some of the large apparent differences 
in survival outcome seen in the ovarian survival data might be due in part to under 
recording of patients who were sufficiently ill to receive a laparotomy. Despite this 
countries with a high 5-year survival and a high microscopic verification rate do appear 
to have a low ‘death certification only’ rate. This signifies that registration is likely to 
be complete (Berrino, Esteve, & Colemanl995). The differences in 5-year survival may 
be due to differences in case mix within the ICD-9 (183) code (ovarian cancer). 
Although it is stated that borderline tumours were excluded from EUROCARE (Gatta, 
Lasota, & Verdecchial998b), it cannot be certain to what extent this is accurate. 
Borderline tumours are difficult to classify and define (Manek & Wells 1999). 
Borderline tumours have a different natural history with a good survival (FIGO2001). It 
is possible that large differences in the 5-year survival of a tumour, that presents 
generally with advanced stage, may be more a reflection of the case mix rather than true 
differences per se.
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The overall survival of patients with ovarian cancer in Europe improved over the time 
from 1978 to 1989. This has been attributed to the introduction of cis-platinum 
chemotherapy (Balvert-Locht, Coebergh, Hop, Brolmann, Crommelin, van, Wijck, & 
Verhagen-Teulingsl991). There was a reduction in the magnitude of the international 
survival differences, however considerable survival variation in between countries 
remains (Gatta, Lasota, & Verdecchial998b).
International variation in survival fo r  endometrial cancer
The international differences are not as marked for cancer of the uterus. The anatomy 
and biology of the uterus makes histological verification possibly more reliable. This is 
reflected in the very high microscopic verification rate seen for most countries. It is thus 
more likely that the differences seen for the survival of endometrial cancer are accurate. 
Over the time period covered by EUROCARE there was no improvement in survival for 
uterine cancer. Also the survival differences between countries remained almost to the 
same extent (Gatta, Lasota, & Verdecchial998b). The authors conclude that the 
differences seen are reflections of the clinical management of patients. They do not give 
specific reasons for this. The possibility of differences in stage at diagnosis remains. 
EUROCARE has not undertaken ‘high-resolution’ population studies for either ovarian 
or endometrial cancer. Chapter 5 of this thesis is a Scottish national population-based 
study that examines variations in clinical management of endometrial cancer and their 
relationship to survival.
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Evidence that there are regional survival variations within the United 
Kingdom
Variation in the survival of patients with ovarian or endometrial cancer within the 
United Kingdom may be compared at a national, inter-regional and between defined 
groups within the population. Such groups include those defined by socio-economic 
deprivation and by age (Coleman, Babb, Damiecki, Grosclaude, Honjo, Jones, Knerer, 
Pitard, Quinn, Sloggett, & De Stavolal999a), (ISD-Scotland2000b). There is 
remarkable similarity between the age-standardised relative 5-year survival rates for 
ovarian and endometrial cancer between Scotland and England Sc Wales (Coleman, 
Babb, Damiecki, Grosclaude, Honjo, Jones, Knerer, Pitard, Quinn, Sloggett, & De 
Stavolal999a), (ISD-Scotland2000b) [Figure 1.2-1: table: age standardised relative 5- 
year survival]. On a regional basis variation is seen both within Scotland and also within 
England & Wales (Coleman, Babb, Damiecki, Grosclaude, Honjo, Jones, Knerer, 
Pitard, Quinn, Sloggett, Sc De Stavola1999a), (ISD-Scotland2000b). A problem with the 
direct comparison of regions is due to the age and socio-economic mix of patients. After 
statistical correction, for age and socio-economic deprivation, regional variation persists 
(ISD-Scotland2000b), (Coleman, Babb, Damiecki, Grosclaude, Honjo, Jones, Knerer, 
Pitard, Quinn, Sloggett, Sc De Stavolal999a). Although absolute survival declines with 
age, (patients are more likely to die from other causes), the concept of relative survival 
takes this into account. Relative survival defines survival relative to the survival in the 
general population (ISD-Scotland2000b). A significant relationship between age and 
survival is seen both within Scotland (ISD-Scotland2000b) and within England Sc 
Wales (Coleman, Babb, Damiecki, Grosclaude, Honjo, Jones, Knerer, Pitard, Quinn, 
Sloggett, Sc De Stavolal999a). There is also a small socio-economic effect on survival 
for ovarian cancer, the most deprived groups experiencing poorer survival, but not for 
uterine cancer in Scotland (ISD-Scotland2000b).
19
Interpretation of EUROCARE
Two hypotheses can be generated from the EUROCARE study if we assume that the 
survival differences are genuine.
The first hypothesis is that in some countries, patients have more advanced cancer at the 
point when treatment is commenced. This assumes that there are barriers of access to 
medical care. This might be the result of intrinsic problems of the healthcare system 
such as delay (Spurgeon, Barwell, & Kerr 2000). There are three possible time lags. 
Cultural impediments that reduce the likelihood of patients seeking medical advice will 
cause delay from the onset of symptoms to first contact with medical professionals. 
Poor diagnostic systems can delay the establishment of diagnosis and delays in 
treatment increase the likelihood of cancer being more advanced at the time of first 
treatment (Burnet et al. 2000).
The second explanation is that patients have difficulty accessing an appropriate quality 
of medical care and as such they have a reduced probability of survival. This 
explanation might reflect problems with specific clinical management (Wolfe, Tilling, 
& Raju 1997), (Redman 2000), (Gillis & Hole 1996), problems with the processes of 
care such as the lack of appropriate equipment, such as radiotherapy capacity, or the 
personnel to operate it (Burnet, Benson, Williams, & Peacock2000), (MacDermid 2001) 
or problems of an organisational or structural nature. The later include lack of 
integration of various aspects of medical treatment (Junor, Hole, & Gillis 1994), (Expert 
Advisory Group on Cancer 1995).
Whilst the EUROCARE study cannot accurately define the exact explanation there is 
some evidence that the two hypotheses presented above might contribute to the poor 
survival seen in the UK. At present there is little in the literature comparing
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international variation in the stage of ovarian cancer at first presentation. However the 
first ‘high-resolution’ study published showed that in colorectal cancer, much of the 
variation is a result of stage at diagnosis and treatment (Gatta, Capocaccia, Sant, Bell, 
Coebergh, Damhuis, Faivre, Martinez-Garcia, Pawlega, de Leon, Pottier, Raverdy, 
Williams, & Berrino2000) There is evidence from a survey of English hospital trusts 
that there were substantial delays from referral by the general practitioner to treatment 
for all cancers (Spurgeon, Barwell, & Kerr2000). Whilst this is generally recognised, 
there is little in the literature, particularly in ovarian and endometrial cancer, about the 
effect that diagnostic or treatment delay has on survival outcome. Nevertheless it is an 
area of great controversy (Sikora 2000), (Summertonl999).
The issue regarding quality of care has received much interest. Again the EUROCARE 
study can only generate the hypothesis that variations in the quality of care might 
explain the survival variation seen. Chapter 4 of this thesis will discuss a study that tries 
to assess whether there are international variations in the quality of surgery performed 
for patients with ovarian cancer and whether these were associated with differences in 
survival.
A positive relationship between national wealth and better national 5-year cancer 
survival data is seen from the EUROCARE-II data. From this the possibility that 
survival variation is a result of differences in quality of care has been suggested 
(Berrino, Gatta, Chessa, Valente, & Capocaccial998). Figure 1.2-5 shows the relation 
of gross domestic product (GDP) to 5-year survival in ovarian and endometrial cancer. 
Whilst the relationship might be spurious and indirect due to the general effect of 
wealth on health (Smith & Egger 1993), the use of relative survival, rather than absolute
21
survival, should correct for this effect. This interpretation could suggest that the 
availability of material resources might be a factor in explaining the observed variation.
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Figure 1.2-5: relationship of age standardised 5-year survival to national wealth
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This graph shows the relationship of survival to national wealth for 
each country participating in EUROCARE II. There is a small positive 
correlation between increasing wealth and increased survival for 
patients with both ovarian cancer and endometrial cancer. The 
regression lines are shown.
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Magnitude o f international survival variation and tumour and treatment type
The size of international survival differences depends upon the tumour type. The
general trend is that survival variation is greatest for tumours managed by surgery, or a
mix of surgery and adjuvant therapy (Coebergh, Sant, Berrino, &
Verdecchial998),(Gatta et al. 1996). There is one counter argument against the
argument that variations in surgery are an important factor explaining survival
variations. Surgery is generally effective for cancer presenting at an early stage. In this
way lack of diagnostic accuracy and late stage at presentation might make surgery
appear less effective than it actually is in a particular country. Those cancers treated by
chemotherapy alone show less international variation. A possible reason for this is that
chemotherapy is easier to standardise and is less susceptible to stage at presentation: its
success being less confined by a window of opportunity. Moreover, as will be discussed
later, surgery is usually effective only if the tumour is completely excised.
The treatment of ovarian and endometrial cancers both involve surgery and an adjuvant 
treatment modality. These treatments are reviewed later in this chapter. Ovarian cancer, 
because complete resection is often not possible in every case, is useful to demonstrate 
how differences in surgery might explain the survival variations seen. However because 
treatment usually involves both surgery and chemotherapy this adds additional variables 
that must be controlled in any analysis.
There has been much interest recently in the role of specialist surgery and the impact on 
survival outcome (Selby, Gillis, & Hawardl996), (Renehan & O'Dwyer 2000). The 
study presented in chapter 2 explores the components of specialist surgery that may 
have resulted in the improvements in survival in ovarian cancer in Scotland that were 
previously reported (Junor, Hole, McNulty, Mason, & Young1999a). If surgery is
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important, and if there are international differences in the nature of the surgery 
performed within countries participating in the EUROCARE study then this might 
explain some of the international variations seen. The EUROCARE ‘high-resolution’ 
studies are using such approaches to answer this question (Gatta, Capocaccia, Sant, 
Bell, Coebergh, Damhuis, Faivre, Martinez-Garcia, Pawlega, de Leon, Pottier, Raverdy, 
Williams, & Berrino2000). The SCOTROC surgical study presented in chapter 4 aims 
to investigate differences in the surgery performed between the UK and other countries, 
some of which are represented in EUROCARE-II. The SCOTROC surgical study is 
unique because it allows an analysis of the association of surgery and survival variation 
where chemotherapy is controlled.
25
Summary
Many countries have published routine survival data, however directly comparing data 
is difficult and there is always doubt whether like is being compared with like. The 
EUROCARE studies have been the first reliable opportunity to directly compare 
survival for specific tumours between populations within Europe. Despite the efforts to 
maximise data completeness and validity these studies can only generate hypotheses. A 
problem has been that the conclusions are diluted by the delay in reporting the findings. 
This delay is a legitimate reflection of the substantial logistic challenges of data 
processing. The first EUROCARE monograph was published in 1995 and reported on 
the cohort of patients first diagnosed between 1978 and 1985. EUROCARE-II was 
published from 1998 and reported on the cohort diagnosed between 1985 and 1989. 
These reporting delays dilute the importance that such studies might have on health care 
policy. Some authors have argued against the more sophisticated high-resolution studies 
(Irwig & Armstrong2000), suggesting that smaller faster studies auditing the 
compliance to patterns and standards of care defined from randomised trials should be 
used.
Despite these difficulties EUROCARE has been influential in highlighting the reality of 
the differences in survival demonstrated previously. This thesis will present some 
studies that explore the effect of surgical management on the survival of patients with 
ovarian cancer.
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1.3 Surgery in the management of ovarian cancer
Introduction
General principles o f  surgery in malignant disease
William Halstead (Halstead 1907) and his peers are accepted as defining the principles 
of surgery in malignant disease (Moffat & Ketcham 1994). He stated that the primary 
malignant lesion should be surgically excised en bloc with adequate surgical margins 
along with the draining lymphatics. Despite being defined over a century ago these 
surgical principals have endured and this is the form of surgical management for most 
other tumours including cervix (Miyazawa 1993), breast (Dunn 2001) and is the basis of 
total mesorectal excision in colon (Heald & Ryall 1986). The primary aim of surgery is 
staging and cure. If cure is not feasible surgical resection is not usually undertaken 
unless for palliative intent.
Surgery in the management o f  ovarian cancer
Surgery remains the main treatment of ovarian cancer but it is not without controversy. 
The surgical management of ovarian cancer is unique in so far as these principles often 
do not apply. It is unique because surgery is frequently performed and pursued even 
though complete surgical resection is known from the outset not to be possible. It is this 
that makes ovarian cancer interesting as it comes between where the role of surgery is 
clear-cut and where it is less so.
Meigs, from the United States in the 1940’s, first described the concept of surgical 
cytoreduction, also known as debulking, and coined the phrase ‘maximal surgical effort’ 
(Meigs 1940). He described the use of surgical removal of the omentum, omentectomy, 
to provide palliation and reduce the accumulation of ascites. He noted that this palliative 
surgery when combined with radiotherapy resulted in prolonged patient survival. Other 
authors around the same time reinforced this idea (Pemberton 1940). Munnell reported a
27
series of 235 patients and argued that survival rates of up to 40% at 5-years were 
achievable (Munnell 1968). This seems improbable, certainly in the light of the 
population based survival figures discussed earlier. It is possible that these favourable 
survival data were a reflection of the case mix of this series.
Maximal surgical debulking and minimal residual disease
It would appear in summary that the concept of surgical cytoreduction, also known as 
debulking, in ovarian cancer arose from observations of the effect that palliative 
surgical procedures had on survival. Griffiths (Griffiths, Grogan, & Hall 1972) 
introduced the concept of maximal surgical debulking and minimal residual disease in 
the 1970’s. In a series of 102 patients with advanced ovarian cancer (Griffiths 1975) 
survival was corrected for multiple factors. Maximum size of residual disease, and 
histological grade were independent predictors of survival. This analysis suggested that 
surgery had to reduce the maximum diameter of remaining disease to less than 1.5cm in 
diameter in order to confer clinical survival benefit. He showed that the average survival 
time in advanced ovarian cancer was inversely proportional to the maximal diameter of 
the residual tumour volume remaining after surgery, but that this relationship held true 
only up to tumour diameters of 1.6cm. If the remaining disease was greater than 1.6cm 
then patient survival greater than 26 months was rare. This paper has been a main 
influence that has defined current surgical management of advanced ovarian cancer and 
is cited in most publications advocating aggressive surgical debulking. The only other 
tumour that debulking appears to have been of benefit was Burkitt’s lymphoma 
(Magrath et al. 1974). This was a small retrospective observational study and only 
complete resection of tumour provided survival benefit.
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From those observations of surgical debulking, showing that residual disease status was 
associated with survival arose the assumption that more aggressive surgery would cause 
a better survival outcome: that if the maximum diameter of residual disease could be 
reduced to a certain level survival benefits would ensue. Subsequent publications 
defined what the aims of surgery should be and how this should be achieved. Griffiths 
reported that optimal cytoreduction was achieved in 12 out of 15 patients (80%) 
(Griffiths, Parker, & Fuller, Jr. 1979). It was noted that patients who had maximal 
cytoreduction surgery followed by adjuvant chemotherapy did best in terms of survival. 
It is of note that this observation was made with only 9 patients. This contrasts with the 
large numbers in more recent series, and as such the confidence in the precision of 
results must be questioned.
Evidence for primary cytoreduction
There are over 40 publications describing clinical series that support the notion of 
aggressive surgical debulking. These studies are summarised in Figure 1.3-4, which lists 
studies that provide evidence for surgical debulking. The methods used in these studies 
are similar. They are mostly, retrospective case note reviews from single institutions, 
usually from the United States and often from well-known cancer centres. Clinical 
factors such as patient age, stage, histological grade, and residual disease status are 
modelled against survival using a multivariable survival model such as Cox’s 
proportional hazards model (Cox 1972).
Almost all of the publications are consistent in reporting the association of optimal 
residual disease status (the diameter of the largest volume of remaining disease being 
less than 1.5 or 2 cm depending on the authors’ definition) with improved survival. In 
the larger retrospective series that have published hazard ratios, the relative hazard ratio
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between optimal and sub-optimal cytoreduction is between 2 and 3. In one study using a 
cut off of 2cm maximum diameter of residual disease the hazard ratio was 2.16 
(95%CI= 1.3 to 3.5) (Gadducci et al. 1998)
Comparing these studies is made difficult due to the heterogenous nature of the patient 
selection and wide differences in chemotherapy used.
There are two important weaknesses of this literature. The methods used to determine 
the diameters of remaining tumour are infrequently described in sufficient detail to 
allow assessment of the accuracy of the stated maximum tumour diameter used as an 
independent variable in the analysis. Secondly, in almost all the publications the 
association between residual disease, following debulking, and survival is used to 
justify aggressive attempts to cytoreduce patients’ tumours to the optimal level. The 
assumption is that this will result in prolonged survival. Whilst this may be true most 
studies do not attempt to justify the causality other than through the demonstrated 
association. These two weaknesses will be discussed further in separate sections of this 
thesis.
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Figure 1.3-4: studies that demonstrate an association between primary surgical 
cytoreduction and improved survival in patients with ovarian cancer.
Date Author/s Study Type Number of 
patients
1968 (MunnelU968) H 235
1972 (Griffiths, Grogan, & Halll972) H 60
1975 (Griffiths 1975) H 102
1979 (Griffiths, Parker, & Fuller, Jr. 1979) H 26
1989 (Krag et al. 1989) H 107
1983 (Hacker et al. 1983) H 47
1984 (Delgado, Oram, & Petrilli 1984) H 142
1985 (Einhom, Nilsson, & Sjovall 1985) P 770
1986 (Heintz et al. 1986) H 70
1987 (Gallion et al. 1987) H 32
1988 (Heintz et al. 1988) H 65
1990 (Bertelsen 1990) T 361
1990 (Marsoni et al. 1990) T 914
1990 (Tummarello et al. 1990) H 40
1991 (Neijt et al. 1991) H 307
1991 (Potter et al. 1991) H 302
1992 (Goodman et al. 1992) H 35
1992 (Hoskins et al. 1992) T (GOG52) 349
1993 (Eisenkop et al. 1993) H-case control 67
1993 (Hogberg, Carstensen, & Simonsen 1993) P 332
1993 (Khoo et al. 1993) H 133
1994 (Baker, Piver, & Hempling 1994) H 136
1994 (Del Campo et al. 1994) H 91
1994 (Farias-Eisner et al. 1994) H 112
1994 (Hoskins et al. 1994) T (GOG97) 294
1994 (Venesmaa 1994) H 523
1995 (Makar et al. 1995) H 455
1995 (Warwick et al. 1995) H 362
1996 (di Re et al. 1996) H 488
1997 (Curtin et al. 1997) H 105
1997 (Liu et al. 1997) H 47
1997 (Munkarah et al. 1997) H 108
1998 (Eisenkop, Friedman, & Wang 1998) H 163
1998 (Gadducci, Sartori, Maggino, Zola, Landoni, 
Fanucchi, Palai, N, Alessi, Ferrero, Cosio, & 
Cristofanil998)
H 192
1999 (Bonnefoi et al. 1999) H 192
1999 (Bristow et al. 1999) H 84
1999 (Kapp et al. 1999) H 46
1999 (Peters-Engl et al. 1999) H 210
1999 (Zang et al. 1999) H 73
2000 (Brun et al. 2000) H 287
2000 (Naik et al. 2000) H 37
2000 (Scarabelli et al. 2000) H 66
GOGxx=gynaecological oncology group trial number xx; H=hospital based study; T=clinical trail; 
P=population based study.
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Significance of residual disease as a prognostic factor
Accuracy o f  measurement
Most of the literature (Figure 1.3-4) fails to describe the exact methods that were 
undertaken to establish the maximum diameter of the residual disease at the end of 
surgery. This is important for several reasons. Accurate assessment of the residual 
tumour volume is necessary for accurate classification. This is particularly important for 
residual tumour volumes that were close to the defined cut off. Without accurate 
classification the significance of residual disease as an important prognostic factor must 
be questioned. One of the problems is that most of the studies are retrospective and 
some cover periods greater than 10 years prior to publication of the study. Thus the 
categorisation will be biased by the subsequent interpretation of the surgeons’ operation 
record.
The accuracy of categorisation will depend upon the thoroughness of the surgeon both 
in staging and documenting the findings. Although the literature does not allow an 
objective assessment, this is likely to have been variable both within studies and 
between studies. One study the GOG-97, which will be discussed in more detail later, 
(Hoskins, McGuire, Brady, Homesley, Creasman, Berman, Ball, & Berekl994) is 
unique in so far as the data were collected prospectively as part of a clinical trial and as 
such standardised staging proformas were used. Thus prospective data collection where 
standardised proformas were used is likely to achieve a greater accuracy and thus 
validity compared to retrospective studies. This issue is of relevance to the studies 
presented in this thesis.
A second reason to question the accuracy of categorisation is the lack of an independent 
secondary measure to assess the accuracy of the recorded residual disease. The studies
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presented in this thesis particularly, that in chapter 4 and to a lesser extent that in 
chapter 2, attempt to address this.
The third problem relates to the methods used by surgeons to measure the residual 
disease. Again this is not stated in any of the literature examined. The author’s 
experience is that assessment of residual disease is based upon a visual estimate by the 
surgeon: no ruler is used. It is likely that many cases with residual disease diameters 
around 2cm will be miscoded. If the prognostic significance of a maximum residual 
disease diameter of 1.5cm vs 2.5cm was significant both statistically and clinically then 
this might have important implications for the interpretation of the literature. Indeed 
accurately defining the cut off in retrospective studies probably imparts a false 
accuracy.
What is it a surrogate of?
Although the literature categorises patients according to the maximum diameter of 
residual disease and then draws inferences about optimal surgical mangement from this 
there is a large gap in the literature regarding what this cut off actually means. This is 
important in the discussion of how accurately tumour needs to be measured. Visible 
tumour exists as groups of cells and this represents a three-dimensional volume. The 
biological theories for the efficacy of surgical debulking are outlined later in this thesis. 
However the important factor in several of the theories is the actual number of tumour 
cells. The published literature fails to account for this. Indeed using a defined cut off of 
say 2cm introduces further inaccuracy whilst giving the impression of precision. This is 
illustrated schematically in Figure 1.3-5.
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Why is it so important?
The literature imparts a great significance on the maximum diameter of residual disease 
because it is the only prognostic factor that the surgeon has any direct control over. 
Indeed it is the only direct measure, which is consistently used in the literature, of the 
extent of surgical intervention. Moreover it is the only current surgical marker that one 
can strive to improve. Other surgical prognostic markers will be explored in the studies 
presented in this thesis.
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Figure 1.3-5: schematic diagram illustrating the relationship between tumour 
diameter, tumour volume and number of tumour cells.
Schematic diagram of tumour 
(maximum diameter of residual tumour^
Volume of tumour Approximate number of
tumour cells9
Single plaque of tumour: RD<2cm
< 2cm >
Single block of tumour: RD <2cm
< 2cm >
Multiple tumour seedlings: RD<2cm
O
< I cm > 
Single plaque: RD>2cm
X 100
<2 x 1 x 0.5cm=<lcnT
<2 x <2 x <2cm=<8cm
(1 x 1 x 0.5) x 100=50cm
4 x 1 x 0.5cm=2cm ’
1 x 10s
9 x 1 0
5 x 1 0 10
2 x 1 0
< 4cm > 
Abdomen with bulk disease: RD>2cm
4 x  10 12
This schematic diagram shows the relationship between the maximum diameter of 
residual disease and the volume of tumour and thus the number of tumour cells 
remaining. This shows that using a single one-dimensional estimate is only a rough 
indicator of the number of tumour cells.
_  Omental cake:
30 x 10 x 5cm= 1500cm1
Pelvic mass:
20 x 10 x 10cm=2000cm’
Total tumour 
burden=3 500cm'
9 Estimate on basis that 1cm3 tumour represents 30 cell doublings(DiSaia & Creasman 1997b)
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Summary
It is likely that many of the patients included in studies examining the association of 
maximum diameter of residual disease and survival will have been mis-classified. It is 
difficult to ascertain the extent to which this might have occurred in the published 
studies and to what extent this potential inaccuracy might have on the results and their 
subsequent interpretation. These factors are discussed further in the studies presented in 
this thesis.
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Is the association o f residual disease with survival causal or confounding?
A fundamental question, that has only been partly resolved is whether the
cytoreducibility of a patient’s tumour is a reflection of the patient’s disease status and
tumour biology; the later influencing patient survival (Zanaboni et al. 1988), (Hogberg
1995), (Covens 2000), (Kehoe 1996). In other words whether a surgeon can actually
remove sufficient tumour, so that the maximum diameter is less than a certain threshold,
is determined by the nature of the tumour not the skill of the surgeon. The alternative
hypothesis is that cytoreduction is the primary determinant of patient survival per se:
that reducing the volume of tumour to a certain threshold imparts a distinct survival
advantage. This concept has been inadequately addressed by most all of the many
published series. The problem is that associations are seen yet causation is being
assumed (Katz1999a). This is a fundamental weakness of the literature as it stands
regarding the association of primary cytoreductive surgery and survival. Although the
literature is consistent this does not fully inform us whether cytoreduction is the cause
of better survival or is merely an epiphenomena in those patients who were going to
have more favourable survival times anyway. This is a statistical problem of
confounding variables yet these assumptions have dictated the surgical gold standard in
ovarian cancer for over three decades. This is shown diagrammatically in Figure 1.3-6.
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Figure 1.3-6: the debulking-survival problem.
Causal ?
Patient factors/ 
Tumour biology
Patient disease 
status
Surgery resulting in
Optimal debulking
. . .
better’ survival
results
better’ survival
Patient disease 
Status &
tumour 
in
Or Confounding?
Patient factors/ 
Favourable
tumour biology 
-eg adherence, 
etc
/  Facilitates
surgery that results in 
\  Optimal debulking
This diagram illustrates two possible explanations for the association between optimal 
debulking and better survival. Surgical debulking may be a direct causal factor or could 
be a proxy marker for characteristics of the disease that would have resulted in better 
survival whatever had been achieved at surgery.
38
Although it is difficult to prove causality outwith a randomised trial, which may at 
present be unethical, there are several factors that can increase the certainty of this 
(CSO-Scotland 1998). These are summarised in figure 1.3-7.
Figure 1.3-7: criteria that support causation
Required Criteria_____________________________ Desirable evidence____________________
S ize o f  effect Large, R elative R isk >2
Strength o f  association P value<0.05
C onsistency o f association R eproducible association in many studies
Specificity  o f association E ffect from a single cause
Tem porality Cause precedes effect
B io log ica l gradient E vidence o f a dose-response effect
B io log ica l plausibility R easonable explanatory m odel
(CSO-Scotl and 1998).
Whilst the published retrospective hospital series satisfy the first three criteria, 
substantiating the other factors requires differing approaches. The literature is weak 
from this perspective and the evidence that exists is now discussed.
Meta-analysis
There are three meta-analyses. Hunter (Hunter, Alexander, & Soutter 1992) 
hypothesized that if maximum cytoreduction conferred survival benefit to patients, then 
the median survival time of groups of patients should increase as the proportion of 
patients that receive optimal cytoreduction increases. This meta-analysis was in effect 
looking for evidence of a dose-effect relationship. Fifty-eight studies containing 6962 
patients were reviewed and multiple linear regression was used to determine whether 
studies, where a high proportion of women had been debulked to beneath defined cut 
offs, survived longer. The authors found a small positive correlation showing that 
cytoreduction improved survival. This showed that there was a 4.1% [95% confidence
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interval was -0.6 to 9.1%] increase in median survival time, for the patients in the 
studies examined, with each 10% increase in maximum cytoreductive surgery. After 
correction for chemotherapy this became statistically non-significant. However it is of 
note that the effect of platinum chemotherapy was shown to be more important. The fact 
that the correlation was slight is not surprising. Two larger retrospective series that have 
published hazard ratios, show that the relative hazard ratio between optimal and sub- 
optimal cytoreduction was 2.16 (95%CI= 1.3 to 3.5) (Gadducci, Sartori, Maggino, Zola, 
Landoni, Fanucchi, Palai, N, Alessi, Ferrero, Cosio, & Cristofanil998) and in another 
was reported as 2.3 (95%CI=1.6 to 3.4) (Brun, Feyler, Chene, Saurel, Brun, & 
Hocke2000). Published series generally have high proportion of patients who are 
optimally cytoreduced thus the difference in relative hazard ratio between the published 
series is likely to be small. This point is shown schematically in Figure 1.3-8. What is 
important is that a biological gradient was seen. This contributes towards the argument 
of causation.
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Figure 1.3-8: diagram illustrating effect of differences in proportion of patients 
optimally cytoreduced and differences in the relative hazard ratio between 
studies.
Relative hazard ratio
study B
0.5
study A
100 90 80 60 40 10 070 50 30 20
proportion of patients within group who are optimally cytoreduced
This graph shows schematically the relationship between the different 
proportions of patients optimally debulked and the relative hazard ratio 
[RHR] between two groups of patients. This is based on an estimate of 
the relative hazard ratio of a patient who is not optimally debulked [ie 
100% of a group of 1 patient] being 2.5 relative to a patient who is 
optimally debulked (Brun, Feyler, Chene, Saurel, Brun, & Hocke2000). 
This shows that studies or groups of patients may differ considerably 
in the proportion of patients who are optimally debulked however there 
may be relatively small effect on the relative hazard ratio between the 
groups.
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Voest (Voest, van Houwelingen, & Neijt 1989) combined the results from 38 studies, 
representing 3443 patients, to create one survival curve. The association of residual 
disease status along with the other prognostic factors was then related to survival in a 
multivariate survival model. Only residual disease status and the use of cisplatinum 
chemotherapy were found to be significant prognostic factors.
Allen (Allen, Heintz, & Touw 1995) combined published series and personal 
communications of patients with FIGO stage III and IV only. 2659 patients were 
grouped. The association with optimal cytoreduction, at the <2cm cut-off, was 
calculated for both stage III and stage IV patient groups. The Odds ratio for optimal 
cytoreduction, showed improved survival at 2-years, for stage III disease was calculated 
as 3.98(95%CI=3.31 to 4.79) and 5.51(95%CI=4.4 to 6.9) at 5-years.
These meta-analyses by Voest and Allen confirm the findings from the various clinical 
series and confirm the strength of association to be both statistically significant and of a 
large magnitude. However the meta-analysis by Hunter (Hunter, Alexander, & 
Soutterl992) adds to our understanding of the causal effect of surgical debulking. 
Nevertheless this is small.
Other studies contributing to interpretation o f  the association o f debulking and 
survival.
There are other studies that contribute to our understanding of the importance of 
surgical debulking. The population-based study of all patients diagnosed with ovarian 
cancer in Scotland in 1987,1992-4 (Junor, Hole, McNulty, Mason, & Youngl999a) also 
suggests a dose-response effect. In this study, patients operated on by specialist 
gynaecologists were found to survive longer. Subgroup analysis by FIGO stage and 
residual disease status showed that this survival advantage was confined to patients with 
FIGO stage III disease who were not optimally cytoreduced; having residual disease
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diameters greater than 2cm. The interpretation of this finding was that in cases that were 
difficult to optimally cytoreduce, specialists were more effective at attempting to 
cytoreduce than their generalist colleagues. This study contributes to the evidence for 
causality. The biological gradient that is suggested here is that it is the relative 
reduction of tumour bulk that is important rather than the ability to reach an absolute 
size of residual disease. This would contradict earlier studies that argue for an ‘all-or- 
nothing’ benefit (Griffithsl975), (Hoskins, McGuire, Brady, Homesley, Creasman, 
Berman, Ball, & Berekl994). Chapter 2 of this thesis presents a follow-on Scottish 
population study that attempts to identify the specific elements of specialist surgery that 
may have contributed to improved survival.
Hoskins (Hoskins, McGuire, Brady, Homesley, Creasman, Berman, Ball, & Berekl994) 
analysed data collected within a carefully conducted prospective chemotherapy trial. An 
entry criterion to the gynaecological oncology group (GOG-97) trial was a specific 
requirement that patients’ residual disease status be accurately defined. This allowed the 
authors to evaluate the effect of specific diameters of residual disease on survival. This 
data is shown in figure 1.3-9.
This data would appear to support the observations of Griffiths (Griffiths 1975) by 
showing an inverse relationship between maximum diameter of residual tumour but 
only up to just less than 2cm.
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Figure 1.3-9: relative hazard ratio of optimal and suboptimally cytoreduced 
patients after primary surgical debulking recruited to the GOG-97 trial.
0
0 1  2 3 4 5 6 7 8 9  10
Maximum diameter of residual disease tumour (cm)
source: (Hoskins, McGuire, Brady, Homesley, Creasman, Berman, Ball, & Berek1994)
This graph shows the relationship between relative hazard ratio (RHR) 
and the maximum diameter of the residual disease after surgery for 
patients recruited into the GOG-97 trial. This shows that patients with 
maximum residual disease diameters of greater than 2cm at the end of 
laparotomy with a RHR (reference group <2cm) of approximately 2. 
There is no change in the relative hazard ratio for maximum diameters 
of residual disease over 2cm.
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Another analysis by Hoskins (Hoskins, Bundy, Thigpen, & Omural992) from the 
GOG-52 trial argues against the magnitude of the benefit suggested by the proponents 
of cytoreduction. One of the entry criteria for the GOG-52 trial was debulking to less 
than 1cm. Multivariate survival analysis was performed to explore the association 
between the volume of disease present before cytoreduction to overall survival. Three 
hundred and forty nine cases that presented with FIGO stage III were analysed. The 
volume of initial disease was found to be inversely associated with survival despite 
optimal cytoreduction being performed on all patients in the trial. This study is 
important because it increases the likelihood of the ‘achievability’ of the surgical 
cytoreduction being a ‘permissive function’ of the tumour biology. This does not 
however argue against the benefit of cytoreduction since all patients in the GOG 52 trial 
were optimally cytoreduced. What is suggested is that the initial volume of disease is an 
additional independent factor that explains some of the variation in survival.
Prospective clinical trials
The strongest piece of evidence supporting the hypothesis that surgical cytoreduction is 
responsible for increased patient survival is from one prospective randomised study of 
interval debulking surgery (van der Burg et al. 1995). Interval debulking surgery 
describes the situation where a patient is re-operated upon mid-way through the 
adjuvant chemotherapy regime. It is sometimes considered in patients in whom optimal 
cytoreduction has not been possible. Three hundred and nineteen patients were 
randomised to further surgery in the form of interval debulking surgery or to no further 
surgery. The absolute survival of patients at two years who received this surgery [56%] 
was greater than those patients who did not receive surgery [46%] and when 
multivariate survival analysis was used, interval-debulking surgery (irrespective of its 
success or otherwise) was associated with prolonged survival [p=0.012]. Although this
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was not a randomised study of primary cytoreduction it is the most quoted direct 
evidence in the literature of the efficacy of surgical cytoreduction.
A similar earlier prospective randomised study showed no benefit of interval debulking 
surgery (Redman et al. 1994). It is likely that this study was significantly underpowered, 
as only 79 patients were recruited, however the survival trend between the two arms, 
although not statistically significant, corroborates the previously described study (van 
der Burg, van Lent, Buyse, Kobierska, Colombo, Favalli, Lacave, Nardi, Renard, & 
Pecorellil995).
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Biological theories for the efficacy of surgical cytoreduction
If cytoreduction is an independent factor improving survival rather than a proxy marker 
for better tumour factors then there should be evidence of a biological basis. There are a 
number of theories and these have been previously reviewed (Hacker 1989), (van der 
Burg 2000).
The efficacy of surgical debulking is thought to relate to how chemotherapy is believed 
to work.
Ovarian cancer is partially chemosensitive. If it were completely chemosensitive, 
surgery would have no place to play in the management of the disease. The perfusion 
and cell kinetic theory argues that cytoreductive surgery increase the chemosensitivity 
of the tumour and hence increases cell kill. This theory acknowledges that in large bulk 
disease most of the tumour cells are in the resting phase of the cell cycle. Cells in this 
phase are less susceptible to chemotherapeutic agents that rely on cell division to be 
effective. Surgically removing a large proportion of a tumour mass has the effect of 
inducing the remaining cells to transform from the resting phase to the growth phase of 
the cell cycle and thus increasing their chemosensitivity (DiSaia & Creasman 1997b). If 
this theory were true then cytoreduction to volumes greater than 1.5 or 2 cm should 
provide therapeutic benefit. Also if this is the true mechanism of action then an attempt 
to cytoreduce all discrete volumes should be undertaken, even if optimal cytoreduction 
is not possible, in order to induce tumour cells from each discrete volume of tumour to 
become active. Moreover the independent effect of surgery would only be expected if 
surgery were followed up by chemotherapy. If this theory were true then one would 
expect such surgically induced chemo-sensitising to occur in other advanced solid
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tumours types that have some susceptibility to chemotherapy. There is no evidence 
either in current clinical practice or in the literature to support this.
Another theory is that surgery might act to reduce the number of tumour cell clones. 
The proponents of this theory argue that this would reduce the likelihood of chemo- 
resistance by the tumour. This theory requires the reduction of a large proportion of the 
volume of the tumour. If this theory is true then what is important is that the large 
volumes of tumour are removed. As illustrated schematically in figure 1.35 it is unlikely 
to matter significantly that a tumour is debulked to 1.5cm compared to 2.5cm what is 
important is that large volumes such as pelvic masses of omental cakes are removed. 
This is contradicted by the data presented from the GOG-97 trial (Hoskins, McGuire, 
Brady, Homesley, Creasman, Berman, Ball, & Berekl994) and shown in figure 1.3-9.
In summary the exact mechanism through which surgical debulking is thought to be 
effective has not yet been established. Although there are plausible theories, the lack of 
an exact mechanism makes it more difficult to establish whether the association 
between debulking and improved survival is causal or not.
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Tinning of surgical cytoreduction
Surgery in ovarian cancer is unlike that in other common solid tumours where the 
timing and use of surgery is generally well defined relative to other treatments. The 
reason that there are a number of times when surgery has been proposed possibly 
reflects the eagerness to ensure that the patient has an opportunity to be cytoreduced to 
optimal levels.
Primary cytoreduction
Primary cytoreduction has been discussed previously but is mentioned here for 
completeness. In very early ovarian cancer FIGO stage la [see appendix for definition] 
staging is of key importance. The accurate definition of such early stage disease is one 
of exclusion and the purpose of surgery is to ensure that all possible sites of metastatic 
spread are reviewed and biopsied (Trimbos et al. 1991),(Zanetta et al. 1998). In very 
early ovarian cancer, surgery offers the prospect of cure.
Interval debulking surgery
Interval debulking surgery describes a second attempt at cytoreduction in a patient 
whose initial laparotomy did not result in optimal cytoreduction. Interval debulking 
surgery is performed mid-way through a course of chemotherapy, after the third or 
fourth pulses. There is good quality evidence from a randomised trial for the efficacy of 
this, and this has been discussed previously (van der Burg, van Lent, Buyse, Kobierska, 
Colombo, Favalli, Lacave, Nardi, Renard, & Pecorellil995).
Delayed primary surgery
Neoadjuvant chemotherapy followed by cytoreduction describes the situation where a 
patient is unable to be considered for primary cytoreductive surgery before adjuvant 
chemotherapy. This is generally where the patient’s condition due to advanced disease
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or co-morbidity is such that surgery is considered too hazardous. One small case- 
controlled study reported that there was no survival difference between primary surgery 
followed on by adjuvant chemotherapy compared with neoadjuvant chemotherapy 
followed on with surgery inpatients with advanced disease (Jacob et al. 1991). Although 
there was no statistically different survival difference only twenty two patients were 
reviewed and this may have been underpowered to demonstrate a difference if this were 
to exist. More recently, a retrospective case-controlled study, could find no survival 
differences between neoadjuvant treatments compared with the current conventional 
management (Schwartz et al. 1999). Again the numbers are small and there is the 
danger that it could have been underpowered. There have not been any randomised 
trials. Despite this neoadjuvant chemotherapy is a pragmatic approach that attempts to 
induce a period of remission in patients who in general have poor performance status.
Second look surgery
The aim of second-look surgery in ovarian cancer was to detect and treat recurrences in 
a pre-clinical state. Rutledge & Bums introduced the procedure into ovarian cancer 
(Rutledge & Bums 1966). The initial aim of second look procedures was surveillance 
only without any intention of cytoreduction. Several authors advocated further 
cytoreduction if disease was found (Lippman et al. 1988), (Hoskins et al. 1989). 
However several studies found that the role of secondary cytoreduction was less clear 
(Lawton et al. 1990), (Tuxen et al. 1993), (Redman et al. 1990).There has been one 
randomised trial of second look laparotomy, which demonstrated no survival benefit 
(Luesley et al. 1988). Overall the evidence for the efficacy of this is mixed 
(Sonnendecker & Beale 1987) and the current consensus is that second look procedures 
add little value out with the clinical trial environment. Laparoscopy as a tool to assess 
the extent of disease has limitations in terms of accuracy (Clough et al. 1999).
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Achievability of primary cytoreduction
Several authors have argued that optimal cytoreduction is possible in up to 85% of 
patients (Hacker1989) and is safe to do (Hempling, Wesolowski, & Piver 1997), 
(Venesmaa & Ylikorkala 1992). Data from a population based study in Scotland 
however showed that optimal debulking was possible in 37% of patients with stage 3 
disease (Junor, Hole, McNulty, Mason, & Young1999a). Optimal cytoreduction is an 
issue because it is difficult to achieve. The intra-abdominal organs are often adherent 
forming a solid mass that obliterates the normal tissue planes between organs. Surgical 
approaches such as the retroperitoneal approach to the pelvis have been described in the 
literature (Hudson & Chir 1973), (Wharton & Herson 1981), (Benedetti-Panici et al. 
1996). Despite significant intraperitoneal tumour, satisfactory surgical tissue planes can 
often be found beneath the peritoneum. The use of this approach requires a familiarity 
with the retroperitoneal anatomy of the pelvis. Specialist gynaecological surgeons are 
generally familiar with this anatomy (Society of gynaecological oncologists 2000) 
however the ‘generalist’ performing few radical procedures will rarely be familiar with 
this approach. This hypothesis is explored further in Chapter 2 of this thesis where the 
surgical approach of generalists and specialists will be presented.
The proportion of cases that could be debulked to less than the optimal cut off (1.5 or 
2cm depending upon the series) varies between published clinical series. These 
differences may reflect case mix but possibly reflect the philosophy and ability of the 
surgeons involved. It is likely that the proportion of patients who are optimally 
debulked in the total population will be less than these reported series. This is because 
series are unlikely to be published by surgeons performing few cases or who have a 
small proportion of cases who were optimally debulked.
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Over the past decade there have been reports of progressively more radical surgical 
debulking procedures. It is generally accepted that bowel resection is often required 
(Heintz, Hacker, Berek, Rose, Munoz, & Lagassel986) either to relieve obstruction or 
to facilitate cytoreduction (Eisenkop, Nalick, & Teng 1991). However more aggressive 
procedures such as splenectomy (Chen et al. 2000), (Gemignani et al. 1999) and 
diaphragramatic resection (Kapnick, Griffiths, & Finkler 1990) have been advocated to 
achieve these goals. The evidence for some of these procedures is limited and there is 
concern that there may be an inappropriate focus on technical feasibility rather than 
what is optimal from a patient’s perspective (Potter, Partridge, Hatch, Soong, Austin, & 
Shingletonl991). If cytoreduction is of primary benefit then surgery should proceed to 
that point where the marginal benefit from proceeding equals the marginal risk to the 
patient. This point is not easy to define and the literature does not contribute much to 
this. Griffiths (Griffiths 1975) defined 1.5 cm as the goal, but this can only be considered 
as a guide. Often it is impossible to debulk to anywhere near this figure without serious 
morbidity and in cases where it is easy to debulk it would seem unreasonable to stop at 
this figure.
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Summary
The evidence for surgery in the management of ovarian cancer is accepted but is not 
without controversy. The literature has become confused between the association of 
optimal debulking and survival and the subsequent justification of aggressive surgical 
debulking as a treatment modality that will result in better survival. Chapter 2 will 
present a Scottish population based study that makes use of variations in surgery 
performed by specialist and general gynaecologists and will explore whether these 
variations are associated with variation in survival outcome. The aim of Chapter 4 of 
this thesis is to explore the hypothesis that if surgery is important, and if the population 
survival differences are true, then there should be differences in the quality of the 
surgery that is performed between these populations and this should be reflected in 
survival.
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1.4 Overview of ovarian cancer
Incidence
Epithelial cancer of the ovary is the most common gynaecological malignancy. 
Malignant epithelial tumours account for about 85% of ovarian cancers (DiSaia & 
Creasman 1997c), there are many other histological types but these will not be 
discussed further (DiSaia & Creasmanl997c). It is the fourth most common female 
cancer in the UK (Coleman et al. 1999b), and around 550 new cases are diagnosed in 
Scotland each year (ISD-Scotland2000b). This relative incidence is similar to that in 
other Western countries. The incidence rises with age to reach its maximum incidence 
in the sixth decade when incidence declines slightly (ISD-Scotland2000b). The tumour 
is rare under the age of 40 years.
Spread
Ovarian cancer is thought to arise from the epithelial surface of the ovary then spreads 
by extension and trans-coelomic spread. Most patients present with advanced disease 
where the tumour has spread from the pelvis to structures in the abdomen. It tends to 
coat and adhere to the peritoneal surfaces of structures rather than infiltrating them per  
se. Fixed pelvic masses commonly arise due to tumour encasing the uterus and adnexae 
to the walls of the pelvis. The omentum in the abdomen is an early site of trans- 
coelomic metastases and in advanced disease the omentum forms a ‘cake’ of tumour, 
which is frequently adherent to the transverse colon and splenic hilum.
Staging
The disease is staged according to the International federation of Obstetrics & 
Gynaecology [FIGO] staging system (Shepherd 1989b). This is shown in Appendix 1. 
This is a surgical-pathological staging system that requires the findings at laparotomy as 
well as histo-pathological data to define the stage.
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Clinical presentation
Patients usually present with advanced disease. Within in Scotland 60% were found to 
present with FIGO stage III disease (Junor, Hole, McNulty, Mason, & Young1999a). 
Despite extensive tumour load and infiltration of the peritoneal surfaces of many 
important organs patients frequently have relatively innocuous symptoms (Wikbom, 
Pettersson, & Moberg 1996) and this delays the presentation. The symptoms frequently 
encountered include non-specific ache, abdominal distension and non-specific bowel 
and bladder dysfunction. Only in late stages do patients present with significant pain, 
bowel obstruction and cachexia (DiSaia & Creasmanl997c).
Aetiology
The aetiology in 95% of patients is unknown. In 5% there is a genetic predisposition 
(Holschneider & Berek 2000). The BRCA1&2 genes are implicated in such patients and 
these frequently have family histories of early onset breast and ovarian cancer in their 
female members (Buller 2000). It is known that late menarche; early menopause, 
multiparity (DiSaia & Creasman1997c) and the use of the combined oral contraceptive 
(Hankinson et al. 1992) are associated with a reduced incidence. It is thought that the 
common factor of these associations is a reduction of the number of ovulations 
throughout a woman’s life. The implication being that ovulation, through increased cell 
division, increases the risk of genetic damage to the surface epithelium (Holschneider & 
Berek2000).
Histopathology
Histologically epithelial ovarian cancer is an adenocarcinoma and there are several 
different subtypes. The most common type is serous adenocarcinoma but other types 
include mucinous, papillary-serous, clear cell and anaplastic (DiSaia & 
Creasman 1997c). These have slightly different natural histories but are commonly
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grouped together. The international classification of diseases code for these tumours is 
ICD 9-183. It is common for the tumour to be graded according to the degree of 
differentiation seen on histology. These grades are known to be prognostically 
important (DiSaia & Creasmanl997c).
Borderline ovarian tumours
It is important to introduce borderline tumours. Their classification is complex and often 
difficult (Manek & Wells 1999). Their natural history is significantly different from the 
epithelial ovarian carcinoma. Their recognition is important, as the overall 5-year 
survival is good 87.6% versus 48.4% for malignant tumours (FIGO2001). If borderline 
tumours are included in published survival data they will both reduce the apparent rate 
of patients dying as well as increasing the overall proportion of patients surviving in the 
long term.
Pre-operative diagnosis
The pre-operative diagnosis of the ovarian cancer is usually by a combination of clinical 
suspicion, radiology including ultrasound and CT-scanning and the use of tumour 
markers such as CA-125 (Markman 1996). A ‘risk of malignancy score’ (RMI), based 
on serum CA125, menopausal status and ultrasound findings, has been devised as a 
method of increasing the accuracy of pre-operative diagnosis (Jacobs et al. 1990). 
However diagnostic certainty is often not possible until laparotomy and sometimes not 
until pathological review.
Potential fo r  screening
No evidence for population screening currently exists for ovarian cancer. However, a 
large Medical Research Council funded prospective trial [United Kingdom-Trial Of
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Cancer Screening (UK-TOCS)] involving 120,000 females has recently commenced 
(Jacobs 1998).
In those patients with a likelihood of a hereditary predisposition, genetic screening has 
been performed on an ad hoc basis using screening for the common variants of the 
BRCA1&2 genes. Mutations of these genes increase the likelihood of developing a 
tumour (Buller2000). Testing for mutations of these genes have enormous ethical 
problems and adequate strategies for the management of patients found to be a risk have 
not yet adequately been defined. Indeed without adequate evidence for the efficacy of 
treatment in those found to be positive for such mutations great caution is required 
(Berchuck et al. 1996).
Management
Treatment of ovarian cancer is bimodal with a combination of surgery and 
chemotherapy. The aim of surgery is firstly to make the diagnosis, accurately stage the 
patient particularly in early stage disease and either completely resect the tumour or 
more commonly reduce the volume of tumour. The role and evidence for surgery is 
discussed in detail later in this chapter. The usual overall aim of surgery is to facilitate 
the efficacy of adjuvant chemotherapy thus achieving a useful period of clinical 
remission and to prolong survival. The current ‘gold-standard’ chemotherapy is 
combination chemotherapy with a platinum/ Taxol combination. Chemotherapy will be 
discussed more fully in chapter 1.4. Most patients diagnosed with all but very early 
stage ovarian cancer will relapse at some point. Second line chemotherapy will often be 
required (Gore 1999).
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Prognosis
The overall prognosis is poor with European population based relative 5-year survival 
of between 25-45% [Figure 1.2-2.]. Survival is dependent on FIGO stage at 
presentation and the data from FIGO10 is shown in figure 1.4-1.
Figure 1.4-1: table showing 5-year survival according to FIGO stage at diagnosis.
FIGO stage at diagnosis 5-year survival (%)
la 89.9
lb 84.7
Ic 80.0
Ha 69.9
lib 63.7
lie 66.5
Ilia 58.5
Illb 39.9
IIIc 28.7
IV 16.8
Source: (FIGO2001)
Although the 5-year survival figure is the universal benchmark of cancer survival, this 
is not a particularly good figure for ovarian cancer where most patients do not achieve 
5-years survival. The median survival is more meaningful. Using this measure, survival 
in Scotland has shown a small but steady increase since the 1970s (ISD- 
Scotland2000b). Figure 1.4-2 shows this.
10 FIGO data is not population based and is derived from specialised reporting centres
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Figure 1.4-2: improvements in median survival of patients with ovarian cancer in 
Scotland.
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This barchart shows median survival times for patients aged 15 to 74 
registered with Scottish population based cancer registration. There 
have been continual improvements, of around 1 year, in the median 
survival of patients since the early 1970s in patients with ovarian 
cancer in Scotland.
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1.5 Chemotherapy in the management of ovarian cancer
Evolution of chemotherapy for epithelial ovarian cancer
Chemotherapy, the clinical application of the chemical treatment of cancer was first 
appreciated in the 1940’s as a by-product of wartime chemical warfare research (Rhoads 
1946), although there is anecdotal evidence that chemicals such as potassium arsenite 
were being tried in leukaemia as early as 1865 (Friedman 1965). The observation of 
haematological suppression after the inadvertent exposure of sailors to mustard gas 
following an explosion, led to its use in Hodgkin’s disease (DeVita 1997). 
Chemotherapy has been used in the management of ovarian cancer since 1952 (Rundles 
& Barton 1952). Initially agents such as triethylene melamine, a nitrogen mustard -like 
compound were used. Initial reports of objective partial responses were reported in up to 
50% of patients (Masterson & Nelson 1965). In the 1970’s alkylating agents such as 
chlorambucil and cyclophosphamide were in common use. A major breakthrough 
occurred in 1975 with the introduction of cisplatin (Wiltshaw & Carr 1974), (Wiltshaw 
& Kroner 1976). The discovery of the cytotoxic activity was a result of serendipity 
when the cell division of E.coli were inhibited when bacteria were studied in a medium 
in which platinum electrodes were used (Resenberg, Van Camp, & Krigas 1965). This 
is a platinum analogue that acts as an intercalating agent that inhibits DNA replication. 
Carboplatin was introduced in 1980 and this combined the therapeutic efficacy of 
cisplatin (Calvert et al. 1985), (Taylor et al. 1994), but with a much reduced toxicity 
profile, (Calvert et al. 1989). In the early 1990’s taxol was seen to have activity in 
relapsed ovarian disease (McGuire et al. 1989), (Einzig et al. 1992), (Thigpen et al. 
1994). This was then introduced into first line treatment. Several large studies 
demonstrated a survival advantage of platinum/taxol over platinum/cyclophosphamide. 
This is the current standard of care (Adams et al. 1998). In the United Kingdom this
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evidence has been endorsed by the National Institute for Clinical Excellence (NICE) 
(National Institute for Clinical Excellence (NICE) 2000).
Unlike surgery the evaluation of chemotherapeutic agents is more readily achievable 
through prospective randomised clinical trials. There has been increasing international 
collaboration and there are now several coordinated international trials groups. These 
include the Gynaecological Oncology Group (GOG)11 based in the United States, 
European Organisation for Trials and Research in Cancer (EORTC)12, Medical 
Research Council (MRC)13 and the Scottish Gynaecological Cancer Trials Group 
(SGCTG). The study described in chapter 4 was conducted under the auspices of this 
latter group.
Evidence for current regimes
Cisplatin
The ‘Advanced Trialists Group’ reviewed 45 trials and found that patients treated with 
platinum had better outcomes than those not treated with platinum (Advanced Ovarian 
Cancer Trialists Group 1991). This was corroborated by the population-based studies of 
Junor, (Junor, Hole, & Gillisl994) and by Hunter (Hunter, Alexander, & Soutterl992). 
A possible confounding factor in earlier studies is patient fitness; toxicity prior to 
introduction of effective anti-emetics such as 5-HT3 antagonists, patients receiving 
platinum would be fitter and would probably be a group that would do better anyway.
nhttp://www.gog.org/
12http:// www.eortc.be/
13http://www.ctu.mrc.ac.uk/
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Cisplatin vs carboplatin
Meta-analyses of thirty-seven trials by the Advanced Ovarian Trialists Group (Aabo et 
al. 1998) found no differences in efficacy between regimes containing cisplatin and 
carboplatin.
Cisplatin/paclitaxel vs Cyclophosphamide/cisplatin
Four large international trials [GOG-111, ‘intergroup’, GOG-114 and GOG-132] have 
been conducted comparing cisplatin and paclitaxel with cisplatin and cyclophosphamide 
or cisplatin alone. These results are complex and are reviewed by Sandercock 
(Sandercock, Parmar, & Torri 1998). However three of the trials suggest that cisplatin/ 
paclitaxel resulted in superior survival.
Carboplatin/paclitaxel vs standard platinum based control arm
Only one large trial has compared the paclitaxel/ carboplatin with a standard platinum 
based control arm. ICON-3 [cyclophosphamide/doxorubicin/carboplatin vs 
taxol/carboplatin] has been published only in abstract form however the interim results 
show no statistical difference between the study arms (Colombo 2000). These results 
have generated considerable debate and the complete paper is awaited.
Taxol/cisplatin vs Taxol/carboplatin
No differences between cisplatin/paxlitaxel and carboplatinum/paclitaxel have been 
noted in the interim analyses of two prospective randomised trials (du Bois A. et al. 
1999), (Neijtet al. 1998).
Doxetaxel/carboplatin vs Paclitaxel/carboplatin
There has been interest in substituting docetaxel for paclitaxel in an attempt to reduce 
toxicity. The SCOTROC trial [paclitaxel-carboplatin vs docetaxel-carboplatin] was used 
for the SCOTROC surgical study that is presented in chapter 4 (Vasey 2001).
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Chemotherapy in early disease
Most of the large trials have recruited patients with advanced ovarian cancer. This 
reflects the common stage at presentation. However there has been clinical uncertainty 
of whether to treat patients with ovarian cancer confined to the ovaries. There is a 
general consensus (Gorel999) that patients with FIGO stage Ic or more [see appendix] 
should be offered adjuvant chemotherapy. There have been two large international trials 
investigating whether early stage disease should be treated.
The ACTION trial organised by European Organisation for the Research and Treatment 
of Cancer [EORTC] recruited 448 patients from 40 European centres between 1990 and 
2000. Patients with FIGO stage 1A/1B G2/3 and all FIGO stage 1C/IIA patients were 
eligible and were randomised to adjuvant chemotherapy of at least four cycles of 
platinum based chemotherapy or to follow up alone. Although there was no difference 
in survival between the two arms [logrank p=0.1] there was a statistically significant 
difference in progression free survival; the chemo-treated patients surviving longer 
[logrank p=0.01] (Colombo et al. 2001).
The ICON-1 trial was an international collaborative trial that recruited patients between 
1991 and 2000. Patients with ‘early stage’ disease were eligible. Eligibility was allowed 
if the referring clinician was uncertain whether chemotherapy was appropriate, and was 
thus ‘loose’. Four hundred and seventy seven patients were randomised to immediate 
adjuvant chemotherapy or to follow up and chemotherapy at relapse. Statistically 
significant differences have been reported for both disease free survival [HR=0.65 
(95%CI=0.46 to 0.92) and overall survival [HR=0.68 (95%CI=0.51-0.92)]; patients 
receiving immediate adjuvant chemotherapy have longer survival times (Colombo, 
Trimbos, Guthrie, Vergote, Mangioni, Vermorken, Qian, Bolis, Torri, Anastasopoulou, 
& Parmar2001).
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Although both trials are useful they do not answer the question of whether 
chemotherapy is required in comprehensively staged FIGO la  disease.
Newer agents.
There are many newer agents that are currently being investigated in phase-I and phase- 
II trials some of these are reviewed by Kaye (Kaye 1999).
Relapse
Most patients who initially present with advanced ovarian cancer will relapse. These 
relapses are usually treated by second line chemotherapy. There are many questions 
regarding the timing of re-treatment and what agents should be used. This is reviewed 
by Gore (Gorel999). In the United Kingdom the National Institute for Clinical 
Excellence (NICE) has reviewed the role of chemotherapy for relapse and has endorsed 
the use of topotecan (National Institute for Clinical Excellence (NICE) 2001).
Summary
Platinum based chemotherapy in combination with taxol prolongs the survival of 
patients with advanced ovarian cancer and is generally well tolerated: this is the current 
standard of care. However this remission for most patients will be temporary and further 
treatment with chemotherapy is often required.
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1.6 Specialisation in ovarian cancer
Introduction
The concept of specialisation is not new. Specialisation and the division of labour was 
discussed by Adam Smith the Scottish economist in the eighteenth century in his book, 
Wealth of Nations (Smith 2001a) as an important factor for the creation of wealth.
Definitions of specialisation include: to make specific, to adapt to conditions, to be 
adapted to special conditions, to narrow and intensify (Chambers English Dictionary 
1996) and fo r  a particular purpose (Concise Oxford Dictionary 1983).
The history of medicine has demonstrated specialisation not in a linear fashion but as a 
series of paradigm shifts. The differentiation into the medical and surgical specialities 
and then sub-specialisation of these two broad arms of medicine is evidence of 
increasing specialisation. Despite this it is surprising that the current interest and debate 
as to the role of specialist surgery in ovarian and endometrial cancer is not generally 
accepted. General obstetricians and gynaecologists in the UK manage cases as diverse 
as the antenatal problems of a diabetic to surgery for advanced ovarian malignancy. 
Despite this there is resistance to further specialisation in Obstetrics & Gynaecology 
even though gynaecological-oncology is a recognised sub-speciality by the Royal 
College of Obstetrics & Gynaecologists.
There is comparatively little in the literature on the subject of specialisation within 
medicine and that, that exists, relates to conditions treated by surgery. There is one 
meta-analysis (Grilli et al. 1998) examining studies that relate specialisation with 
processes of care and with outcome. The overall conclusion was that many of the 
studies were of poor quality with regard to their methodology, in particular in
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minimising bias. Despite this there was a consistent finding that patients treated by 
specialists (however defined) had a lower risk of mortality. There is evidence for the 
benefit of specialist surgery in breast, colorectal and ovarian cancer that will be 
reviewed in detail later. There are also benefits of specialisation in the management of 
rare childhood malignancies (Stiller 1994) and in the management of testicular cancer 
(Harding et al. 1993). To date there is no evidence of a specialist effect in the 
management of endometrial cancer.
Scope o f  specialisation
Specialisation can be examined at the level of the individuals performing specific 
clinical managements. Specialisation can also be examined at the process and structural 
level; at the level of specialist teams and the interaction of multi-modal treatments from 
a number of clinicians and at a higher level at the organisation in which they work. This 
distinction is important, as increasing specialisation is likely to be ineffective without an 
increasing coordination between individual specialist components that might be 
required by the patient with cancer. The evidence that specialist surgery improves the 
survival outcome of patients with colorectal, breast and ovarian cancer will be reviewed 
as well as evidence that the interaction of specialists at a higher organisational level 
might confer survival benefit.
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Evidence for a ‘specialist effect’
Evidence fo r  the benefits o f  specialisation in ovarian cancer.
Gillis (Gillis et al. 1991) in a letter to the Lancet argued for the use of population based 
studies to investigate the effect of specialist treatment on observed variations in survival 
seen in patients with ovarian cancer. They reported on three studies that linked cancer 
registration data with prospective audit and death certification data. They observed a 
small but significant survival benefit of patients with ovarian cancer treated in teaching 
hospitals in the West of Scotland using a multivariate survival model corrected for 
differences in age, stage and tumour type. They also reported a 6% improvement in 
survival seen in patients between 1975 and 1987. This improvement was greatest for 
young patients treated in teaching hospitals. The authors concluded that this was 
possibly the result of more aggressive treatment being used by teaching hospitals in the 
younger patient. Although not specifically mentioned in this letter it is of interest to 
speculate whether these differences were the result of a differential introduction of 
platinum chemotherapy in the late 1970’s. Thus the hypothesis that variation in clinical 
practice in the West of Scotland might account for these observations. Gillis et al 
argued for detailed clinical audit based on populations to examine the specialist effect 
on survival in ovarian cancer.
Following on from this Junor (Junor, Hole, & Gillis 1994) used a population based 
approach to examine the factors associated with variation in survival of 533 patients 
diagnosed in Scotland in 1987. Multivariate survival analysis was used and 
demonstrated a ‘specialist effect’ after adjusting for known prognostic factors. Patients 
first seen by a gynaecologist, operated on by a gynaecologist, having residual tumour at 
the end of surgery of less than 2cm, receiving platinum chemotherapy and attending a 
joint clinic survived longest [all p<0.05]. The influence of the gynaecologist as the
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surgeon was independent of the residual disease status at the end of surgery. Moreover 
the multidisciplinary clinic effect was independent of the use of platinum based 
chemotherapy. This study is important as it demonstrated two aspects of the specialist 
effect that might confer benefit to patients with ovarian cancer both at an individual 
clinician level but also at an organisational level too.
The result of this study was confirmed by two further population-based studies from the 
UK. Kehoe (Kehoe, Powell, Wilson, & Woodmanl994) examined factors associated 
with survival in 1184 histologically verified patients with ovarian cancer in the West 
Midlands between 1983 and 1987. They found that the median survival of patients 
operated on by general surgeons was 9.9 months versus 29 months for patients operated 
on by gynaecologists. They did note that patients operated on by general surgeons were 
older and presented with more advanced disease. Despite adjustments for these factors 
the speciality of operating surgeon remained an important prognostic factor. The 
relative hazard ratio (RHR) of patients operated on by general surgeons was 1.34 
(95%CI=1.05 to 1.71). Despite this finding there have been no explanations for the poor 
survival of patients operated on by general surgeons; whether there are as yet 
unaccounted for case mix differences or whether the philosophy of general surgeons 
differs from that of gynaecologists.
Similar results were reported by Woodman (Woodman, Baghdady, Collins, & 
Clymal997) from a population based study involving 671 histologically verified 
patients with ovarian cancer. Again general surgeons were found to be associated with 
poor survival, RHR=1.58 (95%CI=1.19 to 2.10). This study also confirmed the initial 
results of Junor (Junor, Hole, & Gillisl994) that referral to an oncologist was associated
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with better outcome, RHR=0.54 (95%CI=0.43 to 0.68). No association with caseload
was found.
Nguyen analysed the effect of specialists in the National Survey of Ovarian Cancer than 
was conducted in the USA (Nguyen et al. 1993). The authors found that optimal 
debulking was similar between gynaecological oncologists and general gynaecologists 
at around 45% of cases, but that this figure was significantly better than the rate of 
optimal debulking by general surgeons (25%). Although no difference in survival was 
seen between gynaecological oncologists and general gynaecologists a significant 
improved survival was seen compared with patients operated on by general surgeons 
(p<0.004). It was noted that general surgeons performed more bowel surgery than 
gynaecologists of either type. One can presume this is because a greater proportion of 
these patients presented with conditions necessitating this such as bowel obstruction. 
This hypothesis is explored in chapter 2 of this thesis.
Several small studies based on clinical series have been published that highlight the 
aspects of specialist management that might confer benefit. Eisenkop (Eisenkop et al. 
1992) examined factors associated with survival in 263 cases of advanced ovarian 
cancer. The type of training of the operating surgeon was an independent predicator of 
both the likelihood of optimal cytoreduction but also of survival. Sub-specialist 
gynaecological oncologists were an independent favourable prognostic factor. In a small 
series (n=47) of early ovarian cancers a small but significant difference in survival 
between specialists and non-specialists that was related to the quality and thoroughness 
of surgical staging was observed (Mayer et al. 1992). McGowan in a study evaluating 
the quality of staging noted that gynaecological oncologists were statistically more 
likely to stage adequately (McGowan 1993).
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A more recent Scottish population study by Junor (Junor, Hole, McNulty, Mason, & 
Young1999a) re-examined the effect of specialist status as an independent factor on 
survival outcome. They found that there was a survival benefit for surgeons pre-defined 
as specialist gynaecological oncologists [RHR=0.75 p=0.005]. This benefit was only 
apparent in stage III patients whose cytoreduction was defined as ‘sub optimal’ 
[RHR=0.71 p=0.003]. They found no statistical benefit for stages I, II and IV. It is 
thought that some special aspect of specialist surgery conferred a survival benefit for 
patients with advanced ovarian cancer, the most common presentation of the disease.
All of these studies confirm the association of aspects of specialisation with improved 
survival in patients with ovarian cancer. These studies raise questions and allow the 
generation of hypotheses. These questions and the testing of some of the generated 
hypotheses form the basis for this thesis.
Why do patients operated on by general surgeons perform so badly compared with 
gynaecologists? Is the difference due to unaccounted differences in case-mix that 
previous studies have been unable to correct for or is it a difference in philosophy 
between general surgeons and gynaecologists based on the unusual surgical principles 
of surgery for ovarian cancer? An attempt to address one of these issues is presented in 
Chapter 2.
Why is there an apparent survival benefit from surgery performed by specialist 
gynaecological oncologists? Is there some aspect of the surgery performed that confers 
the benefit? This aspect is explored in the studies presented in chapter 2 and is also 
considered in the study presented in chapter 4.
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Why is there an apparent survival benefit seen in those patients attending a 
multidisciplinary clinic that is independent of the chemotherapy used? These aspects are 
explored in a population study of endometrial cancer, and this is presented in chapter 5.
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1.7 Role of specialist surgery in non-gynaecological 
malignancy
Evidence for a specialist effect in breast cancer
The benefits of specialist surgery have also been demonstrated in patients with breast 
cancer. There have been four important studies from Scotland.
Hypothesis that survival variation may be due to treatment differences
Analysis of regional cancer registry data in the West of Scotland highlighted the fact
that more affluent patients’ survival was longer than poorer patients (Camon 1994).
This population based study which linked cancer registry data with patients’ pathology
reports demonstrated that the distribution of stage, nodal status and aspects of tumour
biology were no different between the more affluent and poorer socio-economic groups.
From this observation the hypothesis that differences in survival might be due to
treatment differences was generated.
Association o f  specialist status with survival
A second population based study based on the well-defined West of Scotland 
population looked at the association of ‘specialist’ status on survival outcome. Data 
from 3786 patients diagnosed between 1980 and 1988 were analysed and adjusted for 
other known prognostic factors in a multivariate survival analysis. Patients treated by 
specialist surgeons had a 9% improved survival at five years compared with non­
specialist treatment. One of the strengths of this study was that specialists were 
carefully defined. They were defined as surgeons having a dedicated breast cancer 
clinic, defined liaisons with pathologists and oncologists, participating in clinical trials 
and maintaining an independent database of breast cancer patients treated by their team. 
Although the ‘specialist effect’ was demonstrated in general terms the specifics could 
not be defined in this study.
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Characteristics o f  specialist breast surgery
A third study audited the surgical management of women in the West of Scotland 
against the King’s Fund Consensus statement (Kings fund 1986). The medical records 
of women aged 75 years or under, diagnosed between 1986 and 1991, were reviewed 
(Kingsmore et al. 1998). Specialists surgically staged the axilla more frequently and 
more thoroughly than non-specialists and were more likely to treat the axilla more 
adequately. It is of note that these differences in approach were associated with 
differences in loco-regional recurrence within the axilla. Axillary recurrence rates were 
found in 3% of patients treated by specialists compared with 10% in non-specialist 
treated patients. This study is important because it explains and confirms the 
observations demonstrated in the initial study (Gillis & Hole1996).
A fourth population based study of the whole Scottish population examined factors 
associated with variation in survival of 1619 patients with early breast cancer diagnosed 
in 1987 (Twelves et al. 1998). After correcting for tumour related prognostic factors and 
patient age, the authors found no relationship between socio-economic deprivation or 
surgical caseload and survival in a multivariate survival analysis. An independent 
association between the health board of treatment and survival was found. This study 
differed from the West of Scotland series (Camonl994), (Gillis & Holel996), 
(Kingsmore, Hole, Gillis, & Georgel998) in that the defined population was the 
national Scottish population rather than one region of the country. However they did not 
classify patients’ treatment according to the specialist status of the operating surgeon. 
Although the authors conclude that the inter-health board survival differences might be 
accounted for by a differential use of adjuvant treatment notably Tamoxifen it is not 
inconceivable that the differences are a reflection of differences in the surgical 
treatments employed within the various health boards.
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Summary o f evidence in breast cancer
In summary observations of differences in survival between different socio-economic 
groups led to the finding that this variation could be accounted for by differences in the 
specialist status of the operating surgeon. Subsequent work has demonstrated that there 
are systematic differences between specialist and non-specialist surgery that almost 
certainly accounts for these survival differences. Comparing these findings with those 
from rectal cancer demonstrates that specialist surgeons use more appropriate surgery 
and this influences outcome.
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Evidence for a specialist effect in colorectal cancer
Hypothesis that inter-surgeon variability might account fo r  differences in outcome
A prospective observational study of 645 sequential patients presenting with colorectal
cancer between 1974 and 1979 to a Glasgow teaching hospital demonstrated large 
variations in the surgical related patient outcomes between the thirteen consultant 
surgeons providing the surgical service (McArdle & Hole 1991). This study found 
differences in technical related outcomes such as anastamotic leak rates as well as 
overall outcome in the survival of patients having ‘curative’ procedures. This study 
raised the possibility that surgery performed by individual surgeons might influence 
patient outcome. Although case mix was not controlled for it did generate the 
hypothesis that surgery performed by individual surgeons might not be as equally 
effective. The authors argued that overall outcome might be improved by increased 
specialisation within the department.
Evidence fo r  a technique
Prior to this report Heald (Heald & Ryalll986) described the survival outcomes of total 
mesorectal excision [TME], where great care was taken to ensure that the excision 
plane was outwith the rectal mesentery. The results of this series were significantly 
better than survival results for traditional techniques. Further evidence for the efficacy 
of this specific surgical approach was described by MacFarlane (Macfarlane 1993) who 
reported on his extensive series of TME in which survival was demonstrated to be better 
that that in conventional surgery. He also carefully defined a subgroup of patients as a 
case-controlled comparison of series of high-risk patients where conventional surgery 
was complemented with adjuvant treatment. The survival in the group of patients where 
TME alone had been performed demonstrated more prolonged survival in terms of 
absolute cure at seven and half years of follow up and for loco-regional recurrence
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compared to the series where conventional surgery was supplemented with adjuvant 
radiotherapy. This paper suggested that the use of a more specialist surgical technique 
was associated with superior survival results. The authors also acknowledged that TME 
took more operating time and might be associated with more surgical complications. 
These factors are important as they might explain why an apparently superior surgical 
approach was not rapidly accepted.
Evidence fo r  surgeons
McArdle and Hole (McArdle & Hole 1991) first demonstrated inter-surgeon variability. 
A number of studies have shown inter-surgeon differences and related differences in the 
use of specialist surgical approaches as the explanation for observed differences in both 
loco-regional recurrence and absolute survival.
Hermanek (Hermanek et al. 1995) reported the results of a German study in 1995. 
Surgeons as individuals and the institutions of treatment were found to be associated 
with the rate of LRR and with survival. One thousand one hundred and twenty one 
patients were analysed in this prospective multicentre observational study.
Holm (Holm et al. 1997) in a similar study from Sweden, re-analysed data from two 
prospective trials of the use of radiotherapy as a neoadjuvant treatment in rectal cancer 
to look at surgeon related associations with survival. One thousand, three hundred and 
ninety nine patients were analysed using a multivariate analysis that was corrected for 
patient age, sex, stage and whether they had been randomised to pre-operative 
radiotherapy. Surgeons who were certified as specialists for at least ten years had the 
best results. The hazard ratio of loco-regional recurrence was 0.8 (95%CI=0.6 to 1.0) 
and that of survival was 0.8 (95%CI=0.7 to 0.9) compared with non-specialists. A 
similar association was demonstrated between treating institutions. What was
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particularly interesting was that the survival differences disappeared within the group of 
patients who received neoadjuvant radiotherapy. This confirmed that the observed 
difference between specialists and non-specialists was almost certainly due to 
differences in the actual surgery done. Radiotherapy in this study appears to have had 
the effect of compensating for less adequate surgery. The authors argue that the basis of 
the specialist effect was a reflection of the surgery performed; specifically the use of 
specialist approaches such as TME. This study is important as it links the benefits seen 
by specialist surgeons with the use of specialist surgical techniques. This study 
demonstrated no association in survival between caseload and survival. Other authors 
(Kee et al. 1999) have confirmed this later finding.
Havenga compared three clinical series from hospitals using different surgical 
approaches in the surgical management of rectal cancer (Havenga et al. 1999). Total 
mesorectal excision (Heald & Ryalll986) performed in Sloan-Kettering in the USA and 
in the North Hampshire hospital in the UK was compared to radical surgery with 
lymphadenectomy [D3 lymphadenectomy] that was performed in Japan with 
conventional surgery performed in Norwegian and Dutch centres. The authors found 
that the loco-regional recurrence was significantly reduced in the series from hospitals 
performing the more specialised surgery. The loco-regional recurrence rate was 4-9% in 
series of patients having specialist surgery compared with 32-35% in patients receiving 
conventional surgery. The entry criterion for tumour stage was carefully defined for this 
study. Although comparisons of clinical series is complicated by ill-defined bias, the 
authors argue that the large differences seen are likely to be due to differences in the 
surgery performed. This study adds to the argument that more specialised surgical 
techniques are better than others in terms of survival outcome.
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Summary o f evidence in colorectal cancer
These studies in colorectal cancer argue towards TME being a surgical approach that 
confers better survival outcome both in terms of decreased loco-regional recurrence but 
also in absolute survival compared with more traditional approaches. These studies of 
surgeons’ and institutions’ associations with survival might be due primarily to the 
adoption of these techniques. In essence specialists adopting more appropriate or 
‘specialist’ techniques explain the specialist effect.
Summary of the benefits of specialist surgery in breast and 
colorectal cancer
Analyses of studies from rectal cancer, breast and ovarian cancers have provided 
evidence that the ‘specialist effect’ is genuine. In rectal cancer this specialist effect 
appears to be related to use of more appropriate and thorough surgical techniques. 
Recent data from breast surgery confirms the same findings that specialists are more 
likely to perform thorough surgery. Although the studies in ovarian cancer have 
highlighted a specialist effect as well as a multidisciplinary effect they have not yet 
identified the specific aspects of surgery that confer the benefit. There is no published 
data regarding the specialist effect in endometrial cancer though a small regional audit 
did report that appropriate management was associated with improved survival (Tilling, 
Wolfe, & Raju 1998b).
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1.8 Contemporary changes in the organisation of health care 
affecting the clinical management of gynaecological cancer
An appreciation of the benefits of specialisation, quality, and the increasing complexity 
of treatment, has increased interest in organisational aspects of clinical practice in the 
UK. The multidisciplinary team, and the introduction of guidelines, are examples of 
these changes in the surgical management of ovarian cancer. It is noteworthy that little 
attention has been given to endometrial cancer in this regard.
Changes in the process of clinical management; the multidisciplinary 
team
The importance of the multidisciplinary team was demonstrated, in ovarian cancer, by 
Junor (Junor, Hole, & Gillis 1994). Patients who attended a multidisciplinary clinic 
(MDC) were associated with improved survival in ovarian cancer [p=0.001]. Part of this 
benefit could be accounted for by the concomitant increase in the use of platinum 
chemotherapy. Despite this, the ‘MDC effect’ remained statistically significant even 
after adjusting for the use of platinum, RHR=0.73 [p<0.01]. This work suggests that 
there are other aspects of the team that confers survival benefit to the patient.
The psychodynamic aspect of teams is currently being scrutinised (Haward et al. 2001). 
Haward is currently examining the composition and factors associated with teams’ 
effectiveness within breast cancer multidisciplinary teams. Whilst this work is at an 
early stage it is of interest that the ‘High performance team’ is a concept that has 
received much interest and scrutiny in business and management during the 1990’s 
(Buchanan & Huczynski 1997a). Despite this a detailed understanding of the 
multidisciplinary clinic is at an early stage. Chapter 5 will present data from the
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management of endometrial cancer in Scotland that might help explain the 
multidisciplinary clinic effect.
Protocols & guidelines
Protocols and guidelines are commonplace in all aspects of clinical practice. Evidence 
for their effectiveness is uncertain. Karjalaener analysed the survival of myeloma 
patients who were treated in geographical areas in Finland in which trials were 
conducted. Despite the fact that the experimental arm of the trial yielded inferior results 
compared with standard treatment there was an overall improvement in population 
survival (Karjalainen & Palva 1989). The authors, and other commentators (McCarthy 
1989), concluded that the benefits in survival seen were a result of more systematic 
treatment.
In ovarian cancer a national guideline was published and disseminated to gynaecologists 
in Scotland in 1995 (CRAG 1995). An Audit Commission Report (Audit commission for 
Scotland 1998) reviewed the implementation of this guideline and found a lack of 
structural and process mechanisms required to allow widespread implementation of it. 
The clinical management was out with the remit if this audit. The lack of guideline 
implementation in the management of ovarian cancer was reported from Italy (Grilli et 
al. 1990). In the UK an audit by Wolfe (Wolfe, Tilling, & Rajul997) found that local 
guidelines in Southeast England were used in less than 43% of cases. They found that 
violations to protocol treatment was associated with poorer survival RHR=1.48 
(95%CI=1.34 to 4.78) in a multivariate survival analysis.
These aspects are important since guidelines are costly to produce; the approximate cost 
of a SIGN guideline is £68,000 (Naim 2001). If they are not an effective way of 
disseminating and encouraging better clinical practice then more appropriate and
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effective use of resources could be used. At present SIGN is commissioning a new 
guideline on the management of ovarian cancer (Siddiqui 2001). Junor (Junor 1999) 
suggested that the only way to truly evaluate a guideline would be to compare clinical 
practice before and after a guideline was introduced. Other more sophisticated 
approaches have been used to evaluate the effectiveness of guidelines (Bero et al. 1998). 
However these approaches are prospective and cannot be used once a guideline has 
already been disseminated.
Chapter 3 of this dissertation will present a comparison of the clinical management of 
ovarian cancer before (Junor, Hole, McNulty, Mason, & Young 1999a) the publication 
of the 1995 CRAG guideline compared to recently abstracted data from 1995-7. This 
will allow changes in management to be audited against standards set out in this 
guideline.
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Changes in organisational structure within the UK
England & Wales
In the early 1990’s it was recognised that the quality of cancer care in the UK might be 
improved. The Calman-Hine report (Expert Advisory Group on Cancerl995) proposed 
the creation of a hierarchical, ‘hub-and-spoke’ system where cancer units would manage 
the more straightforward aspects of clinical management using protocols and guidelines 
to standardise clinical practice. More specialised care would be referred to cancer 
centres. This model aimed to improve the overall quality of the processes of care and by 
implication the outcomes of care. It proposed to utilise the benefits of specialisation 
whilst being able to deliver some aspects of care locally (Kitchener 1997). This system 
whilst attempting to integrate elements of best practice has potential disadvantages too 
(Foy 1999).
Scotland
In Scotland the strategic approach has differed from the English model. Instead of a 
hierarchical structure, Scotland has favoured a network system based on the 
organisational benefits of matrix structures (Buchanan & Huczynski 1997b). This 
results in clinicians being part of a network providing cancer care as well as belonging 
to their traditional departments. Designed to Care (The Scottish Office 1997) was a 
policy document published in 1997 and introduced the concept of clinical governance. 
This represented a change from individual accountability to corporate, or organisational, 
accountability for clinical performance. This policy shift was important as it emphasised 
the role of the organisational system as being responsible for quality. Following this, the 
Acute Services Review (The Scottish Office 1998) set out the vision of managed clinical 
networks. These are problem orientated multidisciplinary groups based around specific 
disease types such as ovarian, breast, colorectal and lung cancer. Along with this a
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national clinical accreditation programme was proposed. The Acute Services Review 
proposed the creation of a body called the Clinical Standards Board fo r Scotland14. This 
was given the responsibility for developing and running a national system of quality 
assurance to ensure that the quality of care, and the processes of care, was of an 
acceptable quality for hospitals participating in the delivery of cancer care within the 
network. The model anticipated that improvements in the quality and consistency of 
care would follow from an iterative process of peer review, as clinicians managed and 
discussed cases within the network. In this way the management of cases would be open 
to scrutiny and it was hoped that this would drive improvements in quality. This system 
has the potential to deliver high quality care at a local level in a way that a more 
centralised, service might be unable to do.
These networks are at an early stage. Nevertheless there are many potential problems. 
Matrix organisational structures can have inherent problems (Buchanan & 
Huczynski 1997b) particularly within organisations such as the NHS which have been 
traditionally inflexible to change (Wall 1998). There is likely to be a natural tendency 
towards ad hoc centralisation towards those clinicians perceived to be dominant, if 
individual clinicians participating in the network feel unable to deliver the perceived 
quality of care. This can be a genuine inability at an individual level or can be due to 
difficulties in managerial process. There are also the ‘people’ problems. Problems of 
power and influence and perceptions of autonomy need to be managed appropriately if 
individuals participating in the network are to function in a manner which benefits the 
whole network. There is often the assumption that all clinicians working within a 
network can easily implement key elements of clinical practice. This assumption may 
be too simple. There may be constraints at an individual level due to lack of experience,
14 www.clinicalstandards.org/
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lack of ability, lack of confidence and lack of belief. The environment of a local 
clinician may mitigate against the safe adoption of elements of ‘quality care’. This is 
particularly relevant in aspects of surgical management for cancers, particularly ovarian 
cancer. The best evidence suggests that an aim of primary surgery is to reduce the 
diameters of remaining tumour to less than 2cm. However this is frequently difficult 
and hazardous. Thus while managed clinical networks might seem appealing, without 
an appreciation of how specific clinical recommendations can and should be 
implemented, it is likely that networks might fail.
Summary
We have seen that the NHS, at a strategic level, has begun to identify that there is a need 
to translate the best elements of research evidence into clinical practice. It has identified 
that this cannot happen at an individual clinician level without a concomitant change in 
organisation. The approach taken in England and Wales is different in some respects 
from Scotland. Although it is too early to assess the effectiveness of one system over 
the other, what is likely is that effectiveness will depend upon how either system is 
implemented, rather than what one is chosen.
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1.9 Endometrial cancer: the neglected gynaecological 
malignancy
Introduction and comparison with ovarian cancer
Although this thesis is concerned primarily with ovarian cancer this overview is 
included to place the study described in chapter 5 within context. Endometrial cancer is 
interesting because it is the other gynaecological cancer that in the UK is not treated 
exclusively by specialist gynaecologists, unlike cervical and vulval cancer. Together 
with ovarian cancer these cases represent over two thirds of patients presenting with 
gynaecological cancer. Like ovarian cancer, endometrial cancer frequently requires 
bimodal treatment involving the multidisciplinary team of gynaecologists and clinical- 
oncologists. Unlike ovarian cancer most patients present at a stage where it is possible 
to successfully achieve the traditional principles of cancer surgery for cure. The overall 
survival rate is comparatively good with a 5-year survival of 74% in Scotland 
(ISD2000b). This reflects the generally early stage at presentation since, survival stage 
for stage is similar to that seen with cervival cancer (FIGO2001) whose overall 5-year 
survival is 58% (ISD2000b). Because of this as well as that fact that the treatment in 
most cases is ‘simple’ total hysterectomy and bilateral salphingo-ophorectomy, there 
has been the assumption that endometrial cancer is easy to treat. There is little in the 
literature examining the benefits that specialisation may add. Chapter 5 examines this 
further.
Incidence
Endometrial cancer is the ninth most frequent cancer of women in Scotland (ISD- 
Scotland2000b) with an age-adjusted incidence of ll/ioo.ooo and around 300 registrations 
annually in 1995. There is a slight increasing trend in incidence in Scotland. The
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incidence of endometrial cancer increases with age. There are few cases before the age 
of 40. The incidence rises rapidly after the menopause and peaks at the age of 70 after 
which there is a slight decline (ISD-Scotland2000b). It is most commonly seen in 
countries such as the USA and France who have age adjusted incidence rates in the 
order of 18/100,ooo» Countries with a low incidence include Japan, Singapore and 
Scotland. Within Scotland there is variation in incidence between different socio­
economic groups, there being a straight-line relationship between incidence and socio­
economic status. In the most affluent quintile of the population the incidence is 12/ioo,ooo 
whereas in the most deprived quintile the incidence is 9/ioo,ooo (ISD2000b). These 
variations in incidence both within Scotland as well as internationally possibly reflect 
what is understood about the risk factors for endomentrial cancer. Affluent populations 
are more likely to suffer from obesity and women are more likely to have smaller 
families. These factors increase the likelihood of prolonged oestrogenic stimulation, 
which is a known risk factor.
Risk factors
Endometrial cancer is associated with factors that increase the unopposed oestrogenic 
stimulation of the endometrium. Thus drugs such as unopposed oestrogen-only hormone 
replacement therapy (HRT) (Weiderpass et al. 1999) and Tamoxifen (van Leeuwen, 
Benraadt, & Coebergh 1994), (Hardell 1988) increase the risk of developing 
endometrial cancer. Factors such as obesity, diabetes and polycystic ovarian syndrome 
all act through the increased and prolonged stimulation of the endometrium by natural 
oestrogens (DiSaia & Creasman 1997a). In the post-menopausal woman oestrone is 
derived from the peripheral conversion by aromatisation of androgens. Conversion 
occurs in the fat and muscle. Thus obesity increases the rate of conversion (Quinn,
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Anderson, & Coulter 1992). Patients with polycystic ovarian syndome are characterised 
by anovulation and the prolonged stimulation of the endometrium by oestrogens.
The majority of cases are sporadic however occasionally there is a genetic association. 
In a small proportion of patients endometrial cancer is the non-colonic manifestation of 
heriditary non-polyposis colorectal cancer (HPNCC) (Vasen et al. 1996). This is an 
autosomal dominant condition that presents in familial aggregations of colorectal and 
other cancers.
Pathology
Endometrial cancer is an adenocarcinoma that arises from the glandular endothelium of 
the uterine cavity. Macroscopically it is seen as a rough raised papillary area covering 
part of the endometrium. There are a number of histological subtypes of which 
endometrioid adenocarcinoma is commonest (DiSaia & Creasmanl997a). Twenty five 
percent of cases of endometrial adenocarcinoma contain areas of squamous metaplasia, 
this subtype is referred to as adenoacanthoma. If these squamous elements are 
histologically malignant then the term adenosquamous carcinoma is used (Quinn, 
Anderson, & Coulterl992). Less commonly observed subtypes are papillary serous 
adenocarcinoma and clear cell carcinoma, which have recently been described. Patients 
with papillary serous or clear cell carcinoma are observed to have a prognosis that is 
poorer on a stage for stage basis (Cirisano et al. 1999). It is thought that atypical 
hyperplasia is a pre-malignant lesion in a proportion of cases (DiSaia & 
Creasman1997a).
The ICD-9 code for endometrial cancer (182) does not include cervix, however, does 
include malignancies of the uterine muscle (sarcomas), which are not endometrial 
carcinomas. The treatment of the uterine sarcomas differs from that of endometrial
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adenocarcinoma and prognosis is generally poorer (DiSaia & Creasmanl997a). 
Approximately 5% of cases in Europe are sarcomas (Gatta, Lasota, & Verdecchia 
1998a). There is a small international variation in the proportion of cases of sarcoma. 
This is seen in the Eurocase study where 7% of Scottish cases of uterine cancer were 
recorded as being sarcoma (Gatta, Lasota, & Verdecchial998a). In the study presented 
in chapter 5 of this thesis 10% of cases of uterine cancer were found to be uterine 
sarcomas. It is possible that this variation in case mix could affect the conclusions 
drawn from comparing international survival data.
Staging
Endometrial cancer is staged using a staging scheme devised by the International 
Federation of Obstetrics & Gynaecology (FIGO). Since 1988 this has been a surgico- 
pathological system based upon the histological analysis of samples collected at 
laparotomy (Shepherd 1989a). The staging system and schema are shown in Appendix 2 
of this thesis. Staging is on the basis of anatomical and histological spread as well as the 
grade of tumour differentiation based upon histological and cytological criteria (DiSaia 
& Creasmanl997a).
Symptoms
The principle symptom is post-menopausal bleeding (PMB). It is thought that around 
90% of patients with endometrial cancer experience symptoms of post-menopausal 
bleeding (Redman2000). However, only around 10% of patients with PMB have cancer 
(SIGN 2002).
Treatment
The treatment and management of patients with endometrial cancer has been reviewed 
(Lawton 1997), (Quinn, Anderson, & Coulter1992).
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Because the endometrial cavity is readily accessible, the majority of patients have a 
histological diagnosis pre-operatively (Crawford et al. 2001), (SIGN2002). Most 
patients are treated with surgery. The role of surgery is to stage the patient and to be the 
primary treatment. There is a group of patients who receive adjuvant radiotherapy. This 
is generally considered to be appropriate where there is either definite metastasis to the 
local lymph nodes in the pelvic sidewall or the risk of this being present is considered to 
be significant. The use of adjuvant chemotherapy is usually restricted to patients with 
very advanced disease or patients who have relapsed disease (Fleming 1999). Recently 
there have been studies demonstrating the use of chemotherapy in patients with the 
papillary serous histological subtype (Ramondetta et al. 2001).
There are two main controversial aspects of clinical management. The specific use of 
radiotherapy has been controversial. Patients with early stage disease, where the disease 
is confined to the inner half of the myometrium [FIGO stage IB] and where the tumour 
is well and moderately differentiated have generally not received radiotherapy 
(Lawtonl997). Patients with advanced disease, where the tumour is poorly 
differentiated and has invaded through at least half of the myometrium or beyond or in 
patients with local spread to the parametrium or pelvic sidewall have received 
radiotherapy. The role of radiotherapy in the ‘intermediate’ group has been 
controversial. This issue has been addressed recently. The post-operative radiation 
therapy in endometrial cancer’ [PORTEC] study was a prospective randomised clinical 
study that defined a group of patients considered to be at intermediate risk of nodal 
metastases (Creutzberg et al. 2000b). This group consisted of patients with FIGO stage 
1C grade 1, 1A-C grade 2 and IB grade 3. These patients who had undergone total 
abdominal hysterectomy and bilateral salphingo-ophorectomy but without pelvic 
lymphadenectomy, were randomised to either pelvic radiotherapy or no further
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treatment. The study demonstrated a greater likelihood of local recurrence in the 
untreated group [4% recurrence in adjuvant radiotherapy group vs 14% in untreated 
group (p<0.0001)]. The study demonstrated no difference in 5-year survival in what 
appears to have been an adequately powered study. This supports the preliminary results 
of a smaller American study, ‘GOG-99’ (Roberts et al. 1998). In this study published 
only in abstract, adjuvant radiotherapy appears to reduce the number of local 
recurrences [88% 2-year progression free interval (PFI) in untreated group vs 96% 2- 
year PFI in the group receiving adjuvant radiotherapy: p=0.004] but was found to have 
little impact on overall study. This study differes from the European one in so far as all 
patients underwent pelvic lymphadenectomy therefore the accuracy of the staging is 
likely to be better. The definition of intermediate risk differed slightly from the 
PORTEC study. It remains to be seen what the effect of lymphadenectomy is upon the 
definitive results from GOG-99 compared to PORTEC.
The second main management controversy involves the role of complete surgical 
staging. The exact role of pelvic lymphadenectomy and para-aortic lymphadenectomy is 
at present uncertain. Proponents of lymphadenectomy argue that this increases the 
certainty of accurate staging so that appropriate treatment can be given (Naumann, 
Higgins, & Hall 1999). Some authors argue that the lymphadenectomy is therapeutic in 
its own right as microscopic metastases are removed in the dissection (Mariani et al. 
2000). Critics of more aggressive staging argue that the procedures add to morbidity 
without increasing the survival benefit either directly or indirectly. Perhaps more 
importantly lymphadenectomy as a surgical procedure tends to be performed only by 
gynaecological-oncology specialists who are more likely to be familiar with the 
anatomy of the pelvic sidewall. Therefore there is a ‘political’ aspect influencing the 
debate too. The Medical Research Council is conducting a randomised trial [ASTEC- A
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study in the treatment of endometrial cancer] examining the role of lymphadenectomy 
(Medical Research Council 1998). This study is still recruiting and no results have been 
presented.
Another uncertainty is the optimal management of patients with malignant cells found 
in the peritoneal cavity. There is evidence that positive intra-peritoneal cytology is a 
predictor of metastatic spread to the pelvic and para-aortic lymph nodes (Boronow et al. 
1984b). There is uncertainty what form of adjuvant treatment should be considered in 
this instance. Often these patients will receive adjuvant radiotherapy because positive 
cytology is frequently associated with other features that would indicate adjuvant 
radiotherapy such as deep myoinvasion. More difficult is whether the patient should 
receive systemic treatment in the form of chemotherapy. In Glasgow colleagues have 
begun to consider the use of cisplatin in these patients even though the research 
evidence is limited to small phase-1 and 2 studies. This area deserves further attention.
Prognosis
The overall adjusted relative 5-year survival in Scotland 73.3% (ISD-Scotland2000b). 
The Eurocare studies [section 1.2] have demonstrated variations in survival between 
European countries. In common with ovarian cancer patients with endometrial cancer in 
Scotland have poorer survival rates compared to other countries in this study [figure 
1.2-3] (Gatta, Lasota, & Verdecchial998b).
Prognostic factors
There are a number of known prognostic factors. Much of the evidence for these was 
derived from analysis of patients with endometrial cancer entered into Gynaecologic 
Oncology Group (GOG) trials in the United States. Christopherson (Christopherson, 
Connelly, & Alberhasky 1983) analysed 634 patients with clinical stage 1 disease [pre
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1988 staging system]. Using univariate analysis and crude survival rates as endpoints it 
was found that patients with certain histological subtypes had a poorer prognosis. 
Patients with papillary carcinoma, clear cell carcinoma and adenosquamous carcinoma 
had a poorer prognosis than those with the more common adenocarcinoma and 
adenoacanthoma. This study also demonstrated that the degree of tumour differentiation 
as well as the depth of myometrial invasion were important prognostic factors. Patients 
with poorly differentiated tumours and those with deep myoinvasion had poorer 
survival.
Three studies analysing data from the GOG were influential in defining the main 
prognostic factors (Boronow et al. 1984a; DiSaia et al. 1985), (Creasman et al. 1987). 
These analyses were on patients defined as clinical stage 1 based upon the pre-1988 
FIGO criteria. The analyses use recurrence as well as lymph node positivity as surrogate 
markers of prognosis. The analyses are univariate and do not adjust for the influence of 
multiple factors. These studies show that patients with poorly differentiated tumours, 
tumours that invade deeply into the myometrium, malignant peritoneal cytology, 
metastatic involvement of the adnexae and capillary like space involvement with 
tumour have a greater likelihood of both pelvic and para-aortic lymph node involvement 
(Creasman, Morrow, Bundy, Homesley, Graham, & Hellerl987). In this study 
histological subtype was not related to the likelihood of lymph node metastases. Many 
of the identified factors are related to each other. In particular patients with only 
superficial myometrial invasion were more likely to have tumours that were well 
differentiated, conversely patients with tumours invading deeply into the myometrium 
were more likely to have poorly differentiated tumours (DiSaia, Creasman, Boronow, & 
Blessing1985). These studies were influential with regards to the change to a surgico- 
pathological staging system by FIGO. This new system addressed degree of myometrial
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invasion, tumour differentiation, involvement of the adnexae and cervix as well as 
positive lymph nodes and malignant peritoneal cytology.
There have been many small studies examining the significance of molecular factors as 
prognostic factors. These studies have tended to be small and the results are not all 
consistent. There has been interest in the expression of oestrogen and progesterone 
receptors. Patients with more advanced are more likely not to express receptors for these 
hormones (Quinn, Anderson, & Coulterl992). There has been interest in defining the 
molecular biological characteristics of endometrial tumours. Pisani (Pisani et al. 1995) 
used multivariate analysis to relate the association of overexpression of genes such as 
p53 and HER-2/neu with outcome. Whilst this study showed that p53 overexpression 
was a strong predictor of poor outcome the use of molecular prognosticators is not yet 
in widespread clinical use.
There is little in the literature examining clinical-process factors as prognostic factors. 
One small study from the South East of England demonstrated that patients receiving 
appropriate treatment, according to local guidelines, had improved survival (Tilling, 
Wolfe, & Raju 1998a). There is no literature examining the effect of the 
multidisciplinary clinic nor of the effect that specialisation might have on outcome. The 
study presented in this thesis will explore this further.
Guidelines
Unlike ovarian cancer there have been a paucity of guidelines. There are no national 
guidelines in Scotland and only recently have national guidance been prepared in 
England & Wales (department of health 1999b), (department of health 1999b), 
(department of health 1999a),(NHS Centre for Reviews and Dissemination 1999b).
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1.10 Conclusion of literature review and outline of research to 
be presented
The cornerstone of the surgical management of ovarian cancer is the reduction of 
tumour bulk by surgical debulking. There is a wealth of retrospective data, and one 
randomised study, that show an association between residual disease and improved 
survival.
International comparisons of ovarian cancer survival data, particularly from the 
EUROCARE studies, have led to the conclusion that cancer survival is poorer in the 
Scotland and the UK compared with other European countries. The conclusion is that 
differences in the stage at presentation or in the quality of treatment, particularly 
surgery, account for these variations in survival. However, these data come from cancer 
registries, are retrospective and do not explain the reasons for these differences.
This thesis will present data from three studies:
Chapter 2 will present data from a population-based study from Scotland of the 
management of ovarian cancer between 1995 and 1997. The purpose of this study was 
to identify the surgical factors associated with differences in survival of patients with 
ovarian cancer operated on by general surgeons, general gynaecologists and specialist 
gynaecologists. This study will attempt to develop the initial observations seen in the 
work by Junor (Junor, Hole, McNulty, Mason, & Youngl999a).
Chapter 3 will present a small study comparing the surgical management of patients 
with ovarian cancer before and after the introduction of a national guideline and 
evaluating the effect of any improvements with survival. This study should allow an 
evaluation of the adoption of recommendations made and should thus allow an appraisal 
of the success of the guideline.
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Chapter 4 will present data from the SCOTROC surgical study. This is an in depth 
analysis of initial surgery carried out in a large scale prospective international clinical 
trial in which information on biological and treatment variables should allow valid 
conclusions to be drawn regarding the impact or outcome of variations in surgical 
practice.
Chapter 5 presents data from a Scottish population based study examining the 
management of patients with endometrial cancer. This study is important because it 
provides evidence of the effect of the failure of surgical staging and provides some 
explanation of the multidisciplinary clinic. The observations drawn are widely 
applicable and add to our understanding of the specialist management of ovarian cancer.
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CHAPTER 2
Identification of the surgical factors associated with improvements in 
survival of patients with ovarian cancer: A population study
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2.1 Aims
To explain the survival variation between patients operated on by general surgeons and 
gynaecologists.
To account for the differences in the surgical management of patients operated on by 
specialist gynaecologists compared with other surgeons and to relate these to variations 
in survival.
2.2 Background
There have been several population-based studies that have demonstrated differences in 
survival outcome between the various groups of surgeons who treat women with 
ovarian cancer.
Three large retrospective studies in the United Kingdom have suggested, that in patients 
with ovarian cancer, being operated on by a general surgeon confers a worse prognosis 
than being operated on by a gynaecologist (Junor, Hole, & Gillisl994; Kehoe, Powell, 
Wilson, & Woodmanl994; Woodman, Baghdady, Collins, & Clymal997). Although 
the results from these studies have been remarkably consistent showing that being 
operated on by a general surgeon was an independent adverse prognostic factor, they 
have not offered an explanation for these differences. Moreover the data from which the 
studies were based is historical being predominantly derived from the 1980’s. Despite 
this, these studies have been influential and have resulted in the recommendations that 
all patients with ovarian cancer should be operated on by a gynaecological surgeon 
whenever possible (CRAG1995), (department of healthl999a), (NHS Centre for 
Reviews and Disseminationl999b).
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The study described in this chapter was conducted to test the hypothesis that patients 
operated on by general surgeons have poorer survival because they are more ill. This 
was based upon the author’s experience having worked in both general surgery and 
gynaecology. This chapter section presents data that might explain some of the survival 
variation between patients operated on by general surgeons and gynaecologists.
A fourth large population study based on women diagnosed with ovarian cancer in 
Scotland during 1987, 1992, 1993 & 1994 demonstrated that patients operated on by 
specialist gynaecologists had a survival advantage over those women operated on by 
general gynaecologists (Junor, Hole, McNulty, Mason, & Youngl999a). This study 
found that there was a statistical difference only in the group of patients with advanced, 
FIGO stage 3, ovarian cancer in whom it was not possible to optimally cytoreduce the 
disease. This survival advantage, which was apparent within three years of diagnosis, 
was not accounted for in multivariate modelling, by the differential use of 
chemotherapy. The interpretation of these data was that there was an ill-defined aspect 
of specialist surgery that conferred the survival benefit. The implication being that if 
cytoreduction is important then the proportion of the patient’s disease remaining might 
relate to the probability of prolonged survival. The survival analysis in this previous 
study corrected for the patient factors; age, socio-economic deprivation, histological 
grade, and FIGO stage and the use of chemotherapy. The specific aspects of surgical 
management were not explored and the explanatory factors remain elusive.
The second hypothesis being tested was that if there are genuine survival differences 
between patients operated on by different groups of surgeons then there should be 
biologically plausible differences in the clinical management and in the processes of 
care. These differences should account for these survival variations. Thus the second
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aim of the study described in this chapter was to account for the differences in the 
surgical management of patients treated by specialist gynaecologists, compared with 
other surgeons, and to relate these to variations in survival.
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2.3 Methods
Study design
The study was a retrospective case note review of all women diagnosed with ovarian 
cancer between 01/01/1995 and 31/12/1997 who were registered on the Scottish Cancer 
Registration dataset (SMR-06) and whose case records were available for review. 1997 
was the latest year for which complete cancer registration was available. All records 
associated with a diagnostic code of C56 or C57 in the 10th revision of the International 
Classification of Disease (ICD 10) were identified and scrutinised. For registrations 
before 1996, the diagnostic code 183, in ICD 9 was used.
Authorisation
The study received authorisation from MREC15 and all LRECs. Authorisation was also 
obtained from the Privacy Advisory Committee of the Information and Statistics 
division of the Scottish Office as well as from all hospital trusts’ Chief Executive 
Officers or Medical Directors. All gynaecology consultants were informed of the study 
in writing.
Data collection
All data collection was by the author over a twelve-month period. This was collected on 
a specially prepared data collection form. The data fields were based upon prior 
hypotheses based upon the author’s experience in gynaecology as well as the previous 
data fields collected in previous studies (Junor, Hole, & Gillisl994), (Woodman, 
Baghdady, Collins, & Clymal997), (Kehoe, Powell, Wilson, & Woodmanl994), (Junor, 
Hole, McNulty, Mason, & Youngl999a). More specifically data pertaining to the intra­
operative findings, what was done surgically, what surgical approach was taken, how
15 MREC/99/0/34: Identification of surgical factors associated with improvements in survival for ovarian 
cancer observed in specialist gynaecologists in Scotland.
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long the surgery took as well as what disease remained at the end of the procedure was 
collected. Data were obtained from the medical record, clinic correspondence, surgical 
record, anaesthetic form as well as the pathology report and any additional imaging 
investigative reports. The data proforma was piloted prior to use and was subsequently 
modified and the data definitions defined. All acute hospitals were visited between two 
and eight times to maximise case note retrieval. Approximately 20 minutes were spent 
abstracting data from each patient medical record. An attempt to gain information 
pertaining to patients registered by hospices and nursing homes/ hospitals and from 
domicilary cancer registrations had to be abandoned early on because no meaningful 
data was forthcoming from these sites.
Data were entered into a specially written database, written by the author, using 
msACCESS-97 (Microsoft inc. 1997a). Extensive use of error checking was used in the 
database. Drop down boxes (combo options) and embedded data validation 
programming was used to minimise both syntactical and logical errors. Identified errors 
on data entry were immediately flagged up. Any obvious error was rechecked on the 
subsequent visit to each acute hospital. At least one record from each hospital (n= 25) 
was re-abstracted by the author on the last visit to the hospital to validate prior data 
abstraction. This number was arbitrarily chosen to be a balance between adequately 
providing a quality control and what was feasible logistically.
At the end of the study the abstracted data set was linked to the cancer registration data 
set and a comparison was performed between the common data fields as a further 
validation check. The error rate was less than 1.7%. Linkage of the main dataset was 
made with the socio-economic data coded on patient postcode. Previously defined 
specialist definitions (vide infra) were linked in at this point.
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Data was then exported to Excel (Microsoft inc. 1997b) to facilitate subsequent 
exportation into SPSS v 9.0 (SPSS inc. 2000) which was used to analyse the data. It was 
not possible to directly export data from the database into the statistical programme.
Definitions
Specialist gynaecologist
The definition of a gynaecology cancer specialist was identical to that used in the 
previous study (Junor, Hole, McNulty, Mason, & Youngl999a). These gynaecologists 
were chosen by the steering committee of the previous study. This was to ensure 
consistency between the studies. General gynaecologists were ascertained by their 
listing in the Royal College of Obstetricians & Gynaecologists list of members and 
fellows (RCOG 1997b). General surgeons could be identified from their descriptions in 
discharge letters. Cases whose operations had both general surgeons and gynaecologists 
present were coded according to the speciality that took the case to theatre.
Survival time
Survival data were obtained from Information & Statistics Division (ISD) of the 
Scottish health department. Survival times were defined as the time in days between the 
date of operation and the date of death. The date of censoring, for patients not known to 
be deceased, was the later of either the last recorded date that the patient was known to 
be alive or the 14th December 1999 (the date that the data file was recorded by ISD). 
The primary end point was death from any cause. This was used over the cancer specific 
cause of death because of possible inaccuracies from death certification (Maudsley & 
Williams 1993).
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Residual disease: ‘<2cm/>2cm * categorisation
The residual disease categorisation was assigned from the interpretation of the medical 
record, specifically the operation record and the pathology report. Evidence was sought 
for optimal debulking (diameter of residual disease < 2cm) having taken place. An 
explicit statement by the surgeon was present in only 30% of the operation notes. The 
interpretation was based upon what was found at operation; the amount and distribution 
as well as the structures to which disease was adherent; what surgery was performed 
and what specimens were received by pathology including their size and completeness 
of excision. This was interpreted in conjunction with any qualitative or quantitative 
description of residual disease in the operating note. These specific details mentioned 
above, upon which the residual disease status was categorised, were recorded in the data 
collection form and database. All interpretation was by the author and was based on the 
author’s surgical experience with ovarian cancer. If there was evidence of bulk disease 
at the beginning of surgery but there was little other information, it was assumed that 
there was insufficient evidence that satisfactory debulking had taken place and the case 
was coded as ‘>2cm’.
FIGO stage
All cases were ascribed, by the author, a ‘retrospective FIGO stage’ based upon the best 
available information in the clinical, operation and pathology report according to 
previously published staging definitions (Shepherd1989b).
Operating times
These were from the anaesthetic chart/graph.
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Multidisciplinary clinic
This based upon the clinic correspondence. Either an explicit statement of a 
multidisciplinary clinic or evidence of follow up by both gynaecologist and medical/ 
clinical oncologist was sought.
The definitions of the other variables used are self evident.
Analysis & Statistical methods
The power calculations from the previous Scottish study (Junor, Hole, McNulty, Mason, 
& Young 1999a) were used to confirm that the three-year period from 1995 to 1997 
would provide sufficient patient numbers sufficient for this study. 725 deaths were 
required to detect a relative hazard ratio of 0.82 with 90% power at the 5% significance 
level. These assumptions were drawn from the differences observed from analysis of the 
effect of specialisation in breast cancer and also from the non-significant benefit of 
specialisation, hazard ratio of 0.86, from the data collected in 1987 [David Hole 
personal communication]. Similar assumptions were made regarding the proportion of 
patients being treated by general gynaecologists and specialists gynaecologists.
Data were statistically analysed using SPSS v 9.0 (SPSS inc.2000). Comparison of
categorical data between groups of patients was performed using the X2-test or Fisher’s
exact test where expected frequencies were small (Colton 1974). Comparison of means 
from continuous normally distributed data was performed using the t-test. The Mann- 
Whitney U test was used for comparing the equality of non-normally distributed 
continuous data.
Multiple logistic regression was used to test the association of multiple independent 
factors with dichotomous dependent variables (Katzl999a). Univariate survival analysis 
was by the Kaplan-Meier method using the Log-rank test to compare the survival times
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between groups of patients. Multivariate survival analysis to explore the association of 
multiple factors with survival used Cox’s proportional hazards model (Coxl972; 
Katz1999a). Statistical significance was at the 95% confidence level unless otherwise 
stated.
To allow the use of parametric statistics to analyse the distribution of the tumour marker 
CA125, the value of CA125 was transformed by taking the natural logarithm of the 
CA125 result [Ln(CA125)]. The distribution of the Ln(CA125) then approximated 
normality allowing the use of parametric statistics.
Data analysis was by the author and the multivariate analysis was checked by Professor 
Hole.
105
2.4 Results
Number o f  cases
Overall, 1724 cases were recorded in SMR-06. Case records could be identified and 
abstracted for 1408 (82%) of registered patients. Of the 331 missing records, 25 (7.6%) 
were domiciliary cancer registrations for which no case records are available, 35 
(10.6%) were registered at nursing homes and hospices and 271 (82%) were missing 
from acute hospital trusts. Of these, six large hospitals accounted for 172 (52%) of the 
missing records. Two of these trusts had a case note destruction policy for deceased 
case records after the minimum permitted time of three years. Forty-one (12%) patients 
were death certificate only registrations with a survival time of 0 days. The median 
survival time for the patients whose records were missing was 349 days.
Of these 1408 cases, 967 patients (69%) had both histologically confirmed epithelial 
ovarian cancer and had undergone laparotomy. This group, which is more homogenous 
and relevant to the hypotheses being tested, is the denominator for the study described 
here unless described otherwise. Gynaecologists operated on 820 (84.8%) patients, with 
138 (14.3%) being operated on by a general surgeon. The median survival of patients in 
this group was 672 days. The anadjusted survival curve of the abstracted cases is shown 
in figure 2-0.
441 patients had neither laparotomy or had an ovarian cancer whose histology was other 
than epithelial ovarian cancer. These patients are only included in one of the analyses to 
allow direct comparison with a previous study and this is explicitly stated. The median 
survival of patients in this group was 253 days.
Figure 2-1 shows a Cox proportional hazards analysis relating the speciality type of the 
surgeon with survival. This analysis was firstly performed in exactly the same manner
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as the previous study (Junor, Hole, McNulty, Mason, & Youngl999a) with the 
complete dataset [n=1408]. This dataset contained patients with non-epithelial ovarian 
cancer and tumours classified as borderline. The previously identified difference in 
survival between general gynaecologists and specialists could not be reproduced despite 
correction for patient prognostic factors. The survival difference between 
gynaecologists and general surgeons was confirmed. The analysis was re-run on the 
more homogenous dataset, limited to patients with histologically confirmed epithelial 
ovarian cancer who underwent laparotomy [n=967]. Again no statistical survival 
difference could be detected between general gynaecologists and specialists after 
correction for the previously used prognostic factors. Again being operated on by a 
general surgeon was a poor prognostic factor.
Figure 2-2 shows a Kaplan Meier survival analysis of patients with FIGO stage III 
ovarian cancer who were not optimally cytoreduced, having an estimated residual 
disease diameter greater than two centimetres. This shows that there was no significant 
difference in the survival curves between patients operated on by general gynaecologists 
and specialist gynaecologists in this group of patients.
Figure 2-3 shows the characteristics of patients operated on by gynaecologists and 
general surgeons. This shows that patients operated on by general surgeons were older 
and had more advanced disease. A greater proportion of patients had bowel obstruction 
noted at the time of laparotomy and were treated on emergency theatre lists. Patients 
treated by gynaecologists were more likely to receive chemotherapy, be referred for a 
post-operative medical oncology opinion and to attend a multidisciplinary clinic.
Figure 2-4  shows a univariate survival analysis of patient, disease and treatment 
factors. The unadjusted survival difference between patients operated on by
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gynaecologists and general surgeons is shown graphically in the Kaplan-Meier plot in 
figure 2-5.
Figure 2-6  shows a multivariate survival analysis using Cox proportional hazards 
model. This shows an initial model adjusted for Age, FIGO stage, histological grade 
and the presence of ascites. This confirms the results of previous studies. Patients 
operated on by general surgeons have an increased likelihood of death with a relative 
hazard ratio or 1.45 (95% confidence interval is 1.16 to 1.80). When the model is 
adjusted for the additional factors of both bowel obstruction and the use of 
chemotherapy, no statistical difference is observed between the two groups of surgeons. 
In this model, patients operated on by general surgeons had a relative hazard ratio of 
1.05 (95% confidence interval is 0.81 to 1.36).
The group of patients with FIGO stage Ic through to stage IV disease (859 patients) was 
further analysed. This is the group of patients who would generally be considered 
suitable for adjuvant chemotherapy. Analysis of this group shows that the median 
survival time of patients not receiving chemotherapy was 55 days compared to 699 days 
for patients who received chemotherapy. This is shown diagrammatically using the 
Kaplan Meier method in figure 2-7.
The biological characteristics of patients operated on by the different groups of surgeons 
are shown in figure 2-8. This shows that mean of CA125 result (log transformed) is 
greater for patients operated on by specialist gynaecologists and general surgeons 
compared with general gynaecologists. Specialist gynaecologists operated on more 
patients with stage III and IV disease compared with general gynaecologists. General 
surgeons operated on patients who in general were older, had FIGO stage III or IV 
disease and whose histopathology was more likely to be an adenocarcinoma subtype.
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The different surgical approaches used by the three categories of surgeons are shown in 
figure 2-9. This shows statistical difference in the manner in which specialist 
gynaecologists perform their surgery in patients with ovarian cancer. This group is more 
likely to use a retroperitoneal approach. These cases are more likely to require blood 
transfusion and also on average take longer to perform compared to cases operated on 
by general gynaecologists or general surgeons. Despite these differences there was no 
difference in the proportion of patients who were optimally cytoreduced between the 
two groups of gynaecologists. Patients operated on by general surgeons were 
significantly less likely to have been optimally cytoreduced.
Figure 2-10 shows a multivariate analysis of the factors associated with optimal 
cytoreduction. This shows that patient and biological factors are strongly associated 
with the achievability of cytoreduction. There was no difference between general and 
specialist gynaecologists. General surgeons are associated with less effective 
cytoreduction after correction for the other factors in the model. Operating time is also 
associated with the likelihood of optimal cytoreduction.
Figure 2-11 shows the association of operating time with the nature and extent of the 
surgical procedures that were performed at the time of operation. The box plots show 
the median and inter-quartile rage of operating times for various described procedures 
that were performed on this group of patients. The data show that when more is 
performed at surgery the operation took a longer time. Procedures limited to biopsy 
took the least amount of operating time (median time=45 minutes) whereas procedures 
such as removal of uterus, ovaries and omentum took twice this time (median time=90 
minutes). The most extensive operations involving bowel surgery or removal of lymph 
nodes took considerably longer (median time between 2 & 4 hours).
109
Figure 2-0: survival curve for all patients whose case notes were retrieved and 
abstracted.
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This Kaplan Meier survival curve shows patient survival for all 
abstracted cases from the cohort of patients diagnosed with ovarian 
cancer in Scotland during 1995-1997 and registered with cancer 
registration. It shows that the median survival of those patients who 
underwent laparotomy and whose histology confirmed epithelial 
ovarian cancer was 672 days. The median survival of patients who 
either did not undergo laparotomy or whose histology was other that 
epithelial ovarian cancer was 253 days.
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Figure 2-1: analysis of survival of patients treated by specialist and non-specialist 
gynaecologists and general surgeons.
General
gynaecologist
Specialist gynaecologist General surgeon
Complete dataset: n=14081<
RHR RHR (95%CI) RHR (95%CI)
unadjusted 1 1.3 (1.05-1.64) 
P =0.016
2.7 (2.24-3.35) 
P  <0.0001
Adjusted for six factors 1 1.24 (0.97-1.59)
P=0.09
1.49 (1.19-1.87)
P=0.0005
Dataset analysed limited to patients receiving laparotomy and epithelial ovarian cancer only: n=967
unadjusted 1 1.32 (1.05-1.66)
P=0.016
2.54 (2.07-3.11)
P<0.0001
Adjusted for six factors 1 1.26 (0.98-1.63)
P=0.07
1.51 (1.20-1.9)
P=0.0005
Model adjusted for FIGO stage, age group, histological grade, histopathology in three prognostic 
categories, presence of ascites, and socio-economic deprivation in three categories.
16 Dataset contains cases with non-epithelial ovarian cancer and patients who did not receive an operation 
to allow valid comparison with previous Scottish studies (Junor, Hole, McNulty, Mason, & Youngl999a).
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Figure 2-2: survival curves of patients with FIGO stage III disease and who had 
tumour diameters greater than 2cm after laparotomy treated by different surgeon 
types.
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This shows the Kaplan Meier survival curves of patients with FIGO 
stage III ovarian cancer who had residual disease diameters of > 2cm 
after laparotomy who were treated by different surgical specialities. No 
other statistical adjustment has been made. It shows that the survival 
curves of patients treated by specialist gynaecologists and general 
gynaecologists are superimposed. Patients treated by general 
surgeons had poorer survival in comparison.
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Figure 2-3: characteristics of patients operated on by gynaecologists and general 
surgeons.
Surgical speciality
Gynaecologist18 General surgeon
n (%) n (%) / 2: p-value19
Age group
<=54 221 (27.0) 18 (13.0)
P<0.0001
55 to 64 223 (27.2) 33 (23.9)
65 to 74 241 (29.4) 40 (29.0)
> 75 135 (16.5) 47 (34.1)
FIGO stage
1 244 (29.8) 5 (3.6)
P<0.0001
2 61 (7.4) 1 (0.7)
3 405 (49.4) 108 (78.3)
4 93 (11.3) 17 (12.3)
Dk 17 (2.1) 7 (5.1)
Histological grade
Well 91 (11.1) 3 (2.2)
P=0.005
Moderate 181 (22.1) 23 (16.7)
Poor 417 (50.9) 79 (57.2)
Not stated 131 (16)) 33 (23.9)
Ascites present
No 269 (32.8) 18 (13.0)
P<0.0001
Yes 459 (56.0) 75 (54.3)
Uncertain 92 (11.2) 45 (32.6)
Theatre list type
Routine 751 (91.6) 51 (37.0)
P<0.0001
Emergency 24 (2.9) 55 (39.9)
Don’t know 45 (5.5) 32 (23.2)
Bowel obstruction recorded
No 653 (79.6) 40 (29.0)
P<0.0001
Yes 25 (3.0) 53 (38.4)
Equivocal 142 (17.3) 45 (32.6)
Chemotherapy used
No 195 (23.8) 51 (37.0)
P=0.003
Yes 599 (73.0) 83 (60.1)
Don’t know 26 (3.2) 4 (2.9)
Post operative referral to medical oncology
No 79 (9.6) 28 (20.3)
P=0.009
Yes 716 (87.3) 105 (76.1)
Don’t know 25 (3.0) 5 (3.6)
Attended multidisciplinary clinic
No 119 (14.5) 35 (25.4)
P=0.0002
Yes 590 (72.0) 74 (53.6)
Don’t know 111 (13.5) 29 (21.0)
Analysis of patients diagnosed with epithelial ovarian cancer during 1995-1997 who underwent 
laparotomy: n=967.
17 In 9 (0.9%) cases the surgeon speciality could not be ascertained and these have been omitted for 
clarity.
18 In this table gynaecologist includes both general and specialist gynaecologist.
19 Fischer’s exact test for analyses with cells with values of 5 or less.
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Figure 2-4: univariate analysis of 3-year survival for patient, disease and 
treatment factors.
n 3-year survival (%) 20^ m e d ia n p-value 1
Age group
< 5 4 243 (50.0)
P<0.0001
55 to 64 259 (31.0) 776
65 to 74 283 (23.5) 571
> 7 5 182 (12.6) 309
FIGO stage
1 252 (71.9)
P <0.0001
2 62 (46.2) 1312
3 516 (14.8) 449
4 111 (7.7) 322
dk 26 (26.0) 547
Histological grade
W ell 94 (70.1)
P<0.0001
M oderate 206 (38.2) 868
Poor 500 (19.1) 517
D o n ’t know 167 (33.8) 814
Ascites at operation
N o 287 (53.6)
P<0.0001
Y es 536 (19.2) 501
D o n ’t know 144 (27.1) 555
Theatre list type
Routine 804 (33.1) 752
P <0.0001
Em ergency 79 (16.8) 351
D o n ’t know 84 (15.9) 489
Bowel obstruction at operation
N o 696 (34.8) 864
P <0.0001
Y es 78 (5.5) 290
Equivocal 193 (23.5) 492
Chemotherapy used
N o 246 (36.9) 349
P =0.016
Y es 690 (28.8) 726
D o n ’t know 31 (17.3) 365
Operator speciality
G ynaecologist 820 (33.8) 773
P <0.0001
General surgeon 138 (8.4) 310
D o n ’t know 9 (48.6) 1056
Post-operative referral to medical 
oncology
N o 107 (14.3) 266
P <0.0001
Y es 830 (31.7) 752
D o n ’t know 30 (45.2) 892
Attended multidisciplinary clinic
N o 154 (22.0) 297
P<0.0001
Y es 670 (32.4) 784
D o n ’t know 143 (28.0) 692
A nalysis o f patients diagnosed with epithelial ovarian cancer during 1995-1997  w ho underwent 
laparotomy: n=967.
20 M edian survival in days.
21 L og rank statistic.
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Figure 2-5: survival curves of patients grouped according to the surgeon
performing the laparotomy.
surgeon type
general surgery
+ censored case
gynaecology
0.0 censored case
0 365 730 1095 1460 1825
survival time /days
Number of patients=958: Log rank statistic: p-value<0.0001
This Kaplan Meier survival curve of patients diagnosed with epithelial 
ovarian cancer during 1995-7 who underwent laparotomy categorised 
by surgeon type. It shows that patients operated on by gynaecologists 
have better survival than those operated on by general surgeons.
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Figure 2-6: table showing results of Cox proportional hazards survival analysis.
Gynaecologist General surgeon
Initial model 
Adjusted for
A ge group 
FIGO stage 
H istological 
grade 
A scites
Also adjustedfor
RHR
1
RHR (95% Cl) 
1.45 1.16-1.80
p-value22
0.0009
A ge group 
FIGO stage 
H istological 
grade 
A scites
+ B ow el
obstruction
1 1.26 (0.99-1.6) 0 .062
A ge group  
FIGO stage 
H istological 
grade 
A scites
+ List type 1 1.30 (0.98-1.69) 0.06
A ge group  
FIGO stage 
H istological 
grade 
A scites
+ B ow el
obstruction + 
List type
1 1.18 (0.89-1.57) 0.24
A ge group 
FIGO stage 
H istological 
grade 
A scites
+ Chemotherapy
used
1 1.15 (0.92-1.46) 0.21
A ge group 
FIGO stage 
H istological 
grade 
A scites
+ B ow el
obstruction +
Chemotherapy
used
1 1.05 (0.81-1.36) 0.68
Hazard ratios (HR) with 95% confidence intervals (Cl) for gynaecologists and general surgeon as 
principal surgeon, entered into separate Cox proportional hazards m odels.
This table shows that when either the prognostic factor ‘bowel 
obstruction’ or ‘chemotherapy used’ is added to the model the 
prognostic significance of the surgeon speciality ceases to become 
statistically significant.
22 p-values are W ald for the surgeon speciality as an independent factor in the m odel, conditional on 
the other factors being present.
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Figure 2-7: survival analysis of patients staged FIGO stage 1C to 4 according to
whether they received chemotherapy.
chemotherapy used
yes
— i- + censored case
no
censored case0.0
0 365 730 1095 1460 1825
survival time
Number of patients =857: Log rank statistic: p-value<0.0001
This Kaplan Meier survival curve shows the survival of patients with 
epithelial ovarian cancer who underwent laparotomy and who were 
who were categorised as having FIGO stage 1c to IV disease grouped 
according to whether they received chemotherapy or not. This shows 
that patients who did not receive chemotherapy had short survival 
(median survival=55 days) compared to those patients receiving 
chemotherapy (median survival=699 days)
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Figure 2-8: biological characteristics of patients operated on by different groups 
of surgeons.
General Specialist General
Gynaecologist Gynaecologist_____________________ surgeon
n (%) n (%) %2: p-value23 n (%)
Age groups
<54 184 (27.2) 37 (26.2)
P=0.99
18 (13.2)
55-64 183 (27.0) 39 (27.7) 34 (25.0)
65-74 198 (29.2) 42 (29.8) 39 (28.7)
>75 112 (16.5) 23 (16.3) 45 (33.1)
Mean (lnCA125) 
Frozen pelvis
Y es
5 .94
104 (15.4)
6.30
22 (15.6)
P =0.033 24 
P =0.65
6.67
27 (19.9)
N o 477 (70.5) 93 (66.0) 34 (25.0)
D o n ’t know 96 (14.2) 26 (18.4) 75 (55.1)
Adherent to pelvic side wall
Y es 363 (53.6) 88 (62.4)
P=0.10
44 (32.4)
N o 242 (35.7) 39 (27.7) 19 (14.0)
D o n ’t know 72 (10.6) 14 (9.9) 73 (53.7)
Histology type
Serous 88 (13.0) 30 (21.4)
P=0.28
19 (14.1)
M ucinous 98 (14.5) 15 (10.7) 12 (8.9)
Clear cell 34 (5.0) 8 (5.7) 3 (2.2)
Endometrioid 101 (15.0) 20 (14.3) 5 (3.7)
Anaplastic 3 (0.4) 1 (0.7) - -
Papillary serous 184 (27.3) 35 (25.0) 31 (23.0)
A denocarcinom a 152 (22.5) 30 (21.4) 64 (47.4)
Other histology 13 (1.9) - - 1 (0.7)
D o n ’t know 4 (0.6) 2 (1.4) 1 (0.7)
FIGO stage
1 207 (31.2) 37 (26.8)
P =0.12
4 (3.1)
2 52 (7.8) 9 (6.5) 1 (0.8)
3 335 (50.5) 68 (49.3) 109 (83.2)
4 69 (10.4) 24 (17.4) 17 (13.0)
Dk 14 (2.1) 3 (2.1) 5 (3.7)
Histological grade
W ell differentiated 80 (11.8) 11 (7.8)
P =0.17
3 (2.2)
M oderately differentiated 151 (22.3) 30 (21.3) 23 (16.9)
Poorly differentiated 333 (49.2) 82 (58.2) 78 (57.4)
N ot stated 113 (16.7) 18 (12.8) 32 (23.5)
Data analysed from patients with h istologically  verified epithelial ovarian cancer w ho underwent 
laparotomy, n=967. thirteen cases could not be accurately ascribed to a particular surgeon group and are 
not show n for clarity.
23 Comparison betw een general gynaecologists and specialist gynaecologists only.
24 t-test
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Figure 2-9: surgical approaches to cytoreduction used by different groups of 
surgeon.
G yn aeco log ist S p ecia list G en era l su rgeon
n (%) n (%) n (%) %2: p -va lu e
R etrop er iton ea l ap p roach
Y es 13 (1.9) 25 (17.7) 4 (2.9)
P <0.0001
N o 612 (90.4) 103 (73.0) 107 (78.7)
Uncertain 52 (7.7) 13 (9.2) 25 (18.3)
U retero ly s is
Y es 28 (4.1) 26 (18.4) 5 (3.7)
P<0.0001
N o 599 (88.5) 102 (72.3) 110 (80.9)
Uncertain 50 (7.4) 13 (9.2) 21 (15.4)
A ttem p ts at retrop eriton ea l 
ap p roach
Y es 74 (10.9) 40 (28.4) 25 (18.4)
P <0.0001
N o 603 (89.1) 101 (71.6) 111 (81.6)
P roxy  m ark ers o f  aggress ive  su rgery  
B lood  tran sfu sion
Y es 105 (15.5) 38 (27.0) 15 (U.0)
P <0.0001
N o 517 (76.4) 85 (60.3) 97 (71.3)
Uncertain 55 (8.1) 18 (12.8) 24 (17.6)
O p era tin g  tim e
M edian time 677 65 min 141 100 min 136 65 min P < 0 .0 0 0 1 "
O u tcom e o f  cy tored u ction
Optimal [<2cm ] 351 (51.8) 70 (49.6) 16 (11.8) P<0.0001
N ot optim al [>2cm ] 326 (48.2) 71 (50.4) 120 (88.2)
Data analysed from the group o f patients w ith histo logically  verified epithelial ovarian cancer w ho  
underwent laparotomy, n=967. thirteen patients could not be accurately assigned to the surgeon categories 
and have been om itted for clarity.
25 Kruskal W allis test
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Figure 2-10: logistic regression analysis of the association of factors with optimal 
cytoreduction.
Factor________________________________________Cytoreductive status
Optimal cytoreduction [<2cm]
(%) Odds ratio (95% Cl) p-value
FIGO stage
1 (54.8) 1 - -
2 (11.0) 0.18 (0.07-0.49) 0.0006
3 (30.3) 0.02 (0.01-0.04) <0.0001
4 (3.9) 0.01 (0.004-0.03) <0.0001
Histological grade
W ell differentiated (16.6) 1 - -
M oderately differentiated (26.5) 1.1 (0.44-2.75) 0.05
Poorly differentiated (38.5) 0.58 (0.24-1.37) 0.82
D o n ’t know (18.4) 0.60 (0.22-1.58) 0.21
Histological subtype
B est prognosis (46.9) 1 - -
Intermediate prognosis (35.4) 1.26 (0.75-2.13) 0.38
Worst prognosis (17.7) 0.98 (0.54-1.78) 0.94
Age group
<54 (37.4) 1 - -
55-64 (24.5) 0.40 (0.24-0.68) 0.0008
65-74 (25.6) 0.31 (0.18-0.53) <0.0001
>75 (12.5) 0.21 (0.11-0.41) <0.0001
Ln(CA125) [p er log unit] 0.69 (0.58-0.82) <0.0001
Surgeon category
General gynaecologist (80.3) 1 - -
Specialist gynaecologist (16.0) 0.97 (0.55-1.70) 0.92
General surgeon (3.7) 0.21 (0.10-0.44) <0.0001
Operation time Iper m in ute] 1.007 (1.004-1.011) 0.0001
Patients with h istologically  verified epithelial ovarian cancer w ho underwent laparotomy, n=967.
H istological grade was subcategorised into three categories. This w as on the basis o f Kaplan M eier 
analysis o f survival for each subtype. ‘B est prognosis’ included m ucinous, clear cell and endom etrioid  
tumours: m edian survival not reached at date o f censoring; ‘Intermediate prognosis’ included serous, 
serous-papillary and ‘other’ tumours: m edian survival=639 days; ‘worst prognosis’ included anaplastic, 
adenocarcinom a (type unspecified): m edian survival=436 days. For ‘FIGO stage’ and ‘surgeon category’, 
m issing value category not included in the analysis because the numbers w ere very sm all.
This table shows the results of a logistic regression analysis showing 
the association of various patient, tumour and surgeon factors with the 
likelihood of optimal debulking. This shows that after correction for 
these factors early FIGO stage, well differentiated tumours, young age, 
low pre-operative CA125, being operated on by a gynaecologist and 
longer operations were associated with a greater likelihood of optimal 
debulking at laparotomy.
120
Figure 2-11: Box plot illustrating operating times of patients who underwent 
specific surgical procedures.
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This plot shows the relationship of operating time according to the 
specific surgery performed at laparotomy. The heavy line represents 
the median operating time and the box represents the inter-quartile 
range, outliers are shown. This shows that more extensive surgery is 
associated with more operating time.
Patient group analysed are those with histologically confirmed epithelial ovarian cancer who underwent 
laparotomy, n=967. The operating time was unavailable for 89 patients.
.00= procedure uncertain; bx only= biopsy only; pOM=partial omentectomy only; USO=unilateral oophorectomy; 
TAHBSOOM=total abdominal hysterectomy, bilateral salphingo-oophorectomy and omentectomy; TAHBSOOM LN=total 
abdominal hysterectomy, bilateral salphingo-oophorectomy, omentectomy and pelvic lymphadenectomy; 
SBresec=procedure included small bowel resection; LBresec=procedure included large bowel resection;
TAHBSOOM LBresecCOL=total abdominal hysterectomy, bilateral salphingo-oophorectomy, omentectomy, large bowel 
resection and colostomy, bypass=palliative bowel bypass procedure; other comb=other combination of procedures
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2.5 Discussion
Factors explaining general surgeons as a poor prognostic factor.
These results reproduce the findings of the previous studies, which suggest that being
operated on by a general surgeon is a negative prognostic factor, and suggest an
explanation for the survival differences observed. The survival differences can be
accounted for, in the Cox multivariate survival model, by the addition of the factors of
bowel obstruction and the use of chemotherapy. This suggests that the survival
differences seen probably reflect differences in the ‘patient status’. It is probable that the
latter dictate survival rather than the surgeon speciality per se in this cohort of patients.
Bowel obstruction occurs late in the natural history of ovarian cancer (DiSaia &
Creasman1997c). Thus the survival advantage conferred by gynaecologists might
represent a ‘lead time’ bias (Berrino, Esteve, & Colemanl995). Patients operated on by
gynaecologists rarely had bowel obstruction whereas more than a third of patients
operated on by general surgeons had bowel obstruction at laparotomy. This is likely to
be a reflection of the fact that patients presenting with bowel obstruction will complain
of acute abdominal symptoms that result in their emergency admission to surgical
wards.
Patients would usually be considered for chemotherapy if the disease were staged as 
FIGO Ic through to stage IV. The median survival for patients not receiving 
chemotherapy in this group is very short (55 days). This suggests overall, that the 
patients who did not receive chemotherapy were possibly not fit enough to receive it, 
rather than there being errors of omission. The reason for this interpretation is that the 
natural history of the disease is such that the delay or omission of chemotherapy, in an 
otherwise fit patient, is unlikely to result in a median survival as short as 55 days.
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The interpretation of these results suggest that general surgeons see and operate on 
patients with more advanced ovarian cancer and it is this that contributes to the reduced 
survival rather than the effect of differences in the surgery performed. These data are 
important as the original studies resulted in recommendations that gynaecologists 
should be the speciality who should operate on these patients. Whilst it may be the case 
that gynaecologists do confer survival advantage, through better understanding and 
experience of the surgery required and also through formalised relationships with 
medical oncologists and other members of the multidisciplinary team, these data 
suggest that there is a group of patients who will present as surgical emergencies. These 
patients probably represent the group who have a very poor prognosis whatever 
treatment is undertaken. The published guidelines should reflect that this is the case. 
Moreover the tone of the guidelines should become more inclusive to reflect the 
contribution that the general surgeon can give for these patients many of whom will do 
poorly.
Specialist gynaecologists and survival
The data and analyses from the cohort of patients diagnosed between 1995 and 1997 fail 
to demonstrate a survival advantage for patients operated on by the surgeons designated 
as gynaecological cancer specialists. It was not possible to reproduce the results from 
the previous Scottish study (Junor, Hole, McNulty, Mason, & Young1999a) with this 
cohort. Indeed before the addition of patient and biological factors to the model, patients 
operated on by gynaecological cancer specialists appeared to be at a survival 
disadvantage. Moreover no difference in survival could be found for the group of 
patients presenting with FIGO stage III disease in which optimal cytoreduction was not 
possible. The definition of the specialist gynaecological surgeon was the same as that 
used in the previous Scottish study to ensure consistency.
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There are a number of possible explanations for this observed inconsistency. Firstly the 
difference between the two studies might be a result of chance, with either representing 
the ‘truth’ and the other being inaccurate. Another explanation is that the current study 
could be underpowered to show a genuine difference between specialist and general 
gynaecologists. A third explanation is that there is now no difference in survival and 
that have been genuine changes in the management of women with ovarian cancer 
between the first cohort of patients (1987, 1992-4) and the currently analysed cohort 
(1995-7) that reduce the influence of the prognostic advantage of being operated on by a 
specialist gynaecologist.
The most recent study was conducted in a similar manner to the previous study, utilising 
a similar method of case note identification, data abstraction, data definitions and 
analysis. Both were large studies. This consistency should reduce the likelihood of 
inconsistent results and analysis through random events.
Because the number of cases available for analysis were fewer than in the previous 
study it is possible that study may have been underpowered to show a difference. 
However this is unlikely for several reasons. The direction of the difference was in the 
opposite direction; i.e. specialist gynaecologists were associated with a slight non­
significant survival disadvantage compared to cases operated on by general 
gynaecologists. Moreover the number of deaths (n=883) in the cohort of all ovarian 
cancer patients (n=1408) was greater than the number required by the power 
calculations based upon the previous study. Thus in these more recent years the 
specialist effect is not statistically apparent.
The third explanation is most plausible. The previous Scottish study examined the 
survival difference between patients operated on by specialist and general
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gynaecologists from a cohort that included the years 1987, 1992, 1993 and 1994. It is 
plausible that over this time, changes in clinical management as well as with the 
processes of care could have improved the relative survival of patients operated on by 
general gynaecologists. This could eliminate the survival advantage previously seen 
with specialist gynaecologists. Chapter 3 examines more fully the effect of changes in 
clinical management and process longitudinally over time and relates these differences 
to improvements in survival. Although there were few changes in surgical practice 
between the early 1990’s and the late 1990’s there were marked increases in the use of 
the multidisciplinary clinic and smaller non-significant increases in the use of platinum 
based chemotherapy [figure 3-2]. A greater utilisation of these may have improved the 
relative survival of patients treated by the general gynaecologist by compensating for 
less extensive surgery.
A final and more controversial explanation is that the actual difference, from a surgical 
perspective, between the ‘non-specialist’ gynaecologist and the ‘specialist’ 
gynaecologist is in fact minimal. The definition of the ‘specialist’ used in this study and 
in the previous ones was made by committee. No objective qualifications or sub­
specialist training were used to categorise the two groups. This would have been 
difficult to do because formal Royal College of Obstetricans & Gynaecologists 
subspeciality training had not been formalised in 1995. If this explanation is true then 
the differences observed, between specialists and non-specialists, in the previous study 
(Junor, Hole, McNulty, Mason, & Young1999a) may have been a result of other non- 
surgical factors.
The original hypothesis hypothesized that if survival differences were genuine, then one 
would expect to observe biological plausible differences in the clinical management and
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in the processes of care. Alternatively, as has been demonstrated in the previous 
analysis of survival differences between general surgeons and gynaecologists, 
unaccounted differences in the biological characteristics of patients could account for 
survival differences. The results in figure 2-8 demonstrate that there are only slight 
differences in the biological characteristics between the patients operated on by general 
gynaecologists and specialist gynaecologists. There are slightly more patients with 
FIGO stage III or IV disease and who have poorly differentiated tumours. This is 
reflected in a higher mean [LnCA125] for the cohort of patients treated by specialists.
There are statistically significant differences in the surgical approach to cytoreduction 
by specialist gynaecologists. There is a greater use of retroperitoneal dissection and this 
confirms the results of previous studies (Benedetti-Panici, Maneschi, Scambia, Cutillo, 
Greggi, Mancuso, & S. 1996), (Rubin & Lewis 1993). Moreover proxy markers of more 
aggressive surgery such as increased likelihood of blood transfusion and of greater 
operating time demonstrate that specialists are surgically more aggressive than general 
gynaecologists. These results are consistent with previous studies (Eisenkop, Spirtos, 
Montag, Nalick, & Wangl992). It is likely that these systematic differences are a 
reflection of the familiarity with the retroperitoneal anatomy that is gained from 
operating on other gynaecological malignancies, notably cervical carcinoma. Despite 
differences in surgical approach there was no statistically significant difference in the 
proportion of patients who were optimally debulked. What is not known is the 
proportion of tumour removed by specialists compared with non-specialists. It may not 
be surprising therefore, that there was no difference in the survival outcome between the 
two groups of patients, particularly if residual disease status is as important a prognostic 
factor as the literature would suggest.
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The analysis presented in figure 2-10 show the factors associated with optimal 
debulking. Biological variables are related statistically to the likelihood of successful 
cytoreduction. Despite correction for differences in case mix, no difference can be 
demonstrated between patients operated on by generalist and specialist gynaecologists. 
This would support the argument, illustrated in figure 1.3-6, that the success of surgical 
debulking is determined primarily by tumour related factors.
Operating time is related to the likelihood of successful cytoreduction. Figure 2-11 
shows the operating times associated with different procedures, suggesting that 
operating time reflects what is done at operation. This is, as one would expect. It is not 
possible to comment on whether the increased operating time in patients who are 
successfully cytoreduced is a reflection on the ‘permissiveness’ of their disease, to 
allow more to be done, or whether the corollary is true; that because more time was 
spent operating more could be achieved. It is likely that operating time is a facilitative 
factor, which when plentiful will not guarantee successful debulking; however if it is 
limited will result in sub-optimal debulking.
Validity, accuracy and bias o f results
The completeness of case finding, accuracy of abstraction, and consistency of date of 
diagnosis determine the confidence that can be imparted to the results of population- 
based studies.
The case-note retrieval was 82% of patients in the cancer registration data set. This level 
of note retrieval was similar to the previous study from 1987, 1992-94. The proportion 
of case record abstraction is shown in figure 3-1. Case note retrieval was 5% better for 
1997 than 1995 and this reflects the difficulty retrieving case records that had been 
destroyed by several hospital trusts. The hospital case notes that could not be retrieved
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are likely to represent patients who had died early after diagnosis, the records must be 
kept by the hospital for at least three years after death. The domiciliary registrations and 
those from nursing homes possibly represent patients who may not have been fit enough 
for hospital treatment. This is because had they been the registration would probably 
have been made from the hospital. The accuracy of diagnosis of the cases registered 
outwith hospitals is likely to be poor. The missing records from community registration 
are unlikely to have affected the analysis since they are less likely to have undergone 
laparotomy (a criterion for the group of patients included in analysis). The missing 
records from hospital registrations are more important and may have excluded patients 
who were eligible for analysis but whose survival was short.
All case note abstraction was by the author using a piloted data-abstraction form with 
written definitions and staging proforma. Many of the data items were objective 
however the assessment of residual disease status was largely subjective. This is 
because despite published national guidance in 1995 (CRAG1995) only a small 
proportion of operation records were explicit in recording residual disease diameters. 
This is a relative weakness but one that has almost certainly affected the previous 
Scottish studies (Junor, Hole, & Gillisl994) (Junor, Hole, McNulty, Mason, & 
Youngl999a). The author had personal and practical experience in surgery for ovarian 
cancer making it likely that the interpretation of the available medical records was as 
accurate as the data allow. However at the same time this may have introduced 
unintentional bias through over interpretation. Data were collected on post-operative CT 
scanning to attempt an independent validation of the residual disease status. However in 
Scotland during 1995-97 only 121/1137 (10.1%) of patients had a post-operative CT 
scan and this made this attempt at validation worthless. It is of note that the prospective 
study described in chapter 4 is more robust in this regard.
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Re abstraction of around 25 case notes was performed and ideally an independent 
abstractor would have performed this. However the medical records could not be 
removed from the respective medical records departments and no other abstractor was 
involved with the study, therefore this validation exercise reflected what was 
logistically feasible. Cross checking of common data fields (including: initials, date of 
birth, unit number, postcode, date of diagnosis, date of death) between the abstracted 
dataset and the cancer registration and survival data demonstrated a very low level of 
inconsistency and this increases confidence in the data.
Analysis was of those patients who underwent laparotomy. Therefore the date of 
diagnosis was defined as the date of first laparotomy. This date was universally 
available in the case record. In the initial comparison, which included all patients, the 
date of diagnosis, for those not undergoing laparotomy, was the earliest date where 
there was reasonable objective evidence that the patient had ovarian cancer (eg 
paracentesis date). Therefore the definition of survival was very consistent. The date of 
death was obtained from the national death registration data. This was cross-checked 
where possible with data in the case records and was invariably accurate.
Conclusions
In summary specialist gynaecological surgeons utilise a more aggressive surgical 
approach to cytoreduction that utilises their knowledge of the retroperitoneal anatomy. 
Despite these differences, they did not result overall in more successful cytoreduction 
compared to general gynaecologists during the years 1995 to 1997. Moreover there was 
no statistically significant, or clinically significant, difference in survival between 
patients operated on by general gynaecologists and specialists over this period. The 
reasons for this could be an improvement in other aspects of clinical management that
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compensated for ‘less effective’ surgery. Alternatively the study might be failing to 
detect variation that truly exists. This is thought to be less likely for the reasons outlined 
previously.
The difference in survival between those patients operated on by general surgeons 
compared with gynaecologists is likely to reflect the patient’s general status and thus 
represents a lead-time bias. This is important, as there has been an implication that 
general surgeons are managing their patients less well. There needs to be a greater 
understanding by gynaecologists of the role that general surgeons play in the 
management of patients with bowel obstruction that is found to be secondary to ovarian 
cancer.
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CHAPTER 3
A longitudinal study of the management and survival of patients with 
ovarian cancer in Scotland diagnosed before and after the 
introduction of a national clinical guideline.
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3.1 Aims
To evaluate variation in;
The clinical management of ovarian cancer,
The survival of patients with ovarian cancer,
treated in Scotland before the introduction of a CRAG guideline in 1995 with those 
managed in the following period.
3.2 Background
Published guidelines are becoming ubiquitous despite the uncertainty of their 
effectiveness. The Clinical Research and Audit Group [CRAG] published their 
guideline: Management o f Ovarian Cancer, in 1995 in response to a previously 
conducted audit highlighting poor survival in Scotland(CRAG1995). The aim of this 
chapter is to describe a study that was performed to examine the changes in clinical 
management and patient survival over time and to evaluate the effectiveness of this 
guideline.
Assessing the impact of a guideline is difficult as changes in clinical practice are a result 
of many factors that influence the way in which clinicians act both as individuals and in 
groups (NHS Centre for Reviews and Dissemination 1999a), (Grimshaw & Russell 
1993). Methodologies such as cluster-randomised trials have been described to assess 
the effectiveness of guidelines as an intervention (Campbell 2001). However such 
methodologies are not always appropriate especially when guidelines are disseminated 
nationally. Often guidelines are disseminated with no prospective strategy for 
evaluation. The GRAG guideline discussed above, as well as the Scottish Intercollegiate
132
Guidelines Network [SIGN] series26 and the Royal College of Obstetricians & 
Gynaecologists27 [RCOG] series of guidelines fall into this category.
The 1995 CRAG guideline was written by an ‘expert committee’ drawing on opinion as 
well as the best evidence available. It was disseminated throughout Scotland to all 
gynaecologists and well as oncologists treating patients with ovarian cancer.
The objective of this chapter is to describe a study that examined the clinical 
management of patients diagnosed with epithelial ovarian cancer in Scotland- the target 
patient population that the guideline was drawn up to serve. The clinical practice for the 
three years before the guideline is compared with the management in the years 
following the guideline. Whilst any observed changes cannot necessarily be attributed 
solely to the guideline, any lack of change suggests a lack of effectiveness. This study is 
important as a large resource is being allocated to guidelines and there is a great 
expectation from them. This is especially pertinent at time when SIGN is developing a 
new guideline for the management of ovarian cancer.
Secondly the introduction of a guideline increases the likelihood of a change in surgical 
practice. This allows the potential to evaluate the effect, on survival, of changes in the 
clinical management of ovarian cancer; in effect seeking a biological gradient that can 
strengthen the causality of association.
3.3 Methods
Auditable standards were identified from the original guideline (CRAG1995) prior to 
the study. Case records from 1408 identified patients, diagnosed with ovarian cancer 
between 1995 and 1997, were abstracted as described in methods in chapter 2. This was
26 www.sign.ac.uk
27 www.rcog.org.uk/
133
compared to similarly collected data from the years 1992 to 1994. This data had been 
abstracted for a previously published study and the methods are detailed elsewhere 
(Junor, Hole, McNulty, Mason, & Young1999a).
Data were analysed in a similar method to that described in previous chapters. 
Specifically, % for trend was used to compare the linear association between the 
proportions of patients treated over time. The Kaplan Meier method was used for 
univariate survival analysis and the 3-year survival rates were calculated using life-table 
analysis. Cox proportional hazards model was used to adjust for prognostic factors in 
multivariate survival analysis and to help explain any survival differences observed 
between the two cohorts. All statistical analysis was performed using the SPSS v9.0 
statistical package (SPSS inc.2000).
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3.4 Results
Figure 3-1 shows the number of patients registered with Scottish cancer registration 
(ISD SMR-06 dataset). This table shows the efficiency of data abstraction and also the 
number and proportion of patients with histologically verified epithelial ovarian cancer 
that underwent a laparotomy. The proportions of patients, whose case records were 
obtained and abstracted is broadly similar for all years. This is despite the fact that 
different data abstractors obtained the data from the earlier series. Missing data from the 
years 1995-7 was discussed in the previous chapter.
Figure 3-1: table showing number of patients registered with cancer registration 
and numbers of patients included in the analyses.
Year of diagnosis
‘92 ‘93 ‘94 ‘95 ‘96 ‘97
n n % n % n % n % n %
Number of 
registrations 
in SMR-06
558
29
- 538 590 - 527 619 - 593
Number ( % )  463 (82.9) 442 (82.2) 482 (81. 7) 411 (78.0)  503 (81.3) 494 (83.0)
of patients
whose notes
were located
and
abstracted
Number (%) 334 (59.9) 325 (60.4) 343 (58.1)  301 (57.1)  365 (58.9)  301 (50. 7)
of patients
with EOC
having
laparotomy
[eligible for
analysis]__________________________________________________________________________________________
SMR-06=Scottish cancer registration dataset; EOC=epithelial ovarian cancer
28 Percentages in reference to the number of ovarian cancer registrations in that year.
29 Number of registration for the years 1992, 1993, 1994 from(ISD-Scotland 2000a), Chapter C9.6 Cancer 
Incidence and Mortality page 80.
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The data in figure 3-2 shows the effectiveness of clinical management in achieving the 
stated auditable standards laid out in the CRAG guideline. Not all data was collected in 
the earlier pre-guideline cohort and this is indicated. Significant increases in the 
likelihood of guideline compliance were observed for only a few of the auditable 
recommendations. ‘Attendance at a multidisciplinary clinic’ was the only auditable 
standard that is a known prognostic factor (Junor, Hole, & Gillisl994), to show 
improvement between the pre and post guideline cohorts. There was a non-significant 
increase in the number of patients receiving platinum based chemotherapy. There was 
no difference in the proportion of patients being optimally debulked despite a non­
significant increase in the proportion of patients undergoing total abdominal 
hysterectomy, bilateral salphingo-ophorectomy and omentectomy. The proportion of 
patients operated on by gynaecologists remained similar throughout the period 1992-97 
and there was no significant trend [p=0.30]. Likewise the proportion of gynaecologists 
that were designated as ‘specialist gynaecologists’ was broadly constant over this period 
and there was no trend seen [^2 for trend: p=0.25].
Figure 3-3 shows a univariate survival analysis of the association of cohort, patient, 
disease and treatment related factors with survival. It shows that unadjusted median 
survival was better in the most recent cohort (1995-7). It also confirms that patients 
categorised with previously demonstrated favourable prognostic factors have better 
survival.
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Figure 3-2: table showing auditable standards in the management of ovarian 
cancer between 1992 and 1997.
1992 1993 1994 1995 1996 1997
n % n % n % n % n % n % X2 for
trend30:
p-value
Pre-op CA125 - - - - - - 208 (69. 1) 248 (67.9) 247 (82. 1) <0.0001
Bowel prep - - - - - - 32 (10.6) 40 (11. 0) 46 (15.3) 0.08
Pre-op stom a  
preparation
- - - - - - 16 (5.30) 35 (9. 60) 21 (7.00) 0.44
G ynaecologist 290 (86. 9) 273 (84.0) 297 (86. 6) 212 (83. 1)31 257 (82.6) 230 (86.5) 0.30
Vertical
incision
- - - - - - 231 (79.4) 292 (80.9) 255 (85. 9) 0.01
Cytology sent 86 (25. 7) 89 (27.4) 94 (27.4) 138 (47.1) 210 (58.0) 208 (70. 0) <0.0001
RD <2cm 32 163 (48.8) 137 (42.2) 171 (49. 9) 129 (42.9) 169 (46.3) 143 (47.5) 0.53
TAH BSO OM 114 (34. 1) 93 (28. 6) 135 (39.4) 111 (37.0) 134 (36.8) 123 (41. 0) 0.07
FIGO stage  
recorded
- - - - - - 135 (44.9) 190 (51.8) 178 (59. 1) <0.0001
MDC 134 (40. 1) 149 (45.8) 157 (45. 8) 210 (71.2) 247 (69.2) 213 (70. 8) <0.0001
Platinum
based
chem otherapy
198 (59.2) 202 (62. 1) 196 (57.2) 205 (68.0) 223 (61.0) 198 (66. 0) 0.08
TAHBSSOOM=total abdominal hysterectomy, bilateral salphingo-oophorectomy and omentectomy; RD=maximum diameter of
residual tumour; MDC=multidisciplinary clinic. To allow valid comparison, cases analysed in this table are histologically confirmed 
epithelial ovarian cancer cases that underwent laparotomy.
30 x2 for trend used to test for differences in the trend of the proportions in each yearly cohort. P-values 
refer to trend for years 1992 to 1997 unless this data was not available for the earlier years in which case 
it refers to 1995-1997.
31 To enable the calculation of % the denominator for the surgeon type for the years 1995,96 & 97 
excludes cases where it was not possible to confidently assign a surgeon speciality.
32The guideline recommended ‘Aim to reduce disease to less than 1cm’; the data collected used 2cm as 
cut off.
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Figure 3-3: univariate survival analysis of patients diagnosed with ovarian cancer
in Scotland between 1992-94 and 1995-97.
Factor n Deaths % 3-year 
survival
^ m e d ia n Log rank: 
p-value
Cohort 0.013
1992,93,94 1387 949 (32.8) 466
1995,96,97 1334 833 (36.4) 604
Relevant group <0.0001
EOC & OP 1964 1268 (36.3) 642
Not [EOC&OP] 757 514 (30.8) 172
FIGO stage <0.0001
1 651 112 (97.5) 33na
2 188 91 (54.8) 1361
3 1176 940 (20.6) 399
4 393 367 (7.4) 159
nk 313 272 (13.3) 51
Histological grade <0.0001
Borderline 101 2 (98.8) na
Well 183 54 (71.4) na
Moderate 467 279 (40.5) 746
Poor 1085 806 (26.8) 463
nk 885 641 (28.2) 254
Ascites <0.0001
Yes 1449 1081 (25.4) 520
No 890 395 (55.6) 1414
nk 382 306 (21.2) 187
Age group <0.0001
Q1 (youngest) 666 263 (60.0) 1890
Q2 655 395 (40.9) 722
Q3 686 509 (25.5) 454
Q4 (oldest) 714 615 (14.1) 101
Residual disease <0.0001
<2cm 1160 390 (66.6) na
>2cm 1561 1392 (11.6) 210
Multidisciplinary clinic <0.0001
Yes 1310 774 (41.2) 797
No 1411 1008 (28.4) 258
Platinum based chemotherapy <0.0001
Yes 1370 883 (36.8) 712
No 1351 899 (32.7) 196
Smedian=median survival in days; EOC & OP= histologically verified epithelial ovarian cancer and laparotomy; Ql-Q4=quartiles 
of age; nk=not known. Although there were 1408 patients in the 1995,6,7 cohort the analysis includes only 1334 due to missing 
survival data in the group of patients not[EOC&OP].
33 Median survival not appropriate as less than 50% of patients have died.
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Figure 3-4  illustrates that there was an improvement in patient survival observed 
between the cohort of 1992-94 and the latest cohort, 1995-97. This survival difference is 
maximal at two years, however by five years the two survival curves meet. This 
anadjusted comparison of survival is statistically significant and represents a 3.6% 
increase in 3-year survival. Figure 3-5  shows a multivariate survival analysis-using Cox 
proportional hazards analysis. This confirms that there is an improved survival for the 
latter cohort. This improved survival is not explained when the model is adjusted for the 
known prognostic factors of FIGO stage, histological grade, the presence of ascites and 
age. Nor was the survival difference explained when the residual disease status was 
added to the model. Only when ‘attendance at a multidisciplinary clinic’ or when use of 
‘platinum based chemotherapy’ was added to the model as variables did the survival 
difference disappear, suggesting that these two variables might statistically account for 
the observed survival differences.
Figure 3-6 shows that even after excluding patients who died shortly after diagnosis 
(within 60 days) there is still a survival advantage towards those patients who attended a 
multidisciplinary clinic.
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Figure 3-4: survival analysis showing improvements in patient survival between
the 1992-94 and 1995-97 cohorts.
cohort
years 1995-7
+ censored cases
years 1992-4
censored cases0.0
0 365 730 1095 1460 1825
survival time to event in days
Number of patients in analysis=2721: Log rank statistic: p=0.013
This Kaplan Meier survival curve shows the survival of patients with 
epithelial ovarian cancer who underwent laparotomy, categorised by 
the cohort in which the diagnosis was made. There are no statistical 
adjustments. This shows that median survival was better in the 1995-97 
cohort but that the overall 5-year survival was unchanged.
140
Figure 3-5: multivariate survival analysis of association of cohort year with 
survival adjusted for known prognostic factors.
Pre-guideline 
(92,93,94) cohort
Post-guideline 
(95,96,97) cohort
Factors in model HR 95% Cl HR 95% Cl p-value34
Year cohort alone [unadjusted] 1 - 0.89 0.81-0.98 0.013
Additionally adjusted for: 
Disease factors 
EOC & OP 1 0.88 0.80-0.97 0.0078
[EOC & OP]+FIGO stage 1 - 0.83 0.76-0.92 0.0002
[EOC & OP]+FIGO stage + grade 1 - 0.88 0.80-0.97 0.01
[EOC & OP]+FIGO stage -t-grade + ascites 1 - 0.87 0.78-0.97 0.013
Disease factors and patient factors 
[EOC & OP]+FIGO stage + grade + ascites 
+ age
1 - 0.88 0.79-0.99 0.026
[EOC & OP]+FIGO stage + grade + ascites 
+ age + depcat
1 - 0.89 0.80-0.99 0.039
Disease & patient, surgical and chemotherapy 
factors
[EOC & OPJ+FIGO stage + grade + ascites 
+ age + depcat + residual disease status
1 - 0.87 0.78-0.97 0.013
[EOC & OPJ+FIGO stage + grade + ascites 
+ age + depcat + residual disease status + 
mdc
1 - 0.97 0.86-1.09 0.58
[EOC & OP]+FIGO stage + grade + ascites 
+ age + depcat +residual disease status + 
platinum
1 - 0.91 0.81-1.02 0.09
Hazard ratios (HR) with 95% confidence intervals (Cl) for pre and post-guideline cohorts entered into 
separate C ox m odels. The pre-guideline cohort 1992-94  is the baseline for all hazard ratios adjusted for 
disease, patient and treatment factors. E O C =epithelial ovarian cancer, O P=patient underwent 
laparotomy, depcat=category o f socio-econ om ic deprivation.
This analysis shows that the effect on the relative hazard ratio between 
the pre-guideline and post-guideline cohort of adjusting for known 
prognostic factors. It shows that only the addition of ‘attendance at a 
multidisciplinary clinic1 or ‘received platinum chemotherapy1 as 
prognostic factors explained the survival differences between the two 
cohorts.
34 P-values are W ald / 2 for the year cohort factor in the m odel, conditional on the other factors being  
present.
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Figure 3-6: survival analysis of patients surviving more than 60 days from
diagnosis according to whether they attended a multidisciplinary clinic.
Attended MDC?
yes
+ censored case
no
+ censored case0.0
0 3 6 5 7 3 0 1 0 9 5 1 8 2 51 4 6 0
survival time to event in days
Number of patients in analysis= 2182: Log rank statistic: p value=0.028
This Kaplan Meier survival curve shows patients with epithelial ovarian 
cancer who underwent laparotomy and who survived more than 60 
days from date of laparotomy categorised according to whether there 
is evidence that they attended a multidisciplinary clinic. This shows 
that even after excluding those patients who might never have 
attended such a clinic due to early death, patients attending a 
multidisciplinary clinic have better survival.
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3.5 Discussion
These results show that there was a small but statistically significant improvement in 
patient survival between patients diagnosed in the most recent cohort compared with the 
earlier cohort of patients. The multivariate survival analysis using Cox regression 
allows the identification of prognostic factors that might ‘statistically explain’ the 
survival differences. Only the attendance at a multidisciplinary clinic or the use of 
platinum chemotherapy could explain the survival difference. The importance of these 
important prognostic factors has been demonstrated previously (Junor, Hole, & 
Gillisl994), however the population effect on survival of an increase in the proportion 
of patients being affected by these factors has not previously been demonstrated. These 
data show that there was a substantial increase in the proportion of patients attending 
the multidisciplinary clinic and this change is associated with improved survival. These 
results are important and encouraging as they suggest that the ‘multidisciplinary clinic 
effect’ is genuine, if still poorly understood.
Figure 3-6  explores whether some of the ‘multidisciplinary clinic effect’ might be due 
to the fact that patients whose survival is short are unlikely to attend a multidisciplinary 
clinic because they die before they reach it. Even after excluding patients who did not 
survive for two months there is still a statistically significant ‘multidisciplinary clinic 
effect’. Thus it would appear that this association is more than being a proxy marker for 
those patients who are fitter than those who might not be well enough to attend a clinic.
There was no change in the proportion of patients who were optimally debulked 
between the two cohorts. It is thus not surprising that the addition of optimal debulking 
as a prognostic factor to the Cox model did not alter the observed survival advantage 
seen in the most recent cohort. If it is accepted (having considered the previous
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discussion of the significance of residual disease) that optimal cytoreduction is the 
primary surgical end point, being the main prognostic factor described in previous 
studies, then there was no opportunity during the period covered by the study for its 
biological gradient to be evaluated against improvements in survival.
The difference in survival between the two cohorts could not be explained by 
differences in the distribution of stage at diagnosis, tumour grade and patient age 
between 1992-4 and 1995-7. This is not surprising since there is no evidence that the 
patient characteristics would have changed over the period. The patient characteristics 
might have changed if for example a new improved method of detecting the disease at 
an earlier stage in its natural history been found. This has not been the case in patients 
with ovarian cancer.
Whilst the guidelines introduced in 1995 may have influenced the creation of 
multidisciplinary clinics and highlighted the importance of platinum based 
chemotherapy, it is not possible to infer that the guideline was the direct antecedent 
cause. It is equally as plausible that these changes were a result of other factors 
occurring in parallel with the timing of the publication of the guideline. What can be 
inferred though is that the guideline has had no appreciable effect on the effectiveness 
of the surgery being performed for ovarian cancer in Scotland over the time period 
examined. A strategy to improve the surgical management of ovarian cancer remains a 
major challenge at a national level. This is particularly important if the forthcoming 
SIGN guideline is to be effective.
One possible problem with encouraging change in surgical practice through the 
publication of guidelines is the assumption that adopting the ‘recommendations’ is both 
logical and easy to achieve. In ovarian cancer neither is necessarily the case. Achieving
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optimal debulking in a patient with ovarian cancer is frequently difficult, time 
consuming, not without hazard for the patient and requires the use of approaches that a 
general gynaecologist, usually operating on patients without cancer, are unlikely to be 
familiar with. These factors, in combination with the fact that at best surgical 
cytoreduction prolongs survival time rather than absolute cure makes it less likely that 
the recommendations in the guideline will be achieved in general gynaecological 
practice. Further research is required to understand these qualitative aspects. On a 
practical level change is unlikely to be achieved unless there are mechanisms for 
improving the overall surgical capability of the country as a whole. This requires either 
development of existing gynaecologists’ skills or training de novo, surgeons capable of 
managing these cases.
Conclusion
In summary there does appear to have been a small improvement in survival, which is 
most apparent at two years after diagnosis that can be accounted for by an increased use 
of the multidisciplinary clinic and to a smaller extent through a greater use of platinum 
based chemotherapy. However there is no change in the overall 5-year survival of 
patients. This is not surprising and fits with our understanding of the natural history of 
the disease and aims of treatment for most patients. There does not appear to have been 
any improvement in the overall surgical management.
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CHAPTER 4
International differences in the surgical management of ovarian
cancer within the SCOTROC trial
146
4.1 Aims
To evaluate differences in the surgical management of ovarian cancer between the 
United Kingdom and other international centres participating in the SCOTROC trial.
To relate these differences in surgical practice to progression free survival.
4.2 Background
International comparisons of ovarian cancer survival data have led many to conclude 
that the quality of treatment, particularly surgery, in the UK is significantly inferior to 
other parts of the world. However, these data come from cancer registries, are 
retrospective, and cannot be considered definitive. Therefore an in depth analysis of the 
initial surgery that was carried out on patients recruited into a large-scale prospective 
international clinical trial [SCOTROC] was undertaken. Information on sufficient 
biological and treatment variables was collected to allow valid conclusions to be drawn 
regarding the impact or outcome of variations in surgical practice.
The SCOTtish Randomised trial in Ovarian Cancer [SCOTROC] was a phase III 
international prospective randomised trial with two arms. Carboplatin & Taxol™ versus 
Carboplatin & Taxotere™. This was conceived and administered by the Scottish 
gynaecological cancer trials group and was a natural progression from previous trials 
organised by the group. Although the trial was principally a chemotherapy trial it was 
seen as an opportunity to explore other aspects of the ovarian cancer including the 
surgical study described in this chapter and a molecular biology study investigating 
mismatch repair. These parallel studies were designed into the study at the outset 
(Vaseyl998). The author became involved through a series of discussions with the
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clinicians leading the trial, both of whom attended the same multidisciplinary clinic as 
the author.
SCOTROC provided an opportunity to investigate differences in surgical practice. 
Firstly patients were recruited from centres chosen from the United Kingdom, Europe- 
including several of the countries (Austria, Finland, Switzerland and Poland) reported in 
EUROCARE, the United States and Australasia. The trial was large, chemotherapy was 
carefully defined, and patient selection was ‘downstream’ of the surgery performed. 
These factors made SCOTROC an appropriate vehicle for examining surgical practice. 
Young and fit patients comprised the patient group and this was felt to be the group 
relevant to the surgical questions. The SCOTROC trial was well resourced both to 
maximise patient recruitment and also by providing the necessary resources and 
logistics for the collection of detailed surgical data on an international level. This later 
point was crucial as the infrastructure and the resourcing of the main SCOTROC trial 
facilitated international collaboration and provided a regular forum to discuss the 
surgical study with the international participants. Moreover the trial environment meant 
that international MREC/LREC approval for the surgical study was feasible.
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4.3 Methods
Study design
The SCOTROC trial was an international prospective randomised phase III 
chemotherapy study. As a consequence the SCOTROC surgical study is a prospective 
observational study based on the cohort participating within the main study.
Study population
Criteria fo r  study centre recruitment
Centres were chosen on the basis of previous participation in the Scottish
35gynaecological cancer trials group trials. The pharmaceutical company Aventis 
identified additional international centres. All centres were required to satisfy the 
requirements of trial participation, both from a clinical capability to administer the 
chemotherapeutic agents safely and effectively but also by being able to manage the 
data collection.
Patient characteristics
The patient group recruited into SCOTROC represented young, fit patients with 
advanced ovarian cancer that was histologically defined. The specific entry and 
exclusion criteria are shown in the Figure 4-1.
35 Formerly Rhone-Poulent Rorer at the time of initiation of the trial.
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Figure 4-1: table of inclusion and exclusion criteria for patient recruitment into 
SCOTROC36
Inclusion Criteria
Stage Women aged over 18 years with FIGO stage Ic-IV epithelial ovarian cancer or 
primary peritoneal cancer following initial surgery. Stage Ic patients were limited to 
those with malignant cells in ascitic fluid, peritoneal washings or with tumour on the 
surface of the ovary. Patients with ruptured capsule as the only evidence of stage Ic 
were not be eligible for entry into the study.
Histology Histologically confirmed epithelial ovarian carcinoma. Patients with peritoneal 
carcinomatosis were also eligible, without necessarily having histological proof of a 
primary source in the ovary, provided that the tumour was not mucin-secreting 
[evidence of a gastro-intestinal tumour].
Surgery With or without successful cytoreductive surgery at staging laparotomy.
Consent Written informed consent and able to comply with follow-up requirements.
Exclusion Criteria
Previously Prior treatment with chemotherapy or radiotherapy.
treatments 
for cancer
Medically unfit Poor performance status [ECOG performance status = 4]
9
Inadequate bone marrow function [defined as neutrophils < 1.5 x 10 /I or platelets
9
<100 x 10 /l.]; Inadequate renal function [defined by serum creatinine > 1.25 x 
upper limit of normal]; Inadequate liver function [defined by bilirubin > upper limit 
of normal or AST/ALT >1.5 x upper limit of normal or ALP>3 x upper limit of 
normal].
Concurrent severe and/or uncontrolled co-morbid medical condition (i.e. 
uncontrolled infection, hypertension, ischaemic heart disease, myocardial infarction 
within previous 6 months, congestive heart failure)
History of prior serious allergic reactions (e.g. anaphylactic shock).
Symptomatic peripheral neuropathy > CTC grade II.
Uncertain Patients with mixed mesodermal tumours.
histology Patients with borderline ovarian tumours or is termed ‘possibly malignant’. 
Adenocarcinoma of unknown origin or if histologically shown to be mucin-secreting 
Previous malignancy within the previous 5 years (except curatively treated 
carcinoma in-situ of the uterine cervix, or basal cell carcinoma of the skin), or 
concurrent malignancy.
36 Source: (Vaseyl998)
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Authorisation and patient recruitment
The protocol (Vaseyl998) was distributed widely both nationally and internationally 
and was discussed at a number of investigator meetings in both Edinburgh and Los 
Angeles. Comments were incorporated into the final study design. The study received 
MREC authorisation [MREC/98/0/61] and all local centres obtained LREC approval. 
Patients at participating centres were offered the opportunity to participate in the trial 
following their initial surgery and histological confirmation of ovarian cancer. 
Recruitment to SCOTROC was therefore after surgical management. All patients 
received an information sheet detailing all aspects of the trial and written consent was a 
pre-requisite of entry. Prior to SCOTROC commencing the proposed surgical study was 
presented, by the author, at the international collaborators’ meeting in London. This was 
a voluntary component of SCOTROC and trial participation payments were not 
contingent upon participating in the surgical study. Despite this there was a widespread 
interest in the surgical study.
Number of cases
The number of cases was determined by the chemotherapy study only. The power 
calculation for the chemotherapy study required 1050 patients, to have 80% power to 
detect a difference of 25% in median progression free survival between the two arms at 
the two-sided 5% level of significance, and required 630 progressions or deaths 
(Vaseyl998). 1077 patients were recruited to the study. The breakdown of country of 
recruitment and numbers is shown in figure 4-2.
At the beginning of the study it was not possible to ascertain what power could be 
derived from the surgical study, as no pilot data was available. Nor was there any 
indication what proportion of patients would be recruited from the UK and from outwith
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the UK. A post hoc power calculation to estimate the power of the surgical study is 
presented in the results. It should be noted that it was not possible, from the perspective 
of the surgical study, to influence the number of patients recruited into SCOTROC.
Time frame
The first patient was recruited on 8th October 1998 and the 1077th patient was recruited 
on 8th May 2000. Thus all patients were recruited over a period of 19 months.
Data collection
Data collection for the surgical study was from two sources. The main patient clinical 
research file (CRF) used by the main SCOTROC study collected several pieces of 
surgical data as well as the data required by the chemotherapy trial. This pertained to 
basic patient data as well as an assessment of the residual disease after surgery and prior 
to chemotherapy. This data on residual disease was detailed and included each site, how 
it had been assessed (CT scan or MRI), how evaluable it was and the dimensions. This 
data was primarily required by the medical oncologists to allow assessment of the 
response to chemotherapy. This data was collected before randomisation took place and 
was entered, by the local data manager, into individual patient CRFs at the local 
recruiting centre. These were subsequently transferred to the clinical trials office at the 
Beatson Oncology centre in Glasgow, which coordinated the data management.
The main surgical data set was collected on the ‘Glasgow ovarian cancer audit form’ 
that was proposed for prospective audit of the surgical management of ovarian cancer 
and is outlined in the CRAG guideline (CRAG1995). The only additional piece of 
information requested was the length of operation. The data forms were distributed to 
all participating centres so that upon entry of a patient the form and an explanation sheet 
would be sent to the operating surgeon for completion. If a surgical data form was not
152
received back within one month of patient recruitment, a personalised reminder letter 
was sent. Surgical data forms were sent directly by the local data managers in the 
respective centres to the author at the data management office at the Beatson Oncology 
Centre. To facilitate data collection for the surgical study a presentation, by the author, 
was made at six investigator meetings that were held in London and Edinburgh, during 
the trial. For cases where there was difficulty retrieving the surgical data form, often 
because of non-participation by the operating surgeon, a request for a copy of the 
operating record and anaesthetic record was made, and in these cases the data was 
abstracted from the written medical records. Two hospitals, one in Greece and one in 
Switzerland, felt unhappy to participate; in the first instance due to the fact that no 
additional financial compensation was being made for the surgical study and in the 
second because of a general unease.
Data validation
A validation check was performed by comparing the data on the surgical form of ninety- 
three (10%) surgical data collection forms with a copy of the operating record and 
anaesthetic record that was requested from the centre. This also allowed validation of 
the data entry. The main surgical parameters that were common on both the surgical 
form and the main CRF were cross-checked for accuracy by linking the two datasets, 
this was done at the end of the study prior to analysis.
An extensive data validation exercise was carried out for the main patient CRF. Data 
monitors, employed by Aventis, checked the data accuracy at the individual centres, 
according to a predefined protocol. Mid-way through the trial there was an external data 
monitoring assessment. The data from the patient CRF was ‘double entered’ at the 
clinical trials office at the Beatson oncology centre by professional data managers. The
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data validation of all data required for the chemotherapy part of the trial was to the 
standard required for drug licensing by the United States Food & Drug Administration 
[FDA]. The surgical form alone did not fall under this scrutiny.
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Definitions
Progression free survival
For the purpose of SCOTROC progression free survival was defined as the time from 
randomisation to progression or death from any cause. Progressive disease was defined 
by strict objective criteria and is detailed in the study protocol (Vaseyl998). The 
progression free survival time for patients who did not progress or die was censored at 
the date that they were last known to be alive.
Total survival time
Survival time was defined from the date of randomisation to death. Censoring was at the 
date that the patient was last known to be alive. It should be noted that this is definition 
is slightly different from that used in chapters 2,3 & 5 which use the date of operation as 
the date of diagnosis. This is because SCOTROC was primarily a chemotherapy trial. 
The impact of this is likely to be insignificant due to the consistency of diagnosis and 
also because chemotherapy commencement was required within six weeks of 
laparotomy.
Residual disease status
The main clinical research file categorised patients according to the maximum diameter 
of residual disease after surgery. This was ‘none’ present, <2cm diameter, >2cm 
diameter (Scottish gynaecology cancer trials group 1998). Optimal debulking was 
defined as the maximum diameters of residual disease being <2cm.
Analysis & Statistical methods
The surgical data from the data form was transferred into an msACCESS-97 database 
(Microsoft inc. 1997a). The author wrote this for the purpose. Data entry accuracy was 
optimised by use of ‘combo-options’ that confined the range of possible entry values. In
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addition logical and syntactical error checking was performed on data entry through the 
extensive use of embedded programming within the database. The database was 
password protected. All surgical data form entry was by the author.
At the end of study important data fields from the main CRF dataset were linked to the 
surgical dataset by the author and Dr J. Paul (statistician). The accuracy of linkage was 
then checked by cross checking common data-fields of study number, patient initials, 
date of birth and centre.
Data were statistically analysed using SPSS v 9.0 (SPSS inc.2000). Comparison of
categorical data between groups of patients was performed using the %2-test or Fisher’s
exact test where expected frequencies were small (Coltonl974). Comparison of means 
from continuous normally distributed data was performed using the t-test. The Mann- 
Whitney U test was used for comparing the equality of non-normally distributed 
continuous data.
Multiple logistic regression was used to test the association of multiple independent 
factors with dichotomous dependent variables (Katz1999a). Univariate survival analysis 
was by the Kaplan-Meier method using the Log-rank test to compare the survival times 
between groups of patients. Multivariate survival analysis to explore the association of 
multiple factors with survival used Cox’s proportional hazards model (Coxl972; 
Katz1999a). Statistical significance was at the 95% confidence level unless otherwise 
stated.
To allow the comparison of CA125 distributions, the value of CA125 was transformed 
by taking the natural logarithm of the CA125 result [Ln(CA125)]. The distribution of 
the Ln(CA125) approximated normality allowing the use of parametric statistics.
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A post hoc estimation of the power of the surgical study to detect a difference in 
survival outcome between the UK and non-UK cohort was performed using nQuery 
Advisor v2.0 (Statistical Solutions 1997) with advice from Professor D. Hole.
All statistical analysis was by the author with advice from Dr J. Paul (Cancer Research 
Campaign statistician) and Professor D. Hole (West of Scotland Cancer Surveillance 
Unit).
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4.4 Results
The findings are summarised in Figures 4-2 to 4-21.
Analysis of contributing centres
1077 patients were entered into the SCOTROC trial, 689 of these were from the UK and 
388 from centres elsewhere in Europe, and in Australasia and USA. Surgical records 
were inspected in detail on 889 patients representing 83% of the study cohort. The 
numbers recruited from each centre are shown in figure 4-2.
Figure 4-2: table showing countries of recruitment of patients participating in 
SCOTROC
Country Number of patients
Australasia 80
Austria 61
Eire 3
Finland 48
Greece 22
Poland 7
Switzerland 41
USA 86
UK 689
total 1077
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Analysis of missing data
The characteristics of patients for which no surgical form was received are shown in 
figure 4-3. The data from the main patient CRF allowed the characteristics of those 
patients for whom a surgical data form was not obtained to be determined. 127 (18%) of 
surgical forms were not obtained from UK centres compared to 61 forms (15%) from 
international centres. The patient disease characteristics in terms of FIGO stage, 
histological grade and mean of Ln(CA125) are statistically similar. Performance status 
as a measure of patients’ overall fitness was similar too. A greater proportion of missing 
surgical forms from UK patients were registered as having residual disease of greater 
than 2 cm diameter at registration.
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Figure 4-3: comparison of characteristics of those patients with a missing 
surgical data form using comparison with main clinical research folder dataset.
Centre group
UK centres Non-UK centres
n (%) n (%) P value
FIGO stage 1C 12 (9.4) 4 (6.6) 0.83
2 15 (11.8) 7 (11.5)
3 84 (66.1) 44 (72.1)
4 16 (12.6) 6 (9.8)
Histological grade Well differentiated 6 (4.7) 5 (8.2) 0.32
Moderately differentiated 33 (26.0) 22 (36.1)
Poorly differentiated 68 (53.5) 27 (44.3)
Not known 20 (15.7) 7 (11.5)
Performance
status at
registration PS=0 43 (33.9) 29 (47.5) 0.17
PS=1 73 (57.5) 29 (47.5)
PS=2 11 (8.7) 3 (4.9)
Residual disease Nil 37 (29.1) 24 (39.3) <0.001
<2cm 26 (20.5) 25 (41.0)
>2cm 64 (50.4) 12 (19.7)
Mean Ln(CA125) 4.98 4.44 0.1 (t-test)
Ln(CA125)=natural logarithm of the pre-operative CA125
This table compares the characteristics of those patients for whom no 
surgical dataform was obtained. The patient characteristics were 
obtained from the main study clinical research file dataset. This shows 
that patients in the UK for whom no form was obtained were more 
likely to have residual disease of greater than 2cm.
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Analysis of biological characteristics between UK and international 
centres
The biological characteristics of stage and grade, between patients recruited from UK 
and non-UK centres are shown in figure 4-4. This shows that the patients from these 
two groups do not differ statistically. There is a statistical difference between the 
performance status at recruitment with slightly more patients from UK centres being 
less fit. There is no difference in the mean of the Ln(CA-125) between UK and non-UK 
centres. There was no attempt at comparing distributions of socio-economic status, as 
this data was not collected.
Figure 4-4: comparison of patient and stage characteristics of patients recruited 
to UK and international centres.
________________________________________________________ Centre___________________________
UK centres Non-UK centres
n (%) n (%) P value
Age Mean (years) 57.4 57.5 0.85(t-test)
Tumour stage 1C 54 (7.7) 25 (6.6) 0.459
2 89 (12.7) 43 (U .4)
3 449 (64.1) 260 (69.0)
4 108 (15.4) 49 (13.0)
Histological grade Well differentiated 45 (6.4) 37 (9.8) 0.224
Moderately differentiated 182 (16.0) 99 (26.3)
Poorly differentiated 387 (55.3) 194 (51.5)
Non known 86 (12.3) 47 (12.5)
Patient 0 212 (30.3) 157 (41.6) 0.001
performance status
1 391 (55.9) 180 (47.7)
2 97 (13.9) 40 (10.6)
Ln(CA125) Mean 4.95 4.82 0.29(t-test)
Data from the complete CRF dataset; n=1077
This table summarises the patient and stage characteristics of patients 
recruited to SCOTROC. This shows that the age and stage distributions 
are similar between the UK and non-UK centres. There is no difference 
in the distributions of the pre-operative CA125 levels. Patients 
recruited to UK centres had poorer post-operative performance status.
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International variation in the surgical management
Residual disease is the most frequently used proxy of surgical success. Figure 4-5  
shows the distribution of residual disease remaining after surgery in patients recruited 
from the UK and from non-UK centres. 59% of UK patients were optimally 
cytoreduced [<2cm] compared with 71% from centres out with the UK. This difference 
is statistically significant.
Whilst residual disease status is often considered the primary endpoint of surgical 
cytoreduction the primary surgical procedure considered essential is hysterectomy, 
bilateral oophorectomy and omentectomy. Figure 4-6 shows the differences in the 
proportion of patients from the UK and non-UK centres undergoing this combination of 
surgical procedures. Patients recruited to non-UK centres were more likely to undergo 
total abdominal hysterectomy, bilateral salphingo-oophorectomy and omentectomy 
[61%] than patients in the UK [50%]. This analysis takes into account past surgical 
history. Therefore if a patient had previously had a hysterectomy for example, providing 
the other components of surgery had been performed the patient would be coded as 
having undergone the complete procedure.
Figure 4-7  shows in detail the proportions of patients undergoing specific surgical 
procedures. This shows that patients recruited into non-UK centres were also more 
likely to undergo advanced staging procedures such as lymphadenectomy and also large 
bowel resection. This was statistically significant.
Figures 4-8 to 4-11 show in detail the proportions of specific surgical procedures 
performed according to the FIGO stage of the patient as defined at registration into the 
trial. There are two broad trends. In early stage disease patients recruited outwith the 
UK undergo more comprehensive staging procedures. Secondly in more advanced
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disease patients outwith the UK undergo procedures that facilitate a greater likelihood 
of debulking such as bowel surgery.
Figure 4-12 shows the differences between recorded operating times for cases treated in 
the UK and non-UK centres. This shows that the median operating time is greater for 
operations performed outwith the UK. The range of time taken, represented by the 
interquartile range, is greater for patients outwith the UK.
Figure 4-13 shows the operating times according to FIGO stage and country of surgery. 
This shows that the median operating time in the UK is around 90 minutes irrespective 
of the stage of disease. Moreover the variation of operating time in the UK is similar 
across FIGO stage categories. The operating time of patients recruited into centres 
outwith the UK is related to the stage of disease. Patients with more advance disease 
had longer operations. Moreover there was much greater variability in the length of 
operation. These differences were statistically significant.
Figure 4-14 shows the association of operating time according to residual disease 
status. This shows that the operating time in the UK is uniform and shows little relation 
to the residual disease status. In patients operated on outwith the UK patients who were 
optimally debulked had longer operating times.
Figure 4-15 is a univariate analysis of patient and tumour factors that are associated 
with optimal cytoreduction. It is of note that the ‘cytoreducibility’ in this analysis is 
associated with FIGO stage, histological grade, post-operative performance status, and 
country of surgery, patient age and pre-op CA125. This emphasises the fact that 
cytoreducibility, to a certain extent, may be a function of tumour biology.
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Figure 4-16 is a multivariate analysis, using logistic regression, of factors associated 
with optimal cytoreduction. In this analysis, after adjustment for prognostic factors, 
FIGO stage, CA125, post-operative performance status and country of surgery remained 
statistically positively associated with optimal cytoreduction [compare with figure 2- 
10\.
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Figure 4-5: international comparison of differences in residual disease remaining 
after primary surgery in patients recruited form UK and international centres.
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Number of patients in analysis=1077: x2d«2) : pO.0001
This barchart shows that patients recruited form non-UK centres were 
more likely to have residual tumour diameters of less than 2cm after 
surgery at recruitment to SCOTROC.
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Figure 4-6: international comparison of the rate of ‘total abdominal hysterectomy 
& bilateral salphingo-oophorectomy and omentectomy’.
Centre group
TAH/BSO&OMENT
UK-centres Non-UK centres 
n (%) n (%)
288 (50.3) 194 (61.4)
p-value
0.0014
TAH/BSO&OMENT=Total abdominal hysterectomy, bilateral salphingo-oophorectomy and 
omentectomy corrected for past surgical history.
Figure 4-7: international comparison of surgical procedures performed for 
patients recruited to UK and international centres.
______________________________________________ Centre group_______________
UK centres Non-UK centres
n37 (%) n (%) p-value
Biopsy only 57 (16.1) 17 (7.7) 0.18
USO 41 (7.2) 23 (7.3) 0.95
BSO 437 (76.3) 256 (81.0) 0.10
TAH 303 (52.9) 195 (61.7) 0.01
STAH 49 (8.6) 14 (4.4) 0.02
Omental Biopsy 55 (9.6) 22 (7.0) 0.18
Omentectomy 435 (75.9) 256 (81.3) 0.066
Pehic LND 33 (5.8) 98 (31.1) <0.0001
Para-aortic LND 23 (4.0) 69 (21.9) <0.0001
Appendicectomy 55 (9.6) 79 (25.0) <0.0001
Colonic resection 35 (6.1) 50 (15.8) <0.0001
Small bowel resection 14 (2.4) 14 (4.4) 0.10
Colostomy 24 (4.2) 12 (3.8) 0.78
Ileostomy 5 (0.9) 1 (0.3) 0.4338
Miscellaneous
procedures
73 (12.7) 69 (21.8) <0.0001
Number of patients in analysis=889 patients.
BSO= Bilateral salphingo-oophorectomy; USO=Unilateral salphingo-oophorectomy; TAH=Total 
abdominal hysterectomy; STAH=Sub-total abdominal hysterectomy; LND=Lymph node dissection.
37 Figures do not add up to number of patients treated due to multiple procedures being performed.
38 Fishers exact test
166
Figure 4-8: international comparison of surgical procedures performed for 
patients with FIGO stage Ic disease.
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Figure 4-9: in FIGO stage II disease.
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n=110
Bx only=biopsy only; USO=unilateral salphingo-oophorectomy; BSO=bilateral salphingo-oophorectomy; TAH=total 
abdominal hysterectomy; STAH= subtotal abdominal hysterectomy; Bx_omentum=omental biopsy, PLND=pelvic 
lymphadenectomy; PALND=para-aortic lymphadenectomy; other=miscellaneous sub-procedures [commonly peritoneal 
biopsies].
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Figure 4-10: in FIGO stage III disease.
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0 
10.0
0.0
□  not-UK
- □  UK
1
—
1c£ CD _  cD [f] _ 1 _ n  - 1 "1 rh.cn...
>* O Oc  w co°  3  CQ
X
£CO
3 Ec 2© P|  |
°i ®X Ecq §
i
CLro
O Eo 2
Figure 4-11: in FIGO stage IV disease.
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These bar charts show the frequency that certain procedures were 
undertaken according to FIGO stage and country of recruitment. Thay 
show that in early stage disease in particular, patients recruited 
outwith the UK underwent more aggressive staging procedures such 
as lymphadenectomy.
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Figure 4-12: comparison of surgical operating time between UK and international 
cases.
480r
420
360
300
240
180
120
60
N = 255 423
Non-UK UK
Country of recruitment
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operating time, outlying values are shown.
This box plot shows the distribution of length of operating time for 
patients recruited into SCOTROC according to the centre of 
recruitment. This shows that the median operating time for patients 
recruited into non-UK centers was greater than for those patients 
recruited to UK centers and also the variation in operating time as 
shown by the inter-quartile range was greater for non-UK patients.
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Figure 4-13: comparison of surgical operating time of UK and international cases 
stratified by FIGO stage.
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The heavy line shows median operating time, the box represents the inter-quartile range of 
operating time. Mann-Witney U-test; [UK vs non UK] p<0.0001
This box plot shows that the median operating time for patients 
recruited from the UK is around 90 minutes irrespective of the FIGO 
stage. There is less variability, represented by a smaller inter-quartile 
range, between patients with different FIGO stages who were recruited 
in the UK.
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Figure 4-14: figure showing difference in surgical operating time by post­
operative residual disease status.
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This box plot shows the relationship between operating time and the 
maximum diameter of residual disease at the end of laparotomy for 
patients according to country of recruitment. This shows that in 
patients recruited in the UK the median operating time is similar 
irrespective of operative outcome. In patients recruited outwith the UK, 
cases where successful debulking leaves disease diameters less than 
2cm the operating time takes longer than in less successful cases.
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Figure 4-15: univariate analysis of patient and tumour factors and their 
association with optimal cytoreduction at completion of primary surgery39.
_________________________________Residual disease status after surgery_________
Optimally Not optimally
cytoreduced40 cytoreduced
n (%) n (%) p-value
FIGO stage 1C 76 (96.2) 3 (3.8) <0.0001
2 120 (90.9) 12 (9.1)
3 420 (59.2) 289 (40.8)
4 63 (40.1) 94 (59.9)
Histological Well 65 (79.3) 17 (20.7) 0.005
grade Moderate 185 (65.8) 96 (34.2)
Poorly 349 (60.1) 232 (39.9)
Not known 80 (60.2) 53 (39.8)
Patient 0 284 (77.0) 85 (23.0) <0.0001
performance 1 345 (60.4) 226 (39.6)
status 2 50 (36.5) 87 (63.5)
Country group UK 402 (58.3) 111 (41.7) <0.0001
Not-UK 277 (71.4) 287 (28.6)
Age categories <50 168 (70.9) 69 (29.1) 0.002
51-60 229 (65.2) 122 (34.8)
61-70 172 (55.1) 140 (44.9)
71-80 44 (56.4) 34 (43.6)
>81 62 (66.0) 32 (34.0)
Mean 4.33 5.88 <0.0001
Ln(CA125) (t-test)
Operating time Median = 120 minutes Median = 100 minutes <0.0001
(Mann-
whitney)
Ln(CA125)=natural logarithm of the pre-operative patient CA-125 result.
This table shows those factors that are related the success of surgical 
debulking. This shows that early stage disease, being operated on 
outwith the UK, younger age, lower pre-operative CA125 and longer 
operating time are related to more successful debulking at laparotomy.
39 n=1077: data from main patient CRF
40 679 patients registered as optimally cytoreduced
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This table shows the results of three separate multiple logistic 
regression analyses of factors associated with optimal (less than 2cm 
residual disease) debulking status. The three analyses are shown to 
allow the effect of missing operation times to be evaluated. The first 
analysis uses the complete clinical research file without operation time 
and shows that after correction for known explanatory factors, being 
operated on outwith the UK is associated with more successful 
surgical debulking. In the second analysis cases where the operation 
time was unavailable have an imputed operation time. The imputed 
operation time is estimated as the median operation time for all 
patients irrespective of country of recruitment. This analysis shows 
that country of operation as well as operation time are independently 
associated with more successful debulking. The third analysis 
excludes those cases where the operation time is missing from the 
analysis. This shows that the country of operation ceases to remain 
significant but that operation time remains a significant independent 
factor associated with the success of debulking.
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Figure 4-16: table showing multiple logistic regression analyses of associations 
between residual disease and country group corrected for age, stage & grade, 
CA125 and operating time.
Association of factors with ‘optimally debulked status’ at registration to 
SCOTROC
From main CRF Missing optime Missing optime
_____________________________ imputed42________________ excluded43
Odds (95% p-value Odds (95% p-value Odds (95%c p-value
ratio Cl) ratio Cl) ratio Cl)
FIGO stage <0.0001 <0.0001 0.0004
1C 12.7 3.7-43.4 13.1 3.83-44.9 18.1 2.31-141
2 5.96 2.9-12.3 5.97 2.90-12.3 5.21 2.04-13.3
3 1.59 1.08-2.33 1.53 1.04-2.25 1.30 0.79-2.15
4 1 - 1 - 1 -
Histological grade 0.52 0.60 0.67
Well 1.64 0.79-3.42 1.60 0.77-3.34 1.74 0.62-4.88
Moderate 1.22 0.74-2.01 1.21 0.73-1.99 1.21 0.61-2.43
Poorly 1.32 0.84-2.08 1.30 0.81-2.02 1.05 0.56-1.98
D k 1 - 1 - 1 -
L n iC A U S )44 0.69 0.63-0.77 <0.0001 0.71 0.64-0.77 <0.0001 0.69 0.61-0.78 <0.0001
Performance status <0.0001 <0.0001 <0.0001
0 3.43 2.2-5.4 3.74 2.33-6.01 3.92 2.18-7.05
1 2.05 1.3-3.1 2.22 1.44-3.42 3.05 1.79-5.18
2 1 - 1 - 1 -
Age (terciles) 0.053 0.038 0.16
Youngest 1.38 0.97-1.95 1.37 0.96-1.95 1.25 0.80-1.98
Middle 1.48 1.06-2.09 1.54 1.09-2.18 1.54 0.99-2.41
Oldest 1 - 1 - 1 -
Country group 0.0001 0.0064 0.64
UK 1 - 1 - 1 -
Not UK 1.81 1.34-2.44 1.54 1.13-2.11 1.10 0.74 1.65
Operation time45 - - - 1.005 1.002- 0.0006 1.006 1.003- 0.0002
1.008 1.009
41 Analysis from main clinical research file [CRF] only with operation time not included in the analysis. 
Number of patients included and analysed is 1077.
42 Analysis from main CRF and surgical data form. Missing operating times imputed into analysis. 
Missing operating times estimated as median operating time for all patients i.e. 110 minutes. Number of 
patients is 1077.
43 Analysis of main CRF and surgical dataform. Cases with missing operating times are excluded from the 
analysis. Therefore 399 patients excluded.
44 Continuous variable
45 continuous variable; Odds ratio per minute
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Progression free survival
Figure 4-17  shows the initial overall progression free survival data for all 1077 patients. 
The date of censoring was 5th October 2001 and 575 events (progressions or deaths) had 
occurred at this point. The median progression free survival was 15.3 months. Only an 
interim analysis was possible at the time of preparing this thesis.
Figure 4-18 shows the association of known prognostic factors with progression free 
survival. It is noteworthy that there is no evidence of any difference in efficacy between 
the two chemotherapy arms in this study (Vasey2001). The results show that post 
operative patient performance status, FIGO stage, histological grade, the presence of 
ascites, the presence of omental ‘cake’ (omentum completely replaced with tumour) and 
tumour invasion into the pelvic side wall were associated with poorer progression free 
survival. These results re-confirm the association of optimal cytoreduction and 
improved survival. Successfully achieving total abdominal hysterectomy with bilateral 
salphingo-oophorectomy and omentectomy showed a non-significant survival benefit, 
whereas achieving a biopsy only at laparotomy was associated with poorer survival. No 
statistical difference in survival was found between patients recruited from UK and non- 
UK centres. There was no significant difference in the association of operating time 
with survival. However a gradient effect was seen with patients undergoing longer 
operations surviving longer.
Figure 4-19 shows graphically the progression free survival according to country group 
of patient recruitment. This shows that the survival curves are superimposed through to 
around 18 months; thereafter they diverge with more progressions being observed in the 
UK recruited patients.
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Figure 4-20 shows the Kaplan Meier survival curves for patients according to the 
success of surgical cytoreduction.
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Figure 4-17: figure showing Kaplan-Meier curve of progression free survival for
complete SCOTROC cohort.
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Number of patients in analysis=1077, number of events=575, date of censoring for patients not 
experiencing an event was 05/10/2001
This Kaplan Meier survival curve shows the unadjusted progression 
free survival of all patients recruited into SCOTROC. At the time of 
analysis only around half of patients had experienced an event. The 
median progression free survival is around 18 months.
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Figure 4-18: univariate survival analysis of factors with progression free survival.
Factor n 2-yearpfs (%) Median survival p-value
(logrank)
Age group (terciles)
Youngest (<53) 359 (38.4) 16.8
0.10
Middle (54-62) 357 (31.9) 14.8
Oldest (>62) 359 (26.5) 14.7
Performance status
0 368 (40.0) 20.4
<0.0001
1 570 (28.9) 14.1
2 137 (22.7) 11.9
Country group
Non-UK 386 (36.6) 15.3
0.71
UK 689 (30.6) 15.3
Surgical dataform
Not received 187 (30.3) 14.6
0.77
Received 888 (32.1) 15.6
FIGO stage
lc 79 (81.7) >30 months
<0.0001
2 132 (69.1) >30 months
3 707 (22.5) 14.1
4 157 (18.4) 10.2
Histological grade
Well differentiated 82 (66.8) 27.9
0.0015
Moderate 281 (31.1) 14.1
Poor 579 (27.3) 15.5
Unknown 133 (32.8) 13.6
Ascites
No 199 (45.9) 23.8
0.0003
Yes 593 (29.0) 14.6
Omental cake
No 357 (48.9) 24.4
<0.0001
Yes 320 (11.4) 11.5
Invasion of pelvic side wall
No 309 (43.3) 21.1
<0.0001
Yes 470 (28.0) 14.4
Chemotherapy
Arm A 537
0.94
Arm B 538 - -
Residual disease status
<2 cm 678 (43.5) 22.2
<0.0001
>2 cm 397 (12.6) 10.6
Surgery=T AHBSOOM
No 462 (27.7) 14.4
0.064
Yes 426 (38.1) 16.8)
Surgery=biopsy only
No 814 (34.9) 16.7
<0.0001
Yes 74 (7.13) 9.7
Operating time/ quartiles
Fastest (<80 min) 158 (26.4) 14.9
0.45
(80-110min) 182 (26.7) 15.1
(lll-151m in) 169 (35.6) 15.9
Longest (>151 min) 168 (38.5) 19.4
TAHBSOOM=total abdominal hysterectomy, bilateral salphingo-ophorectomy & omentectomy, 
pfs=progression free survival
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Figure 4-19: comparison of progression free survival according to the country 
group of recruitment for patients in SCOTROC.
Number of cases in analysis=1077, number of events=575, Log rank statistic: p=0.71
progression free survival at 05-10-2001
Country of surgery 
n UK
+ Censored case 
° non UK 
+ Censored case
This Kaplan Meier survival curve shows the unadjusted progression 
free survival of patients recruited into SCOTROC according to their 
country of recruitment. At the time of analysis and censoring only half 
of patients had experienced an event. Therefore this data should be 
viewed as being preliminary.
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Figure 4-20: comparison of progression free survival according to the residual
disease status after laparotomy for patients in SCOTROC.
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0.0 + Censored case
0 12 24 36
progression free survival/ months
Number of cases analysed=1077, number of events=572, date of censoring=05/10/2001; log 
rank statistic: p<0.0001
This Kaplan Meier survival curve shows the progression free survival 
of all patients recruited into SCOTROC according to the success of 
debulking at laparotomy. This confirms that patients who had tumour 
diameters less than 2cm after debulking had better survival.
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Figure 4-21 shows the results of a multivariate survival analysis using Cox’s 
proportional hazard model. This shows that, at present, there is no statistical difference 
in progression free survival for patients recruited in UK and non-UK centres after 
adjustment for differences in patient and disease factors.
A repeat analysis (not shown) was performed for survival after 18 months, on the ‘tail 
of the curves’ after the survival curves diverged {figure 4-19). This part of the survival 
curve is represented by 55 events and the relative hazard rate (RHR) of patients 
recruited from non-UK centres is 0.56 (95% Cl is 0.25 to 1.26), p=0.16. After 
correction for performance status, the prognostic factor showing greatest difference 
between UK and non-UK centres, the RHR of non-UK centres is 0.54 (95% Cl is 0.24 
to 1.22), p=0.14. This shows that even though the survival curves begin to diverge after 
eighteen months this is non-significant with the number of events at the time of 
analysis.
On the basis of the relative proportions of patients recruited into SCOTROC from the 
UK and non-UK centres, an estimate of the possible power of the surgical study to 
detect a difference in survival was performed. The study was estimated to have around 
70% power to detect a RHR of 0.81 using a two-sided log-rank test of survival at the 
5% level of significance. The assumption of the expected difference in RHR of 0.81 was 
drawn from the previous differences seen between specialist and non-specialist 
management of ovarian cancer (Junor et al. 1999b)and from the non-significant benefit 
of specialisation in breast cancer [David Hole personal communication].
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Figure 4-21: multivariate survival analysis of the association of country group 
with progression free survival after adjustment for prognostic factors.
Country group
Factors in model UK Non-UK
HR HR 95% Cl p-value
Country group alone [unadjusted] 1 0.97 0.81-1.15 0.71
Adjusted for: 
Patient factors
+age 1 0.97 0.81-1.16 0.75
+age+ps 1 1.02 0.86-1.22 0.80
Patient and disease factors 
+age+ps+FIGOstage 1 1.01 0.85-1.21 0.89
+age+ps+FIGO+grade 1 1.01 0.85-1.21 0.87
+age+ps+FIGO+grade+ln (C A 125) 1 1.06 0.89-1.28 0.49
+age+ps+FIGO+grade+ln(C A 125) +ascites 1 1.08 0.90-1.29 0.43
+age+ps+FIGO+grade+ln (C A 125)+ascites+invPS W 1 1.10 0.92-1.33 0.30
+age+ps+FIGO+grade+ln (C A 125) +ascites+invPS W 
+omCake
1 1.12 0.93-1.35 0.23
ps=patient performance status at recruitment; grade=histological grade; ln(CA125)=natural logarithm of 
CA125; invPSW=invasion of pelvic side wall reported at laparotomy; omCake=omentum replaced with 
cake of tumour.
This table shows the result of Cox proportional hazards analyses 
examining the relationship of the relative hazard ratio between UK and 
non-UK recruited patients and how this relatioship is altered by the 
correction for several known prognostic factors. In these analyses 
there is no statistical survival difference even after adjustment for 
factors. This data is preliminary based upon 575 events censored on 
the 05/10/2001.
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4.5 Discussion
This study is unique insofar as it is a large prospective international study, where 
chemotherapy is controlled, that allows the exploration of the influence that variations 
in surgical practice have on patient survival. It also allows an examination for 
explanatory factors for poor survival outcome in the UK.
This study demonstrates clear differences in the surgical practice amongst 
gynaecologists referring patients into this clinical trial, comparing the UK with non-UK 
centres. These differences in surgical practice are particularly relevant to the 
management of stage III tumours where there appears to be a greater likelihood of 
residual disease greater than 2 cm following the procedure. As this is known to be a key 
prognostic factor, these are potentially large enough to impact significantly on treatment 
outcome and may explain some of the variability in survival outcome seen in the 
EUROCARE studies.
Validity of comparing patients treated in UK and non-UK centres
Characteristics o f  patients in UK and non-UK centres
The results presented in Figures 4-2, 4-3 and 4-4 suggest that the patient characteristics 
of the UK and non-UK cohorts are similar. The important patient/ tumour factors; FIGO 
stage, histological grade and patient age, of patients recruited from UK centres are 
similar to those recruited from non-UK centres. Although UK patients have a poorer 
performance status at registration this is unlikely to have affected the surgery done. This 
is because the performance status assessment was post surgery at the time of 
registration. Secondly all patients were sufficiently fit to satisfy stringent criteria for 
entry into the trial.
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Comparison of the two datasets permitted the patient characteristics of missing surgical 
forms to be assessed. Eighty three percent of surgical data forms were obtained. The 
proportion of missing surgical forms from both UK and non-UK groups is similar and 
the patient characteristics are broadly similar in terms of FIGO stage. A greater 
proportion of UK patients with missing surgical forms were sub-optimally debulked 
compared to the proportion from international centres. This would have the effect of 
reducing the observed difference in cytoreduction, and by implication the surgery 
performed, i.e. the true differences are likely to be greater than those demonstrated in 
the results of these analyses had all of the data forms had been received. It is difficult to 
comment whether the characterisitics of the missing data in the SCOTROC surgical 
study are typical of the missing data in other published studies. By having both the main 
Clinical Research File data set as well as the surgical form data set, this valuable 
assessment could be made.
Therefore the comparison of surgery performed, the outcome of surgery and the 
operating time comparisons would appear to be valid.
The multiple logistic regression analysis figure 4-16) correcting for factors known to 
be associated with the outcome of surgery shows that there are differences in the rate of 
optimal debulking achieved between UK treated patients and those treated outwith the 
UK.
How representative are SCOTROC patients o f the population from  which they are 
drawn?
A key question is how representative SCOTROC patients are of the population from 
which they are drawn. It is not possible to answer this question with accuracy however 
there are a number of factors that influence this. There is nothing more selective than a 
clinical trial. It is likely that a large proportion of all ovarian cancer patients from
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Scotland were recruited into the SCOTROC trial. This is because the Scottish 
gynaecological trials group conducted the trial and all the medical oncology centres 
participated. Moreover the economic advantages of trial participation, free Taxane drug 
(at a time when Taxol was not universally available) plus participation fee, suggest that 
there were significant incentives to trial participation where possible. Indeed 169 
patients were recruited from Scotland over a nineteen-month period. During this time it 
is estimated that there would be an estimated 450 eligible patients with stage Ic-IV 
ovarian cancer [from estimates from cancer registration and case mix calculated from 
data presented in chapter 2]. Thus 37% of Scottish patients were possibly recruited.
Is the surgical management o f patients recruited to SCOTROC representative o f  the 
surgical management o f  patients within the national populations from  which they are 
drawn?
Because SCOTROC was primarily a drug trial selection bias was at the level of 
choosing the medical oncology centres that could participate in SCOTROC both in the 
UK and abroad. There is the possibility that we are comparing the ‘general’, in the case 
of the UK patients, with the ‘best’ internationally thus biasing the results. While this 
may be true there are three factors that mitigate against this.
The surgeons who would perform the primary surgical treatment were not selected. 
Recruitment of individual patients was after the surgery had been performed. The 
standard of surgery was irrelevant for recruitment. The only criterion was that the 
residual disease was defined.
Thus being recruited into SCOTROC is unlikely to have influenced the surgery that was 
performed. Secondly the data show that a large number of surgeons46 contributed 
patients into SCOTROC both in the UK and internationally. It is almost certainly the
46 259 surgeons from the UK and 174 surgeons from centres outwith the UK.
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case that the medical oncology centres admit patients from a defined geographical area. 
The quality of surgery received by patients being treated by the oncology centre 
therefore represents the quality of surgery performed by surgeons working in that area. 
Finally the economic incentives to the oncology centre to enter patients into SCOTROC 
were significant. The Taxane was provided free of charge and there were fees to cover 
additional costs. Additionally the combination of carboplatin/ Taxol™ was considered 
state of the art chemotherapy at the time that the study was conducted. Moreover 
anecdotally, there was a general perception that there probably would not be a 
significant survival difference between the two SCOTROC arms. These factors make it 
very likely that if patients were suitable for recruitment they probably were recruited. 
This reduces the likelihood of bias from participation of only the favourably debulked 
patient from non-UK centres.
It is not possible to be certain of how accurately SCOTROC represents the overall 
surgical management of patients in all the countries represented. There are strong 
arguments that patients recruited into SCOTROC represent the overall quality of 
surgery performed in areas served by the medical oncology centres participating in 
SCOTROC.
In terms of bias; at best the SCOTROC data is an accurate reflection of surgical 
management in the countries represented; at worst it compares the UK in general with 
the best surgery internationally. It is likely that the true picture is between these two 
extremes. Despite this uncertainty important conclusions can be drawn and further 
understandings developed. It is important to acknowledge the uncertainties in 
comparison.
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The question of how representative SCOTROC is is only relevant when exploring the 
‘EUROCARE question’. It is not relevant to the discussion of the role of surgery in 
survival.
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Observed variations in surgical management
Differences in the residual disease at the point o f  recruitment into SCOTROC
One of the strengths of the SCOTROC surgical study is that the estimate of residual
disease at the end of surgery is likely to be accurate. This is because the chemotherapy 
aspect of SCOTROC required radiological verification of the remaining disease through 
the use of CT scanning. The extent and size of radiological visible disease was 
objectively recorded in order to assess chemotherapy response. Thus in this study there 
is an independent verification of the surgeons’ findings. This level of verification is rare 
in the literature.
Residual disease is the prognostic factor most frequently used to define the outcome of 
surgical activity. In this trial patients treated in non-UK centres were more likely to 
have been optimally cytoreduced.
The ability of the surgeon to cytoreduce a patient’s tumour was likely to be dependent 
upon many factors. These factors include the extent and characteristics of the tumour as 
well as surgeon specific factors. Figure 4-15 shows that in SCOTROC, patients with 
more advanced disease were less likely to be optimally cytoreduced. This is consistent 
with previous studies. It has been reported previously that pre-operative CA-125 is a 
predictive factor for the likelihood of optimal debulking (Chi et al. 2000),(Berek 2000). 
It has been reported as an independent prognostic factor for survival (Sevelda, 
Schemper, & Spona 1989). Thus by implication is likely to be a marker of the extent of 
disease. In this study there was a correlation between the Ln(CA125) and the FIGO 
stage of the disease. This variable along with FIGO stage and histological grade were 
associated with the likelihood of optimal cytoreduction. Patient factors such as age and 
post-operative performance status were associated with cytoreducibility too. Older
188
patients are more likely to have more advanced disease (Yancik, Ries, & Yates 1986) 
and may be less able to tolerate more aggressive surgery. Performance status is a 
measure of a patient’s overall health and functional ability. The post-operative 
performance status is likely to reflect upon the pre-operative performance status. 
Patients with poor pre-operative performance status are likely to have more advanced 
disease and are less likely to tolerate more aggressive surgery.
The associations of all of these factors with optimal cytoreduction were modelled using 
multiple logistic regression analysis. Figure 4-16 shows the results of logistic 
regression analysis. After adjustment for possible explanatory factors; FIGO stage, 
Ln(CA125), post-operative performance status and country of surgery group were all 
statistically significant. This means that after adjusting for factors known to influence 
the likelihood of achieving optimal surgery, the country in which a patient has her 
surgery appears to be important. The probability of optimal debulking at surgery would 
appear to be less for patients recruited from centres in the United Knigdom even after 
adjusting for patient factors.
Differences in surgery performed.
The results show that there are systematic differences in the surgery performed. Patients 
treated by UK centres are less likely to have had a pelvic clearance (total abdominal 
hysterectomy and bilateral salphingo-oophorectomy) and omentectomy compared to 
patients recruited by centres overseas. Furthermore there are differences in the surgery 
performed in earlier stage disease compared with more advanced stage disease. In FIGO 
stage Ic, non-UK patients are more likely to have been aggressively surgically staged 
with either pelvic lymphadenectomy or para-aortic lymphadenectomy compared to 
patients recruited by UK centres. In FIGO stage III and IV disease, UK patients are less
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likely to have procedures that would facilitate optimal cytoreduction. Of note, there is a 
greater proportion of large bowel resection performed in non-UK centres, however the 
colostomy rate is similar. This implies that large bowel resection performed in non-UK 
centres is associated with a greater likelihood of anastamosis at the time of surgery. This 
suggests that either the surgeons in non-UK centres are more able to perform this type 
of procedure, which is technically difficult, or they have a greater cooperation with 
other surgeons who have more experience repairing the bowel.
The overall pattern and significance of these data is that patients treated in the UK are 
less likely to have had the surgical procedures performed that make the goal of 
achieving optimal cytoreduction more likely.
Differences in operating time
The results shown in figures 4-12 to 4-14 show that surgical operating time is longer in 
non-UK centres. There are a number of possible interpretations. As operating time 
reflects the ‘volume of activity’ performed during surgery, operating time may simply 
reflect an ability or inability of the surgeon to achieve any meaningful cytoreduction at 
operation. The other alternative, which is not mutually exclusive, is that if operating 
time is a limited resource it curtails what would otherwise be possible at surgery. In the 
UK, operating time for each individual patient might be a limiting factor. In the UK it is 
widely acknowledged that operating list time is a limiting factor (2002). It is possible 
that the manner in which theatre lists are constructed result in a pre-operative constraint. 
This means that irrespective of how able the surgeon is, there may be insufficient time 
available to achieve the quality of surgery that would have been otherwise possible. 
There is a greater inter-quartile range in the operating time in non-UK centres. This may 
suggest that for those patients the time spent was tailored to the extent of the patient’s
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disease, to allow what was necessary and possible to be done. In the UK centres in 
contrast the median operating time is short and the inter-quartile range is uniform. This 
suggests that a limited time was allocated for the operation thus reducing the variation. 
From the data in this study it is not possible to be more certain of the exact nature of the 
difference in operating time. The consistency between the findings of what is done at 
surgery, how long the surgery takes and the outcome of the surgery is very consistent. 
This suggests that for patients recruited from non-UK centres more surgery was 
performed which left less bulky disease at the end of surgery and this was reflected in 
the surgery taking longer.
It is of interest to compare operating time with the Scottish population based data 
presented in chapter 2. Figure 2-11 shows the range of operating times for various 
procedure combinations. This corroborates the above that ‘doing more surgery’ takes 
longer. Figure 2-9 shows that the median operating time by a general gynaecologist 
was just 65 minutes considerably less than the median time taken by patients operated 
on in the UK (90 minutes) or outwith the UK (140 minutes).
Analysis o f early progression free survival data.
The progression free survival data presented earlier is early and incomplete and any 
interpretation must reflect this. This is becase the initial analysis was undertaken to 
allow inclusion of the results in this thesis. The difference in survival between UK and 
non-UK centres is equivocal. There appears on both univariate and multivariate analysis 
to be no difference in survival up to eighteen months where the survival is seen to be 
identical. However after this point there is a divergence of survival that is non­
significant. It remains to be seen whether, as the survival data matures, a significant 
difference becomes apparent. It should be noted that in the analysis of the association of
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residual disease status with survival in the previously discussed GOG-97 trial (Hoskins, 
McGuire, Brady, Homesley, Creasman, Berman, Ball, & Berekl994) no divergence of 
the survival curves occurred until 12 months. It is thus too early to be certain of the final 
results from the SCOTROC surgical study. This first analysis has used progression free 
survival rather than overall survival. This is because progression free survival was the 
primary end point for the comparison of the two chemotherapeutic regimes. 
Nevertheless it is wise to be cautious in using this as a accurate marker of overall 
survival.
It is possible that there will be no significant difference in survival between the country 
groups. If this is the case there are two possible explanations. Firstly the study could be 
underpowered to show a difference that genuinely exists. Although the study is 
moderately powered (70%) to detect a difference in relative hazard ratio of 0.81 the 
assumption of the anticipated RHR might be incorrect. It is more likely that, if anything 
the survival difference between the two cohorts would be smaller. This would reduce 
the power of the current study. Secondly it could be a genuine result. This would be an 
important finding as it argues against the causality of optimal cytoreduction improving 
survival. A difference of 13% in the probability of optimal debulking was demonstrated 
between UK and non-UK centres. This provides the opportunity to look for a survival 
gradient. Despite the large literature showing the association between optimal 
cytoreduction and survival, there have been no single studies that have attempted to 
demonstrate a survival gradient being related to differences in surgery or to the success 
of surgical cytoreduction.
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Can we make valid comparisons with EUROCARE?
In EUROCARE the United Kingdom ranked poorly in those countries participating. 
Several of the countries participating in SCOTROC (Austria, Finland and Switwerland) 
achieved better survival results in EUROCARE. For this reason it is interesting to 
consider whether valid comparisons can be made with EUROCARE. It should be noted 
that Poland contributed some patients to SCOTROC and these were categorised into the 
‘non-UK centres’. The Polish survival in EUROCARE was the worst (Gatta, Lasota, & 
Verdecchial998b). This is unlikely to affect any analysis as Poland contributed very 
few patients (n=7), figure 4-2.
As mature survival data is awaited we need to accept the assumption, from previous 
studies, that residual disease status is an accurate prognostic factor and can be used as a 
surrogate end point for survival. If we assume that residual disease status is important 
and causal, and if we assume that SCOTROC represents the trend of surgery performed 
in the participating countries, then the SCOTROC surgical data would support the 
EUROCARE conclusions that there are systematic survival differences between the UK 
and other European countries. Moreover the data suggests a possible explanation for 
survival differences, insofar as the surgery performed in the UK is less extensive and is 
less likely to achieve the sizes of residual disease achieved in other countries. We need 
to assume that the direction of the differences in surgery and residual disease are 
accurate, although the magnitude can only be estimated depending upon how 
representative SCOTROC is of the participating countries. It is important to recognise 
however that the survival data are not yet mature and that the above are inferred.
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Implications of the study for the United Kingdom
If the results in this study can be generalised, then there is an urgent need to review the 
structures and processes whereby an organisation such as the NHS improves its overall 
surgical capability. The evidence suggests that in the past this has been haphazard and 
ill conceived and that there has been an overall constraint of minimising financial cost. 
These require a re-appraisal.
The SCOTROC data is consistent with the Scottish population data and shows that in 
the UK and Scotland there is a reduced likelihood of the surgery being performed that 
results in a high probability of surgical debulking. Moreover the time spend at surgery is 
uniformly low, compared to non-UK centres.
If operating time is a limiting factor, then efforts to improve the quality of surgery will 
be ineffective unless operating time ceases to be limiting. This is of strategic importance 
in the UK particularly at a time where there are increased efforts to improve quality in 
the NHS. As theatre time has an opportunity cost, this makes this issue an important 
strategic issue.
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CHAPTER 5
Survival is associated with staging quality in endometrial cancer: A
population study
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5.1 Aims
To characterise the adequacy of surgical staging in the management of endometrial 
cancer in Scotland.
To investigate the factors associated with variations in survival in patients with 
endometrial cancer in Scotland.
5.2 Background
The previous studies described in the earlier chapters have concentrated on variations of 
clinical management and survival in ovarian cancer both within Scotland and elsewhere. 
Endometrial cancer, like ovarian cancer, is a gynaecological cancer that is managed 
predominantly by non-specialist gynaecologists. However in contrast to ovarian cancer 
there has been less attention to the association between variations in clinical 
management and variations in survival. As was described in chapter 1, patients 
diagnosed with endometrial cancer in Scotland have in some studies been shown to 
have poorer survival compared with other European countries (Gatta, Lasota, & 
Verdecchial998b).
The Scottish Endometrial Cancer study was a large population based study that was 
undertaken to characterise and describe variations in the management of endometrial 
cancer in Scotland and to investigate variations in survival of women with endometrial 
cancer in Scotland. This is the first such study of endometrial cancer that is based on a 
national population, though a smaller regional audit has been published from the South 
East of England (Tilling, Wolfe, & Raju1998b).
This chapter describes the relationship between variation in surgical staging 
performance and use of adjuvant radiotherapy and patient survival. This is important as
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the quality of staging represents the information that is used for decision-making. Thus 
this chapter may provide some insight into how the multidisciplinary team might 
contribute to the improved outcomes seen previously for ovarian cancer. This is another 
aspect of specialisation. This is particularly relevant, as national cancer plans that have 
been drawn up for England (department of health1999b), (department of health2000), 
and Scotland (NHS Scotland 2001) have emphasised the importance of 
multidisciplinary working across all tumour types.
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5.3 Methods
Study design
The study was a retrospective case note review of all women with endometrial 
carcinoma who were resident in Scotland with a diagnosis first made between 1.1.96 
and 31.12.97, the latest years for which complete data are currently available. Cases of 
endometrial carcinoma were identified from the Scottish Morbidity Record (SMR-1; in­
patient and day case hospital discharge data). Cases were defined as patients who were 
coded as C54 and C55 in the 10th revision of the International Classification of Disease 
(ICD10). Prior to March 1996, the equivalent codes in ICD9 were used. At the end of 
the study, Cancer Registration (SMR-6) and SMR-1 data sets were linked to ensure 
completeness and any additional records were reviewed. SMR-1 was used initially as 
the cancer registration dataset was incomplete at the time that the study began [February 
1999].
Authorisation
The study was conducted under the auspices of the Scottish Programme for Clinical 
effectiveness in Reproductive Health (SPCERH) and permissions were sought from 
MREC, the privacy committee of the Information and Statistics Division, hospital trusts 
and all consultant gynaecologists in Scotland. An ad hoc committee composed of the 
author, Dr L deCaestaker (consultant in public health), Professor C Gillis (West of 
Scotland cancer surveillance unit), Professor D Hole (Professor of epidemiology & 
biostatistics), Dr G Penney (SPCERH), Dr J Davis (consultant in gynaecological 
oncology) and Dr N Siddiqui (consultant in gynaecological oncology) oversaw the 
study.
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Data collection
Prior to the study a pilot study was conducted at a teaching hospital and at a district 
general hospital. This allowed the generation of hypotheses and informed the choice of 
variables to be collected. Data were collected from hospital medical records on 
diagnosis and staging, surgical treatment and adjuvant radiotherapy. Two experienced 
clinical data abstractors, acknowledged previously, recorded data according to 
definitions pre-defined by the study committee. Data were collected from both the 
hospital of the definitive operation and radiotherapy centres. The data abstractors cross­
checked 1 in 50 (24) abstracted records for accuracy. Data was entered into an Access- 
97 database (Microsoft inc. 1997a) and statistical analysis was carried out in SPSSv9.0 
for Windows (SPSS inc.2000). At the end of the study when the complete cancer 
registration (SMR-6) dataset was received, the abstractors revisited every hospital to 
obtain the case records of additionally identified patients. This second visit provided a 
further opportunity to attempt to obtain missing data and to review data queries 
identified in an initial analysis.
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Definitions
Histopathology review and retrospectively defined FIGO stage, Tumour Grade & 
FIGO stage category
The data abstractors photocopied all pathology reports. The author reviewed all 
available pathology reports and a ‘retrospectively derived’ FIGO (International 
Federation of Obstetrics & Gynaecology) stage as well as the degree of differentiation 
[tumour grade] was determined for each case. This was based upon the best available 
information from the clinical and pathology reports using the published FIGO staging 
nomenclature (Shepherd1989b). If the cytology result was unavailable the result was 
assumed to be negative. Cases were defined as ‘unstageable’ if there was no operation, 
there was insufficient or ambiguous histological information or if there were 
synchronous tumours present.
Patients were then grouped into four categories on the basis of their retrospective FIGO 
stage. These groups represent the likelihood of metastatic spread and thus the use of 
adjuvant radiotherapy: ‘low risk’ of metastatic spread [FIGO stages 1AG1 & 1BG1], 
‘intermediate risk’ [FIGO stages 1AG2/G3, 1BG2/G3, 1CG1/G2], ‘high risk’ [FIGO 
stages 1CG3 & stages 2/3/4] and ‘unstageable’. These definitions were based upon the 
definitions used in the recent PORTEC randomised trial of post-operative radiotherapy 
in endometrial cancer that was discussed previously (Creutzberg, van Putten, Koper, 
Lybeert, Jobsen, Warlam-Rodenhuis, De Winter, Lutgens, van den Bergh, van, Steen- 
Banasik, Beerman, & van Lent2000b). Figure 5-0 diagramatically illustrates how the 
categorisation was performed.
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Figure 5-0; relationship between FIGO stage, tumour grade and FIGO stage 
category
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This diagram illustrates how FIGO stage and Tumour grade was used 
to categorise patients into three categories according to their likely risk 
in terms of lymph node metastases. This diagram illustrates why the 
number of patients whose FIGO stage (43) was uncertain is different 
from the number of patients for whom it is not possible to accurately 
assign a FIGO stage category (50).
Key. Turquoise=low risk; purple=intermediate risk; red high risk based 
on (Creutzberg et al. 2000a)
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Socio-economic deprivation
The Carstairs classification of socio-economic deprivation (Carstairs & Morris 1991) 
was used to allocate patients to categories of socio-economic deprivation. The seven 
categories were aggregated to three categories (1&2, 3-5,6-8) to facilitate analysis. 
Socio-economic deprivation was included in the analyses for two reasons. Firstly the 
incidence and survival is higher in more affluent socio-economic groups (ISD 2000a). 
Secondly since death from any cause was used as the primary end point {vide infra), 
including socio-economic deprivation allows for potential adjustment in the multivariate 
survival analysis of the excess mortality observed in less affluent patients (ISD2000a).
Indices o f  staging quality
Data from the initial pilot audit indicated that staging was generally poorly performed. 
Two aspects of staging were examined, whether fluid was sent for cytological 
examination and whether the FIGO stage was worked out and documented in the 
medical record by either the surgeon and/or the pathologist.
Gynaecology cancer specialist
For the purposes of this study a gynaecology cancer specialist was defined as a 
gynaecologist performing radical surgery for cervical carcinoma in 1996/7. It should be 
noted that this definition was slightly more specific and restrictive that the definition 
used for the ovarian cancer studies, which was defined by the previous steering 
committee of the initial ovarian cancer studies. The definition was not the same as for 
ovary because the two studies were conducted separately. However the consultant list 
was identical apart from one consultant who was not included within the definition of a 
specialist for the purposes of the endometrial cancer study.
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MRCOG pass date
Prior to the study, it had been noted that some senior clinicians were less likely to 
perform staging as thoroughly as younger consultants. Until 1988, the staging of 
endometrial cancer was based on the results of a clinical examination under anaesthesia. 
The International Federation of Obstetrics and Gynaecology [FIGO] introduced a 
system in 1988 that involved combining information collected at the time of surgery 
with histological data from the subsequent pathology report. This change was first 
reported in the UK literature in 1989 (Shepherd1989b). Each gynaecologist was 
categorised according to their year of passing the examination of Member of the Royal 
College of Obstetricians and Gynaecologists (MRCOG) (RCOG1997b). In each case 
the senior surgeon present at operation wras classified as obtaining MRCOG before or 
after 1989 [<1989; >1989]. This allowed gynaecologists to be categorised according to 
the FIGO staging system that they had been accustomed to during their early training.
Surgeon and Hospital caseload
Surgeon caseload was represented by the number of cases of endometrial cancer that 
had been treated over the two years of the study cohort. Each surgeon was ranked 
according to the number of cases undertaken during 1996.7. Surgeons were then 
categorised into one of three terciles according to their workload. Thirty-six cases could 
not be assigned, as the identity of the operating surgeon was uncertain. The lowest 
tercile represented surgeons undertaking between 1-5 cases in 1996/97; the middle 
tercile represented those undertaking 6-8 cases and the highest tercile represented those 
surgeons undertaking 9-18 cases in the period. Likewise each hospital was ranked 
according to workload and then categorised into one of three terciles. Three groups were 
defined: 1-21 cases; 23-34 cases & 36-52 cases.
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Patient age
Patient age was categorised into two categories: <60 and >60. The reason for this is that 
these categories had previously been demonstrated to be prognostically significant 
(Creutzberg, van Putten, Koper, Lybeert, Jobsen, Warlam-Rodenhuis, De Winter, 
Lutgens, van den Bergh, van, Steen-Banasik, Beerman, & van Lent2000a).
Multidisciplinary clinic
This based upon the clinic correspondence. Either an explicit statement of a 
multidisciplinary clinic or evidence of follow up by both gynaecologist and medical/ 
clinical oncologist was sought.
Survival time
Survival data, by computerised probability matching to the Registrar General’s death 
records (Kendrick & Clarke 1993), was obtained from ISD-Scotland. The primary end 
point in the survival analysis was death from any cause. This was used instead of the 
cancer specific cause of death due to acknowledged inaccuracies in death certificate 
information (Maudsley & Williams 1993). The date of censoring was 31st March 2000. 
Fifty-nine cases of proven endometrial cancer were not linkable to the Registrar 
General’s death records. These cases were included in the analysis. In these cases the 
date of censoring was defined as the date of data abstraction if the case record indicated 
the likelihood of the patient still being alive. The rationale for this was that case records 
are usually ‘marked’ by medical record’ staff when a patient becomes deceased.
The reason for the date of censoring not being the date that the patient was last known 
to be alive based on correspondance from the case notes was because the death record 
dataset that was obtained from ISD was not received until some time after the data
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collection had been completed. At this time there was no resource to re-abstract the case 
records that were not included in this death record dataset.
The definitions of the other variables used are self evident.
Analysis and statistical methods
Power
The study was initially designed to explore variations in clinical practice as well as 
survival. A power calculation demonstrated that it was not practicable seek to 
demonstrate a specialist effect because of the requirement of an unfeasibly large study 
population. In the absence of comparable studies the power calculation used the 
assumption used in the previous chapters. This was calculated using nQuery Advisor 
(Statistical Solutions 1997) with the help of Professor D. Hole. It was estimated that, 
assuming that equal numbers of patients being treated by specialist gynaecologists as by 
general gynaecologists {vide infra), a study population of 3898 patients would be 
required yielding 719 deaths. This would give an 80% power to detect a relative hazard 
ratio of 0.82 between specialists and non-specialists at the two-sided 5% level of 
significance. This assumed a 5-year survival in the region of 80%. On the basis of the 
incidence of endometrial cancer in Scotland this would have required at least 10 years 
of data. The actual study population would have to be considerably greater than this as, 
is demonstrated in this study, only a small proportion of patients were treated by 
gynaecologists considered to be gynaecological cancer specialists. In view of the 
unequal proportions the actual study population would require around 5600 patients 
[David Hole- personal communication]. In the context of this study it was therefore not 
feasible to expect the study to be powered to demonstrate the presence or absence of a
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survival benefit attributable to specialist surgery. For this reason the study sought to 
examine variations in surgical practice and explore possible factors that might be related 
to survival.
Analysis
Simple tabulation followed by multiple logistic regression was used to explore four 
factors that were initially perceived to have a potential bearing on the quality of surgical 
staging. These were ‘specialist’-gynaecological surgeons; surgeon caseload, the date of 
postgraduate education (MRCOG pass date) and hospital caseload.
Univariate survival analysis was used to assess each possible prognostic factor with 
survival using the Kaplan-Meier method. The Log rank statistic was used to compare 
individual survival curves. In the final analysis a Cox proportional hazards model was 
used to adjust for prognostic factors (Katz 1999c).
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5.4 Results
Data
One thousand and eighty five possible cases were identified from SMR-1 and a further 
149 cases from SMR-6. Of these, 67 records could not be located and 299 cases were 
excluded. Of these 172 cases were diagnosed outwith 1996/7 and 127 cases were 
tumours other than uterine cancer. Of those 127 cases found to have tumours other than 
endometrial cancer, 41 were ovarian cancer, 21 cervical cancer and 22 unspecified 
pelvic tumours. A further 87 cases of uterine sarcoma were also excluded. Thus, 781 
patients with endometrial carcinoma diagnosed in 1996/7 were available for analysis. Of 
these, 703 were initially treated by surgery and this is the group discussed in this thesis. 
This is shown schematically in figure 5-1.
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Figure 5-1; Venn diagram of study population
SMR:1 [2469 records] SMR:6[934 records]
Patients=1085
Missing 67
Notin SMR: 1=149
Abstracted=1167
Excluded=299 ---------
Sarcoma/MMT=87
▼
Confirmed endometrial cancer=781
i
Patients undergoing surgery=703
Venn diagram showing the method through which the study population 
was identified. Although 2469 entries were included in SMR-1 (in­
patient and day case hospital discharge data) this represents only 1085 
patients. This is because SMR-1 records each patient episode, thus if a 
patient has been admitted and discharged on multiple occasions then 
multiple entries will be recorded. SMR-6 is the cancer registration 
dataset. This was found to be more accurate but was not available at 
the time that the study commenced.
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Quality of staging
The FIGO stage was defined in the case record by the surgeon and/or pathologist in 
only 257 (36.4%) of cases who underwent surgery despite the fact that the information 
to do so was invariably present within the case record. Of those defined 185/257 (72%) 
concurred exactly with the retrospectively assigned FIGO stage.
Fluid was sent for cytological examination in only 46.6% of cases. The intra-peritoneal 
cytology rate could be validated. A 96% concurrence was found between whether 
cytology was recorded in the operation record and whether a cytology report was issued. 
This is shown in figure 5-2. This suggests that if this aspect of staging was performed 
then it was recorded in the operation record.
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Figure 5-2; relationship between cytology being sent and presence of result in 
notes
Cytology result found in notes
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Table showing the relationship between there being a statement that 
fluid for cytological analysis was sent at the time of operation and 
there being a cytology result in the case record. This shows that there 
was a high level of agreement. Kappa statistic: p<0.0001
Figure 5-3 shows the surgeon and workload factors that were associated with more 
comprehensive staging. This shows that younger surgeons passing their MRCOG after 
1998, specialist gynaecologists and gynaecologists with high caseloads were more 
likely to send fluid to assess peritoneal cytology. Hospital caseload had an inconsistent 
relationship with low and high caseload hospitals performing better than hospitals with 
intermediate caseloads. Documentation of the FIGO stage in the medical notes was 
more likely if the surgeon was defined as a specialist gynaecologist. The differences 
seen within the three categories of hospital caseload are statistically significant however 
the relationship is inconsistent. Low and high caseload hospitals performed this aspect 
of staging better than hospitals undertaking an intermediate number of cases. 
Documenting the FIGO stage was not statistically related to the year of passing the 
MRCOG exam nor was it associated with individual surgeon caseload. It was not 
possible to assign a MRCOG pass date for the surgeon in 47 cases. This was due to the
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fact that for several cases it was not possible to be certain who the operating surgeon 
was. In several cases the surgeon was known however there was no entry in the Royal 
College of Obstetricians & Gynaecologist’s list of Members & Fellows(RCOG 1997a).
Figure 5-4 shows the results of two multiple logistic regression analyses that were used 
to identify the strengths of association between the factors. In each of the analyses there 
is an increased likelihood of more adequate staging by surgeons passing the MRCOG 
after 1989 or having ‘specialist’ status. The relationship between surgeon caseload and 
whether cytology was sent is just significant. In both multivariate analyses there was no 
relationship between surgeon caseload and staging quality. Hospital caseload had a 
statistically significant association with both indices of staging. In both cases hospitals 
performing an intermediate number of cases were less likely to send fluid for 
cytological analysis and were less likely to document the FIGO stage in the patient 
casenotes.
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This table shows a univariate analysis of the association of surgeon 
and workload factors with two aspects of improved staging. It shows 
that younger surgeons passing their MRCOG after 1988, specialist 
gynaecologists and gynaecologists with higher caseloads were more 
likely to send fluid to assess peritoneal cytology. Patients whose 
surgery was performed in hospitals with intermediate caseloads were 
less likely to have fluid sent for cytological analysis.
Documentation of the FIGO stage in the medical notes was more likely 
if the surgeon was defined as a specialist gynaecologist. It was 
statistically less likely if the case was undertaken in a hospital 
performing an intermediate number of cases. Documenting the FIGO 
stage was not statistically related to the year of passing the MRCOG 
exam nor was it associated with individual surgeon caseload.
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Figure 5-3; univariate analysis of the association of surgeon and workload factors 
with more comprehensive staging in endometrial cancer.
Peritoneal cytology done
yes (%) no (%) x 2
MRCOG pass date
<1989 192 (39.9) 289 (60.1) P<0.0001
>=1989 108 (61.7) 67 (38.3)
Not known 12 (25.5) 35 (74.5)
Surgeon category
Not ‘specialist’ 246 (39.9) 370 (60.1) P<0.0001
Gynaecology cancer specialist 66 (75.9) 21 (24.1)
Surgeon caseload
Lowest tercile [1-5 cases] 83 (37.6) 138 (62.4) P<0.0001
Middle tercile [6-8 cases] 87 (38.7) 138 (61.3)
Highest tercile [9-18 cases] 132 (59.7) 89 (40.3)
Not categorisable 10 (27.8) 26 (72.2)
Hospital volume
Lowest tercile [1-22 cases] 114 (50.2) 113 (49.8) P=0.016
Middle tercile [23-34 cases] 97 (37.6) 161 (62.4)
Highest tercile [35-52 cases] 101 (46.3) 117 (53.7)
MRCOG pass date
<1989 
>=1989 
Not known
Surgeon category
Not ‘specialist’
Gynaecology cancer specialist
Surgeon caseload
Lowest tercile [1-5 cases] 
Middle tercile [6-8 cases] 
Highest tercile [9-18 cases] 
Not categorisable
FIGO stage documented
yes (%) no (%) X2
167 (34.7) 314 (65.3) P=0.16
74 (42.3) 101 (57.7)
15 (31.9) 32 (68.1)
211 (34.3) 405 (65.7) P=0.002
45 (51.7) 42 (48.3)
68 (17.2) 153 (69.2) P=0.16
87 (38.7) 138 (38.7)
89 (40.3) 132 (40.3)
12 (33.3) 24 (66.7)
Hospital volume
Lowest tercile [1-22 cases] 
Middle tercile [23-34 cases] 
Highest tercile [35-52 cases]
86 (37.9) 141 (62.1)
62 (24.0) 196 (76.0)
108 (49.5) 110 (50.5)
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Figure 5-4; logistic regression analysis of factors associated with differences in 
staging quality.
Odds ratio
Cytology sent
(95% Cl) P value
FIGO documented 
Odds ratio (95% Cl) P value
Surgeon category
Not ‘specialist’ 1 P<0.0001 1 . P<0.0018
Gynaecology cancer specialist 4.2 (2.4-7.5) 2.29 (1.4-3.9)
MRCOG pass date
<1989 1 P<0.0001 1 P<0.0066
>=1989 2.9 (2.0-4.3) 1.75 (1.2-2.6)
dk 0.4 (0.1-2.0) 0.48 (0.1-1.9)
Surgeon caseload
Lowest tercile [1-5 cases] 1 P=0.054 1 P=0.061
Middle tercile [6-8 cases] 1.1 (0.8-1.7) 1.6 (1.1-2.5)
Highest tercile [9-18 cases] 1.7 (1.1-2.7) 1.0 (0.7-1.6)
unclassifiable 2.1 (0.4-12.0) 2.7 (0.6-13.2)
Hospital volume
Lowest tercile [1-21 cases] 1 P=0.0045 1 P<0.0001
Middle tercile [22-34 cases] 0.5 (0.4-0.7) 0.46 (0.3-0.7)
Highest tercile [35-52 cases] 0.7 (0.5-1.1) 1.6 (1.1-2.4)
This table shows two multiple logistic regression analyses of the 
relationship of surgeon and workload characteristics with two aspects 
of improved staging. This shows that when all factors are included in a 
multivariate model surgeon category, the year of MRCOG pass of the 
gynaecologist are associated with better staging. The surgeon’s 
workload volume has no significant relationship. Intermediate volume 
hospitals are statistically less likely to stage adequately.
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Survival analysis
Survival data were obtained to 31st March 2000. The follow up for patients ranged from 
2.25 years to 4.25 years. At the date of censoring there had been 119 (17%) deaths in 
those patients who had had surgical treatment. The survival curves of those patients as 
well as those excluded from analysis on the basis that they did not undergo laparotomy 
are shown in figure 5-5.
Figure 5-6  presents two univariate survival analyses of the contributions to survival 
outcome of a number of variables that are related to the patient, their tumour, and the 
operating surgeon and of factors relating to processes of care. The first analysis includes 
all patients (n=703) who underwent laparotomy. In this group 50 patients with proven 
endometrial cancer were not linkable to the dataset obtained from the Scottish cancer 
registration/Registrar General’s death records. In this first analysis these patients were 
assumed to be alive to the date that the data was abstracted from the case record. In the 
second analysis these 50 cases are excluded from analysis. These two analyses are 
shown to allow the effect of patients with uncertain ‘death status’ on the results of 
analysis. Five factors were found to be statistically associated with differences in 
survival outcome: FIGO stage [p<0.0001] and histological grade [p<0.0001], FIGO 
stage category [p<0.0001], documentation of the FIGO stage [p=0.021] and the patient 
age category [p=0.023]. In this univariate analysis hospital caseload, surgeon type, 
surgeon caseload, surgeon MRCOG date and attendance at the Multidisciplinary clinic 
(MDC) were not significant. Comparing these two analyses shows that the assumption 
made about the 50 cases that were censored on the date of abstraction, has no effect on 
the results of the univariate analysis.
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The strength of association of the various factors was modelled in a Cox’s proportional 
hazards model. Several analyses are shown in figure 5-7. Analysis 1 shows the results 
of a model where all terms that had been examined in the univariate analysis figure 5- 
6] were added sequentially using a forward stepwise selection method. Although 703 
cases were read, 76 cases were excluded because of missing values thus this analysis is 
based on 627 cases where data is complete across all independent variables. A forward 
selection technique was used as this allowed the selection of variables most related to 
outcome until adding further variables ceases to improve the model. This approach 
minimises the effect of missing variables (Katz 1999b). This analysis shows that FIGO 
stage category, the use of Adjuvant radiotherapy and whether FIGO stage (was) 
documented in the medical notes remain statistically significant prognostic factors. 
Despite being tested in the model attendance at the Multidisciplinary clinic, age 
category, socio-economic deprivation, specialist status, surgeon workload category and 
hospital workload category did not improve the fit of the model and were thus excluded 
from it.
The second analysis (analysis 2) shows the results of a Cox proportional hazards model 
where only the previously identified significant prognostic factors are included. There 
was no missing data across these factors. This analysis shows that the model is robust 
because the patients that were excluded from the first analysis do not appear to 
materially affect the results of the analysis.
Although attendance at the multidisciplinary clinic was not statistically significant both 
in the univariate survival analysis and in the multivariate analysis, further analyses were 
performed to exclude the possibility of the multidisciplinary effect being masked by 
closely related prognostic factors. This possibility was considered for two reasons.
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Firstly the prognostic significance of the multidisciplinary clinic has been a consistent 
feature in the management and survival of patients with ovarian cancer in Scotland. The 
same clinicians who treat endometrial cancer treat patients with ovarian cancer. 
Secondly, in the author’s anecdotal experience, communication and more appropriate 
decision-making are features of the multidisciplinary clinic.
Analysis 3 shows the adding the factor attendance at the multidisciplinary clinic does 
not affect the significance of the previously identified important factors. This is not 
surprising as analysis 1 tested for this. However analyses 4, 5 & 6 show that when the 
model was run with the factor use of adjuvant radiotherapy removed, attendance at the 
MDC became statistically important with patients attending such clinics having 
improved survival. Removing the factor, FIGO stage documented, increases the 
importance of the MDC but not to a statistically significant level. When both factors are 
removed simultaneously (analysis 6) the factor attendance at the multidisciplinary clinic 
becomes statistically significant with those patients attending such clinics having 
improved survival outcome [RHR=0.6 (95%CI: 0.41 to 0.88), p=0.0084].
Survival subgroup analysis
It was not expected that all patients would show a survival advantage by having their 
FIGO stage documented, neither is adjuvant radiotherapy indicated in all patients. More 
detailed subgroup analysis was performed to determine if there were specific FIGO 
stages where staging and the use of adjuvant radiotherapy were associated with 
significant differences in survival. Two groups were examined. These were stage 1AG1 
through to 1CG2 (previously defined as low and medium risk) and stage 1CG3 through 
to stage 3 only. Stage 4 was excluded for two reasons. It was excluded because this 
represents patients with advanced disease where the tumour is outwith the pelvis. In
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such patients radiotherapy is frequently not indicated. The aim of treatment is frequently 
palliative and radiotherapy is used for symptom control rather than control of disease 
confined to the pelvis. Thus including this group of patients, though only a small 
number would potentially bias the results.
Figure 5-8 shows a univariate survival analysis demonstrated statistically significant 
associations between documenting the FIGO stage in the casenote, the use of adjuvant 
radiotherapy and attendance at the multidisciplinary clinic in stages 1CG3 through to 
stage 3 only. Figure 5-10 shows the Kaplan-Meier survival curves examining the 
relationship of documentation of FIGO stage in the notes and survival for this subgroup. 
The two curves are significantly different, (log rank statistic: p=0.005). Similar analysis 
on this subgroup was performed looking at the effect of adjuvant radiotherapy on 
survival. The Kaplan-Meier survival curves are shown in Figure 5-11. The survival 
curves are significantly different (log rank statistic: p=0.0007). Figure 5-12 shows the 
Kaplan Meier suvival curve examining the relationship between attendance at the 
multidisciplinary clinic and survival for this subgroup. The survival curves are 
statistically different (p=0.0016).
A Cross-tabulation analysis was performed to examine the stage distribution within 
each subgroup for each significant independent factor examined above. This is shown in 
Figure 5-9. This shows that the distribution of patients having their FIGO documented 
in the notes, receiving adjuvant radiotherapy and attending the MDC is equally 
distributed across all stages. This suggests that the survival differences seen in the 
subgroup analysis is likely to be genuine.
218
Cu
m
ul
at
ive
 
Su
rv
iv
al
Figure 5-5: survival of patients undergoing laparotomy for endometrial cancer
and of those who did not undergo laparotomy.
n____
laparotomy: n=703
+ laparotomy-censored
no operation: n=78
no operation 
-censored0.0
0 365 730 1095 1460 1825
survival time/ days
This Kaplan Meier survival curve shows the unadjusted survival of 
patients who underwent laparotomy for endometrial cancer as well as 
the survival for those who did not. It shows that the survival for those 
not undergoing laparotomy was substantially worse than for those who 
were not treated by surgery. This is statistically significant, Log rank 
statistic: p<0.0001.
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This table shows the results of two separate univaritate analyses of 
patient, tumour, surgeon and treatment factors for patients diagnosed 
with endometrial cancer in 1996 & 97 who underwent laparotomy. The 
first column includes all patients (n=703) who underwent laparotomy. 
In this group 50 patients with proven endometrial cancer were not 
linkable to the dataset obtained from the Scottish cancer 
registration/Registrar General’s death records. In this first analysis 
these patients were assumed to be alive to the date that the data was 
abstracted from the case record. In the second analysis these 50 cases 
are excluded from analysis. These two analyses are shown to allow the 
effect of patients with uncertain ‘death status’ on the results of 
analysis. In these analysis FIGO stage, Tumour grade, FIGO stage 
category, patient age category and whether the FIGO stage was defined 
and written in the case notes are significant factors associated with 
differences in survival outcome. In this univariate analysis neither 
hospital caseload, surgeon type, surgeon caseload, surgeon MRCOG 
date nor attendance at the Multidisciplinary clinic were significant in 
the univariate analysis.
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Figure 5-6; univariate survival analysis of tumour, patient, surgeon and treatment
factors
Factor All patients undergoing laparotomy Analysis excluding patients with
_________________________________________________________ (n=703)_____________________ uncertain ‘death status’ (n=653)
n deaths 4-yrS p value47 n deaths 4-yrS p-value
(%) (%)
FIGO stage
Cis 9 0 (100) <0.0001 6 0 (100) <0.0001
1 511 54 (86.6) 478 54 (85.9)
2 59 8 (82.1) 56 8 (81.2)
3 68 39 (35.4) 65 39 (33.4)
4 13 8 (33.1) 10 8 (20.0)
Don’t know48 43 10 (73.0) 38 10 (69.8)
Histological grade
1 217 10 (93.8) <0.0001 205 10 (93.5) <0.0001
2 288 43 (80.1) 271 43 (79.2)
3 136 53 (56.8) 122 53 (53.2)
dk 62 13 (78.8) 55 13 (76.1)
FIGO stage category
Low [Cis, 1AG1, 1BG1] 182 7 (85.5) <0.0001 168 7 (95.2) <0.0001
Intermediate [1AG2/3, 1BG2/3, 1CG1/2] 289 34 (84.1) 271 34 (83.4)
High [1CG3, stage2, 3 & 4] 182 68 (56.4) 169 68 (53.8)
Uncategorisable 50 10 (79.6) 45 10 (77.4)
Age
<60 143 15 (88.2) 0.023 132 15 (87.3) 0.025
V II Os O 560 104 (77.6) 521 104 (76.3)
FIGO stage defined
No 447 87 (77.7) 0.021 414 87 (76.2) 0.017
Yes 256 32 (83.4) 239 32 (82.6)
Hospital caseload category
Lowest third [1-21 cases in 1996/7] 227 49 (74.5) 0.09 212 49 (73.0) 0.10
Middle third [22-34 cases in 1996/7] 258 37 (82.8) 242 37 (81.8)
Highest third [35-52 cases in 1996/7] 218 33 (82.0) 199 33 (80.6)
Adjuvant radiotherapy given
No 428 67 (82.0) 0.30 394 67 (80.6) 0.36
Yes 275 52 (76.5) 259 52 (75.3)
Socio-economic deprivation
Least deprived 125 18 (81.7) 0.74 117 18 (80.7) 0.70
Intermediate deprivation 490 87 (78.9) 457 87 (77.6)
Most deprived 88 14 (80.3) 79 14 (78.2)
Specialist
No 616 103 (80.0) 0.69 573 103 (78.4) 0.68
Yes 87 16 (80.9) 80 16 (79.5)
M ultidisciplinary clinic
No 378 63 (79.7) 0.83 352 63 (78.4) 0.88
Yes 315 55 (79.7) 293 55 (78.5)
dk 10 1 (89.5) 8 1 (87.5)
MRCOG date
<1989 481 77 (81.5) 0.09 449 77 (80.4) 0.09
>=1989 175 29 (78.9) 160 29 (77.4)
dk 47 13 (65.9) 44 13 (62.3)
Surgeon workload category
Lowest third [1-5 cases in 1996/7] 221 41 (76.1) 0.20 209 41 (75.0) 0.18
Middle third [6-8 cases in 1996/7] 225 35 (82.7) 207 35 (81.4)
Highest third [9-18 cases in 1996/7] 221 33 (83.2) 204 33 (82.1)
dk 36 10 (62.2) 33 10 (58.4)
Cis=carcinoma in situ
47 Logrank statistic
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Figure 5.7: multivariate survival analysis of FIGO staging and adjuvant
radiotherapy with survival.
Analysis 1 (n=627) Analysis 2 (n=703) Analysis 3 (n=703)
Variable n RHR (95%CI) p-value n RHR (95%CI) p-value n RHR (95%CI) p-value
FIGO stage 
category
Low  risk 159 1 <0.0001 182 1 <0.0001 182 1 <0.0001
Intermediate 258 3.6 (1.5-8.8) 289 3.8 (1.7-8.5) 289 3.9 (1.7-8.8)
risk
H igh risk 169 23.6 (9.8-56.7) 182 21.7 (9.6-48.9) 182 22.5 (9.9-50.9)
N ot 41 5.3 (1.8-15.4) 50 5.6 (2.1-14.6) 50 5.7 (2.1-14.9)
categorisable
Adjuvant
radiotherapy
Y es 252 1 275 1 275 1
N o 375 2.2 (1.5-3.5) 0.0002 428 2.1 (1.4-3.2) 0.0003 428 2.0 (1.3-3.1) 0.002
FIGO stage 
documented
Y es 232 1 256 1 256 1
N o 395 2.0 (1.3-3.1) 0.0022 447 1.7 (1.1-2.6) 0.0096 447 1.7 (1.1-2.5) 0.015
M D C
N o 378 1
Y es 315 0.84 (0.6-1.3) 0.40
dk 10 0.57 (0.1-4.1) 0.57
This table shows the results of six separate Cox proportional hazard 
analyses examining the relationship between patient, disease and 
treatment factors with survival.
Analysis 1 shows the results of a model where all terms included in the 
univariate analysis [figure 5-6] were added sequentially using a forward 
stepwise selection method. Although 703 cases were read, 76 cases 
were excluded because of missing values thus this analysis is based 
on 627 cases where data is complete across all independent variables. 
This table shows that FIGO stage category, the use of Adjuvant 
radiotherapy and whether FIGO stage (was) documented in the medical 
notes remain statistically significant prognostic factors. Despite being 
tested in the model attendance at the Multidisciplinary clinic, age 
category, socio-economic deprivation, specialist status, surgeon 
workload category and hospital workload category did not improve the 
fit of the model and were thus excluded from it.
Analysis 2 is a model where only the significant factors identified in 
analysis 1 were included simultaneously. This analysis was based on 
703 patients since there was no missing data across these 
independent factors.
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Figure 5.7: multivariate survival analysis of FIGO staging and adjuvant
radiotherapy with survival./ cont
Analysis 4 (n=703) Analysis 5 (n=703) Analysis 6 (n=703)
V ariab le n RHR (95%CI)
F IG O  stage  
r isk  category
Low 182 1
Intermediate 289 3.3 (1.5-7.6)
High 182 15.9 (7.2-35.1)
Not 50 5.5 (2.1-14.5)
categorisable
A d ju van t
rad io th erap y
Yes
No
F IG O  stage  
d ocu m en ted
Yes 256 1
No 447 1.7 (1.1-2.6)
M D C
No 378 1
Yes 315 0.66 (0.45-0.98)
dk 10 0.58 (0.08-4.2)
p -v a lu e
< 0.0001
0.01
0.037
0.59
n RHR (95%CI) p-value n
182 1 <0.0001 182
289 4.0 (1.8-9.2) 289
182 22.9 (10.1-51.9) 182
50 6.2 (2.4-16.3) 50
275 1
428 2.0 (1.3-3.1) 0.0015
378 1
■ ='*. /  ,
378
315 0.76 (0.51-1.1) 0.19 315
10 0.60 (0.08-4.4) 0.62 10
RHR (95%CI) p-value
1
3.5
15.9
5.9
1
0.60
0.61
< 0.0001
(1.5-7.9)
(7.2-35.4)
(2.3-15.7)
vt :i,■.'■■I-.:-!
r r / . :
(0.41-0.88)
(0.08-4.4)
0.0084
0.62
Analysis 3 is a rerun of analysis 2 but with attendance at the MDC 
included. This shows that when Adjuvant radiotherapy and FIGO stage 
documented are included in the model attendance at the MDC is 
statistically insignificant.
Analysis 4 is a rerun of analysis 3 but where the variable use of 
Adjuvant radiotherapy has been removed. This shows that the other 
factors in the model remain significant but now attendance at the MDC 
becomes statistically significant. This suggests that the factors use of 
adjuvant radiotherapy and attendance at the MDC are in some way 
related.
Analysis 5 is a rerun of analysis 3 where the variable FIGO stage 
documented has been removed. In this case attendance at the MDC 
remains insignificant.
The final analysis 6 is a rerun of analysis 3 where both the variables 
Adjuvant radiotherapy as well as FIGO stage documented are removed 
from the model. In this analysis attendance at the MDC becomes highly 
significant. This suggests that in some way the factors use of Adjuvant 
radiotherapy and whether the FIGO stage documented are related to 
attendance at the MDC in terms of their effect on survival.
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Figure 5-8 showing univariate survival subgroup analysis
Subgroup________________ Stage 1CG3 to stage 3 only Stage 1AG1 to Stage 1CG2 only
n
p ", «  value
Kaplan- 
Meier curve
n p-value Kaplan-Meier
curve
FIGO staged defined
Yes 73 0.005 [Fig 5-10] 170 0.61 [not shown]
No 93 302
Adjuvant radiotherapy
Yes 124 0.0007 [Fig 5-11] 136 0.49
No 42 336
MDC
Yes 105 0.0016 [Fig 5-12] 180 0.82
No 61 284
dk 0 8
This tables shows a subgroup analysis examining which groups of 
patients’ survival is associated with defining the FIGO stage in the case 
note, receiving adjuvant radiotherapy and attending the 
multidisciplinary clinic. These factors are beneficial in patients with 
more advanced disease. The individual survival curves for the 
significant factors are shown in Figures 5-10 to 5-12.
Figure 5-9 showing cross-tabulation analysis of distribution of stage for each 
important independent factor in the subgroup stage 1CG3 through to stage 3 
only.
FIGO defined Adjuvant radiotherapy_________ MDC
Stage No yes X2 :p-value No yes X2 :p-value No yes X2 :p-value
1CG3 24 15 0.25 8 31 0.56 17 22 0.51
Stage 2 28 31 14 45 22 37
Stage 3 41 27 20 48 22 46
This table shows that for each prognostic factor cases are distributed 
eventiy across each FIGO stage.
49 Statistic testing equality of the survival curves using the Logrank test.
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Figure 5.10: association of FIGO staging with survival for patients with FIGO
stage 1CG3, stage 2 and stage 3 disease only.
1 0  r
FIGO stage in notes?
yes
+  yes-censored
no
0.0 no-censored
0 365 730 1095 1460 1825
time [days]
FIGO stage documented = 73; not documented = 93; Log rank statistic: p=0.005
This Kaplan Meier survival curve shows the unadjusted survival of 
patients with FIGO stage 1CG3, stage 2 and stage 3 categorised 
according to whether they had a FIGO stage written in their notes. This 
shows, for this group of patients, that those patients who had a stage 
written in their notes had better survival.
225
Cu
m
ul
at
iv
e 
su
rv
iv
al
 (
%
)
Figure 5.11: association of use of adjuvant radiotherapy with survival in FIGO
stage 1CG3, stage 2 and stage 3 disease only.
adjuv't radiotherapy
yes
+  yes-censored
no
+  no-censored0.0
0 365 730 1095 1460 1825
time [days]
Receiving adjuvant radiotherapy= 124; not receiving radiotherapy=42; Log rank statistic: 
p=0.0007
This Kaplan Meier survival curve shows the unadjusted survival of 
patients with FIGO stage 1CG3, stage 2 and stage 3 categorised 
according to whether they received adjuvant radiotherapy. This shows, 
for this group of patients, that those patients who received adjuvant 
radiotherapy had better survival.
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Figure 5.12: association of attendance at MDC with survival in FIGO stage 1CG3,
stage 2 and stage 3 disease only.
1.0 t
—L
L1___
H-m—H-H -H— I—f
attended MDC
yes
+  yes-censored
no
+  no-censored0.0
0 365 730 1095 1460 1825
time [days]
Attending MDC= 105; not receiving radiotherapy=61; Log rank statistic: p=0.0016
This Kaplan Meier survival curve shows the unadjusted survival of 
patients with FIGO stage 1CG3, stage 2 and stage 3 categorised 
according to whether they attended the multidisciplinary clinic. This 
shows, for this group of patients, that those patients who attended 
such a clinic had better survival.
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5.5 Discussion
Data
Identification of case records
One of the strengths of this study is that the data relate to a well-defined national 
population with a robust mechanism for case identification and record retrieval. The 
completeness of case identification is likely to be high. Cases were identified 
independently from two sources, SMR-1 and SMR-6, and over 95% of identified 
records were located and abstracted. The actual histo-pathology report was available in 
96% of cases. The pathology report was missing from the case record in the remaining 
4%, however the diagnosis was confirmed in correspondence between consultant and 
general practitioner.
Although not a primary aim of the study the search strategy for cases allowed an 
assessment of the quality of the national SMR-1 & SMR-6 datasets. In the study 
presented in this chapter 172 cases (14%) were excluded on the basis of the diagnosis 
being diagnosed outwith the defined time window [01/01/1996-31/12/1997]. Whilst the 
numbers excluded on this basis is quite high it is perhaps not surprising since patients 
diagnosed in the preceeding year who were still being treated within the time window 
would correctly have been included in the SMR-1 dataset. In a previously published 
audit of the data quality of Scottish cancer registration data 11% of cases were found to 
have inaccuracies [error > 6 weeks] in the date of diagnosis (Brewster, Crichton, & Muir 
1994).
The proportion of cases that had an incorrect histological diagnosis was 127 cases 
(10%). Of these 44 cases (3.5%) were found on review of the pathology report to be 
ovarian cancer, 22 cases (1.7%) were pelvic tumours of unspecified primary site and in
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21 cases (1.7%) the primary site was the cervix. It is not surprising that the miscoding in 
over 6% was of tumours with an anatomical proximity to the uterus. This miscoding 
could have an effect on the published national survival statistics (ISD2000a). This is 
because the survival of patients with ovarian cancer is poorer than that of patients with 
endometrial cancer. Thus the overall effect might worsen the apparent overall survival 
of patients with endometrial cancer. The quality of Scottish cancer registration data has 
been previously audited (Brewster, Crichton, & Muirl994). In this study 5.4% of entries 
were miscoded for their ICD-9 site code. Thus the discrepancy found in this study is 
comparable, when the use of the less accurate SMR-1 dataset is taken into 
consideration, to the previously published data.
Patients with uterine sarcoma and mixed mesodermal tumours (n=87) were excluded 
from analysis. Whilst they are correctly categorised with endometrial cancer under the 
international classification of diseases ICD-9: 182 and ICD-10: C54-55 their biological 
behaviour and treatment particularly adjuvant treatment is different from endometrial 
cancer (Quinn, Anderson, & Coulter1992).
The purpose of the study was to examine aspects of staging and survival. It was 
necessary to exclude patients who did not undergo surgical treatment. This is a 
heterogenous group of older patients [77ys vs 68ys] who were not fit for surgery. This 
is reflected in their poor survival [3-year survival 19.2% vs 79.2%]. It was not possible 
to include these patients in the analyses as no accurate staging data was available, thus 
without imputing the unavailable data these cases would have been automatically 
excluded from analysis.
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Missing data
Despite 95% of the identified case records being abstracted many factors examined in 
the analyses had missing data. This was for various reasons. Although the 
histopathology report was available in 96% of cases several reports were ambiguous 
and it was not possible to accurately define the stage, depth of myometrial invasion or 
histological grade of tumour. The use of the composite stage category; FIGO stage 
category not only makes analysis feasible by reducing around 30 stage/grade 
combinations into three but also minimises the effect of missing data items. The reason 
for this is illustrated in figure 5-0. The only way of further reducing the number of 
missing pieces of data would have been to have archival pathology slides reviewed. 
This was not feasible within the context of this study. The identity of the surgeon could 
not be obtained in 36 cases. This was because the name of the surgeon was not on the 
operation record or was illegible. This was particularly problematic in hand written 
notes. It would have been possible to obtain some of this missing data by reviewing the 
gynaecology operating theatre record book that is kept in each operating theatre. This 
would have required separate permission and the study did not have the resource to 
pursue this. In 47 cases the MRCOG date could not be ascertained. Most of these cases 
were due to ambiguity regarding the operating surgeon but for three cases there was no 
entry of the surgeon’s name in the RCOG list of members and fellows. One may 
speculate that the surgeon in those cases might have been a locum doctor.
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There are a number of methods that can be used to manage the effect of missing data 
and these are outlined in the literature (Katzl999b).
Options available for managing missing data
1 Delete cases with any missing data
2 Create variables to represent missing data
3 Make additional effort to obtain data
4 Decrease the number of independent variables in the analysis
5 Estimate the value of the missing cases
From (Katz1999b); page 100
In this study attempts to obtain the missing data were made within the resources 
available to the study. In several analyses the analysis has been run with the missing 
data categorised as missing thus including all cases. The effect on the univariate 
analysis of survival (figure 5-6), of the cases where the date of censoring is based on 
assumptions, was tested by performing a second analysis. In this analysis these cases are 
excluded. Likewise in the multivariate survival analysis the effect of missing data was 
tested by performing multiple analyses (figure 5-7). In these analyses the missing data 
does not change the results of the analysis in a significant way.
Once the study had been completed the dataset was linked to the dataset obtained from 
ISD-Scotland that contained the status (dead yes/no) and the survival time to death or 
censoring for all patients diagnosed with endometrial cancer in Scotland. As discussed 
previously this dataset did not provide data for 59 patients. In these cases the date of 
censoring was defined as the date of data abstraction from the case record. This 
assumption is based on the fact that the medical records are usually [personal 
communication with medical records department Stobhill hospital Glasgow] informed 
of a death so that further clinic appointments can be cancelled. The records are then 
marked as deceased. The assumption made was that if there was no indication of death
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at the time of abstraction then the patient was alive on this date. This may not be correct 
in every case but is an estimate.
Four other options are possible. The best option would have been to reabstract the case 
record and censor the last date that the patient was known to be alive. The other option 
would have been to contact the patient’s general practitioner to seek the last known date 
of contact and define this the date of censoring. The third approach would be to wait for 
further data from ISD-Scotland. The dataset from ISD is ‘dynamic’ and the data 
contained will vary with time. The forth method would have been to estimate the 
survival time based upon the characteristics of the case (Katzl999b). If this had been 
done the survival time of the case with the missing dependent could have been 
estimated from the survival time of similar cases. This would have relied on the FIGO 
stage category since this was found to be the most important prognostic factor.
It is argued that the assumptions used in the analysis to deal with this missing data are 
sufficiently valid to legitimise their inclusion in the survival analysis. The resources of 
the study would not have allowed further reabstraction of the case records.
Abstraction quality
In this study a small proportion (2%) of case records were randomly re-abstracted. The 
number of re-abstracted records was chosen as a trade-off between available resources 
and the potential additional benefit obtained. The concordance between the re­
abstracted cases was good across the variables that were chosen for analysis. The only 
errors found were an incorrect date of birth (day of month), an error in whether cytology 
had been sent and a misspelled surgeon name.
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The data abstraction excercise commenced at Stobhill hospital in Glasgow (where the 
author was working at the time). This allowed supervision and on site help with both the 
abstraction but use of laptop computers. Prior to the study commencing it had been 
intended that the abstractors would define the retrospective FIGO stage according to a 
detailed staging proforma. It immediately became apparent that the abstractors found 
this difficult and the accuracy of this was poor. For this reason all pathology reports 
were photocopied and reviewed in one location by the author at Greater Glasgow Health 
Board.
Quality o f  staging
A new finding was the association between the MRCOG pass date and the quality of 
staging. Taken together the ‘specialist effect’ and the ‘MRCOG date’ point towards 
knowledge being the common factor that results in improved staging quality. Younger 
gynaecologists may have more up to date knowledge of the current staging systems and 
may be more aware of the benefits of staging. No independent association was found 
between surgeon caseload and staging quality despite the fact that 80% of cases were 
performed by gynaecologists operating on less than six cases a year. The association 
between hospital volume and staging quality is more complex. Staging was performed 
less well in hospitals performing an intermediate number of cases. These findings 
support data from other studies where specialist surgeons were observed to stage more 
adequately (Kingsmore, Hole, Gillis, & Georgel998). Of note is the fact that staging 
procedures are not technically difficult. Sending intra-peritoneal washings for cytology 
requires no particular skill, only to remember that they should be taken and a belief that 
it is worthwhile. Likewise, recording the FIGO stage in the notes requires recognition of 
its importance, knowledge of the staging system and remembering to do it. ‘Specialists’
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were more likely to document stage. These findings support the idea that part of the 
‘specialist effect’ is a greater understanding of the reasons for the surgery performed.
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Survival analysis
The univariate survival analysis showed that the most important prognostic factor was 
the stage and grade of the tumour. This is unsurprising and confirms the results of the 
previously discussed studies (Boronow, Morrow, Creasman, DiSaia, Silverberg, Miller, 
& Blessing1984a) (DiSaia, Creasman, Boronow, & Blessingl985), (Creasman, 
Morrow, Bundy, Homesley, Graham, & Hellerl987). A new finding is that having the 
FIGO stage defined in the case notes is associated with better survival. However in this 
analysis both use of adjuvant radiotherapy as well as attendance at the multidisciplinary 
clinic were not found to be statistically significant factors.
In the first multivariate survival analysis all variables were entered into the model and 
those contributing to the ‘fit’ of the model were retained. In all multivariate models the 
strongest prognostic factor after adjustment for other factors is FIGO stage category. In 
this analysis the process of documenting the FIGO stage remains a statistically 
significant prognostic factor after adjusting for other known factors including the use of 
adjuvant radiotherapy. This confirms and emphasises its importance. It is not proposed 
that this process itself confers a direct surgical benefit. This point is important since 
advanced staging procedures such as pelvic lymphadenectomy and para-aortic 
lymphadenectomy, more commonly performed in other countries such as the United 
States, have been argued as surgically therapeutic in their own right (Orr 1998). These 
more comprehensive surgical staging procedures were uncommonly performed in this 
Scottish cohort (4% patients had pelvic lymphadenectomy and only 0.57% had para­
aortic lymphadenectomy). It is suggested that staging may result in more effective 
clinical decision making which will improve the survival in some patients.
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The use of adjuvant radiotherapy was also a significant prognostic factor in the 
multivariate survival analysis. Adjuvant radiotherapy is known to reduce local 
recurrence, however its effect on actual survival outcome is less certain (Lawtonl-99-7).-
In the multivariate survival analysis where all variables were entered, attendance at the 
multidisciplinary clinic remained non-significant as a factor. It is not surprising that in 
the univariate analysis this factor was insignificant. This is because patients with 
advanced disease might be more likely to be referred to such a clinic. This would have 
the effect of worsening the overall survival of MDC patients. It was surprising that there 
was no ‘MDC effect’ in the multivariate model though. This is because the 
multidisciplinary clinic has been found in ovarian cancer patients to be a consistently 
important prognostic factor in ovarian cancer patients (Junor, Hole, & Gillisl994). 
Patients with endometrial cancer, in common with ovarian cancer often require 
multimodal treatment and in Scotland, these cases are managed both surgically as well 
as oncologically by the same clinicians who manage cases of ovarian cancer.
Analyses 4-6 in figure 5-7  were performed to explore whether a ‘MDC effect’ was 
being ‘masked’ by other important variables. This was found to be the case. Attendance 
at a multidisciplinary clinic is statistically significant for patients in this study only 
when the variables, staging documented and use of adjuvant radiotherapy were 
removed from the multivariate analysis. It is hypothecated that in this cohort at least, 
part of the ‘multidisciplinary effect’ may be related to staging performance and the 
concomitant and appropriate use of adjuvant radiotherapy. This means that the 
multidisciplinary clinic might contribute to patient survival by providing a mechanism 
to ensure that those patients who need adjuvant treatments actually receive them.
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At the time of defining the stage, all relevant details pertaining to the disease are 
brought together. This collation and standardisation may facilitate decision-making. 
This is likely to be important where a patient requires referral to another clinician for 
further management. This situation is common in the management of other cancers.
Further sub-group analysis was performed to see whether there were specific groups of 
patients who might have benefited from better quality staging or adjuvant radiotherapy. 
The prognostic benefit of staging and of radiotherapy was limited to FIGO stages 
1CG3, stage 2 and stage 3. Stage 4 was excluded from this sub-analysis as the use of 
adjuvant treatments in this group are usually of a palliative nature and will be 
contingent upon the patient. A large proportion of those patients (25.3%) in this sub­
group did not receive adjuvant radiotherapy. This probably represents genuine under­
treatment of disease in this group. Moreover, many of these patients had no stage 
documented, despite the fact that the information to do so was contained within the 
patient’s case notes. This sub-group analysis supports the role of the multidisciplinary 
clinic as an important factor in this sub-group of patients. It is argued that in this group 
of patients it may provide a mechanism for improving the quality and consistency of 
clinical management.
Association o f  specialisation and survival
Specialist status and the year of the surgeons’ MRCOG examination had no 
independent association with survival either in univariate analysis or in the multivariate 
model. The previously performed power calculation has indicated that the study is 
considerable underpowered in this respect. ‘Specialists’ operated on only 87 cases 
(12%). The number of cases who underwent ‘specialist surgical staging’ 
(lymphadenectomy) was very small (4%). It is very unlikely that this study was
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powered to detect significant survival differences from differences in the actual surgery 
performed.
Conclusions
This study shows that the overall quality of staging was poorly performed and that 
adjuvant radiotherapy was inconsistently used particularly in more advanced tumours. 
Staging, as a process, is a significant prognostic factor particularly in patients with more 
advanced cancer. It is likely that the main benefit of staging is to provide key 
information required for subsequent clinical management decisions, particularly within 
the multidisciplinary context. One of the most important decisions is whether the patient 
should receive any further treatment. These data support a greater emphasis towards 
improving the overall quality of staging. In particular there needs to be an improvement 
in the understanding of the purpose of surgery, not just to remove the cancer, but also to 
provide the information required for subsequent management decisions. This is 
especially important in Scotland where endometrial cancer continues to be managed by 
general gynaecologists rather than specialist gynaecological oncologists.
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CHAPTER 6
Final Discussion and Suggestions for Future work
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Ovarian cancer as a model
It has been easier to demonstrate the benefit of specialisation for tumour types such as 
breast and colon. Ovarian cancer is a more difficult model in which to study the role of 
specialisation, particularly specialist surgery. One reason for this is that there is a 
stronger evidence base for the benefit of surgery in breast and colon. In these tumours 
complete excision of the tumour is often feasible. The feasibility depends on technique 
used and who performs the surgery. A conclusion from the literature is that ‘specialists’ 
are more likely to utilise approaches and surgical techniques that result in complete 
removal of the tumour, thus satisfying well-established surgical principles.
A reason for this difficulty in ovary is that most patients present with advanced disease, 
at a point where the possibility of complete removal of the tumour is uncommon and 
where absolute cure is rare. Moreover in those patients the evidence for the role of 
surgery is less clear than much of the literature would suggest. This means that however 
‘good’ specialist surgery is, the actual benefit from specialist surgery may be small. It is 
possible that specialist surgeons are tailoring their approach based upon the wrong 
assumptions.
There may be survival benefits for patients with early stage disease. This has not been 
demonstrated either in the literature nor in the studies presented here. Because patients 
rarely present with early disease the numbers of patients is small and this makes it likely 
that studies are underpowered to show differences were they to exist. Nevertheless the 
role of surgery and the adequacy of staging are important in patients with FIGO stage 
1A. The reason for this is that these patients have a high chance of cure and 
chemotherapy may not be required if the stage were known with certainty. SCOTROC
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shows that, in the UK at least, the adequacy of staging is questionable. This is an area 
for future research.
Residual disease and survival
The literature has had difficulty demonstrating a causal relationship between residual 
disease and survival. This is a major weakness of the literature. The literature is 
insufficiently robust both methodologically, in suggesting causality other than through 
association, but also in the certainty with which the size of the residual disease is being 
measured.
The SCOTROC surgical study in chapter 4, though the data is immature, provides a 
novel way of exploring causality. The definition of residual disease is defined and 
validated and chemotherapy is standardised. The trial is large and prospective. 
Moreover it was fortunate that significant differences in the surgery performed and the 
disease left at the end of surgery were found between centres in the UK and ‘overseas’. 
This provides a unique opportunity to examine whether there is a survival gradient 
between the two groups.
Understanding the exact role of surgery is a pre-requisite before the role of 
specialisation can be fully determined. A greater participation in surgical trials in 
ovarian cancer should be encouraged.
Scotland as a country to study the role o f specialisation
Scotland has provided a forum for population based studies because the cancer 
registration data is of good quality and the population is neither too large nor too small 
to make studies manageable. Moreover there is relatively low population mobility. 
Nevertheless for a relatively rare tumour such as ovarian cancer (compared to breast and 
bowel) the country may be too small to demonstrate the effect of specialist surgery. One
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reason for this is that the proportion and number of cases treated by specialists is small. 
Though possibly controversial, the group of clinicians defined as specialists may not be 
homogenous in their surgical ability nor may they be as able as specialists in countries 
outwith the UK. This would have the effect of reducing any potential variation and 
would make differences more difficult to examine.
No differences were seen within Scotland between specialist and non-specialist 
gynaecologists and these results are different from the earlier published findings. 
Nevertheless a difference in the approach to surgery was demonstrated even though 
these differences were not related to variations in survival.
Multidisciplinary teams
This thesis has not only examined specialist surgery. The benefits of the 
multidisciplinary clinic as an important beneficial prognostic factor have been supported 
by the results in chapter 2. The results of chapter 3 that show a survival gradient, created 
by the trend of increased multidisciplinary clinic usage over time, support a causal 
relationship. It is likely that the multidisciplinary clinic is important because it acts as a 
legitimate forum for communication between professional groups involved in the 
management of ovarian cancer, namely surgeons and oncologists. This benefit may 
extend, in the case of ovary, beyond the primary treatment to the management of 
relapsed disease. The studies described in this thesis did not pursue the role of the 
multidisciplinary clinic in relapsed disease. The datasets collected for the Scottish 
studies described in chapters 2 & 3 contain detailed information on each course of 
chemotherapy that each patient received. This data that would allow the exploration of 
differences in chemotherapy given in context of the multidisciplinary clinic compared to 
those patients who were not. The endometrial cancer study presented in chapter 5 shows
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that the process of collating the staging information and writing down the stage is 
associated with survival. It is likely that this is both an overall proxy marker for quality 
but also more directly by providing information required for decision-making. In this 
study ‘attendance at a multidisciplinary clinic’ was only associated with better survival 
when the factors ‘stage defined in notes’ and ‘adjuvant radiotherapy used’ were not 
included in the multivariate survival model. This supports the argument that the 
importance of the multidisciplinary clinic is as a decision-making forum. As clinicians 
specialise, their field of interest narrows and there needs to be a concomitant increase in 
the coordination between specialists. This is particularly the case when patients require 
treatment from multiple specialities.
Relationship o f the management o f endometrial cancer to that o f  ovarian cancer in 
Scotland
The management of endometrial cancer has been relatively neglected both in the 
literature and in clinical practice. The EUROCARE data show that in the 1980’s 
patients with endometrial cancer in Scotland, like ovary, had poorer survival compared 
with other participating countries. Like ovarian cancer, endometrial cancer frequently 
requires bimodal treatement by surgeons and oncologists. In Scotland the same 
gynaecologists that treat patients with ovarian cancer treat patients with endometrial 
cancer. Most patients do not have their cancer operated on by a gynaecological cancer 
specialist. These studies show broad parallels. The studies presented in chapter 2 and 
chapter 5 both relate to the same national population, cover a similar time span and were 
conducted in similar ways. The most significant similarity is the importance of the 
multidisciplinary approach. This confirms that like ovary, the outcome of patients with 
endometrial cancer may be improved by an improvement in the overall coordination of 
patients’ management.
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Other possible benefits o f  specialisation
This thesis has focused on survival as an endpoint. In many respects this is a good end 
point because survival is important but also because it is easily measurable. This may 
not be the most important end point from the patient’s perspective. Issues of quality of 
life are likely to be as least as important. They are more difficult to measure and 
validate and are thus rarely used. The role of the specialist may be more important in 
these qualitative issues. Through greater familiarity with the problems that such patients 
experience, specialists may be able to provide a greater benefit than a general 
gynaecologist. This is speculative and this thesis has no data to support this hypothesis. 
Further examination of the qualitative aspects is an area that should develop in the 
future once a greater familiarity with the investigative techniques available becomes 
more established (Pope & Mays 2000).
A benefit that has not been previously discussed is that the move towards centralisation 
and specialisation makes it more likely that the management of cases will be performed 
by small numbers of clinicans in fewer hospitals than currently is the case. This means 
that in the future it may be possible to more precisely estimate the survival outcome of 
patients managed both by individual clinicians as well as at an institutional level. This is 
because large sample sizes are required for statistical analysis. This is especially 
important if the effect of casemix is accounted for. The importance of accounting for 
casemix was illustrated in chapter 2. Centralisation and specialisation means that 
treatments are more likely to be homogenous and each individual surgeon is likely to do 
more cases than was previously the case. Thus specialisation can aid statistical analysis. 
This should not be an argument for specialisation, however it may be the only way in 
which meaningful outcome data can be compared between individual surgeons or 
between institutions. For the sake of illustration, if the analysis of one surgeon’s
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survival outcome requires analysis of 100 cases, a generalist performing 4 cases a year 
will require a career’s worth of cases whereas a specialist performing 50/year will 
accrue sufficient cases in two years. It will thus be easier for the specialist to monitor 
their performance.
Additional implications fo r  the NHS
An important additional finding that has wide implication for the NHS is the importance 
of correcting survival data for prognostic factors. The results in chapter 2 suggested a 
possible explanation for the difference in survival for patients operated on by general 
surgeons and gynaecologists. This is important because it demonstrates how a possible 
lead time bias can lead to the conclusion that one group of surgeons is less effective 
than another. This is important at a time when the NHS and the country is becoming 
concerned with surgical performance and outcome measures both for surgeons as 
individuals and as members of institutions (Smith 2001b). There has been professional 
concern that misinterpretation of the results might occur (Camm 2002). The results in 
this thesis confirm this.
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How do the studies affect the way that the EUROCARE is viewed?
All of the studies in this thesis suggest reasons why survival in the UK, for patients with
both ovarian and endometrial cancer, may have been less optimal in the past; thus
increasing confidence that the EUROCARE data might be valid. The comparison of
Scottish ovarian cancer through the 1990’s shows a survival improvement that was
associated with increased attendance at specialist clinics. SCOTROC shows how there
might be differences in the way that ovarian cancer is managed, not only in what
operations are done but also by the suggestion that resources such as operating time
might be less limited elsewhere. The endometrial study shows that improved staging
results in fewer treatment omissions resulting in better survival. All of these studies
show how management of these two cancers in the UK could be improved.
Final conclusion
In final conclusion, within Scotland, the current survival benefit of specialist surgery 
may be less than previously reported. The importance of the multidisciplinary team is 
strengthened. One can argue that real and tangible benefits can be obtained from 
encouraging specialisation at an organisational level, i.e. creating a specialist service. 
The NHS has embraced the multidisciplinary approach and there is an argument that it 
should become the accepted model for any medical condition whose treatment is by 
more than one speciality.
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APPENDICES
A1 FIGO staging: ovarian cancer
Carcinoma of the ovary: FIGO nomenclature (Rio de Janeiro) 1988.
Stage I  Growth limited to the ovaries
la Growth limited to one ovary; no ascites present containing malignant cells.
No tumour on the external surface; capsule intact 
lb Growth limited to both ovaries; no ascites present containing malignant cells 
No tumour on the external surfaces; capsules intact 
Ic Tumour either Stage la or lb, but with tumour on surface of one or both 
ovaries, or with capsule ruptured, or with ascites present containing malignant 
cells, or with positive peritoneal washings
Stage II  Growth involving one or both ovaries with pelvic extension
Ha Extension and/or metastases to the uterus and/or tubes 
lib Extension to other pelvic tissues
lie  Tumour either Stage Ha or lib, but with tumour on surface of one or both 
ovaries; or with capsule(s) ruptured; or with ascites present containing 
malignant cells or with positive peritoneal washings
Stage III Tumour involving one or both ovaries with histologically confirmed 
peritoneal implants outside the pelvis and/or positive retroperitoneal or inguinal nodes.
Superficial liver metastases equals Stage III. Tumour is limited to the true 
pelvis, but with histologically proven malignant extension to small bowel or 
omentum
Ilia Tumour grossly limited to the true pelvis, with negative nodes, but with 
histologically confirmed microscopic seeding of abdominal peritoneal 
surfaces, or histologically proven extension to small bowel or mesentery 
Illb Tumour of one or both ovaries with histologically confirmed implants,
peritoneal metastasis of abdominal peritoneal surfaces, none exceeding 2 cm 
in diameter; nodes are negative 
IIIc Peritoneal metastasis beyond the pelvis > 2 cm in diameter and/or positive 
retroperitoneal or inguinal nodes
Stage IV  Growth involving one or both ovaries with distant metastases. If pleural 
effusion is present, there must be positive cytology to allot a case to Stage IV.
Parenchymal liver metastasis equals Stage IV________________________________________
In order to evaluate the impact on prognosis o f  the different criteria for allotting cases to Stage Ic or l ie ,  it would be o f value to know  if rupture o f the 
capsule w as spontaneous, or caused by the surgeon; and if the source o f m alignant ce lls  detected was peritoneal w ashings, or ascites.
source: (FIGO2001)
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FIGO staging schema:-ovary: source (FIGO2001)
Malignant ceils 
in ascites
Rectum  -
A orta
Malignant cells 
in ascites
I I IA/3a
Microscopic only
111 C/3c
Peritoneal
m etastases I I IB/3b 
M acroscopic 
peritoneal 
m etastases 
2S 2cm
Liver capsule
Parenchymal
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A2 FIGO staging: endometrial cancer
Carcinoma of the corpus uteri: FIGO nomenclature (Rio de Janeiro, 1988)
Stage la  * Tumour limited to the endometrium
Stage lb  * Invasion to less th'anlialf of the myometrium............................................................
Stage Ic * Invasion equal to or more than half of the myometrium
Stage Ha * Endocervical glandular involvement only 
Stage lib  * Cervical stromal invasion
Stage I lia  * Tumour invades the serosa of the corpus uteri and/or adnexae and/or positive 
cytological findings 
Stage Illb  * Vaginal metastases
Stage IIIc * Metastases to pelvic and/or para-aortic lymph nodes 
Stage IVa * Tumour invasion of bladder and/or bowel mucosa
Stage IVb * Distant metastases, including intra-abdominal metastasis and/or inguinal lymph 
nodes_____________________________________________________________________________
♦Either G l,  G 2 or G 3.
source: (FIGO2001)
FIGO staging schem aendom etrial cancer, source (FIG02001)
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